A Phase 3 interventional study of Belantamab mafodotin and Pom/dex (Pomalidomide plus low dose Dexamethasone) in Multiple Myeloma, sponsored by GlaxoSmithKline. Active, not recruiting at 136 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.
Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 4th largest by enrollment, is one of 6 that started in 2020, is one of 9 in phase 3, reaches primary completion later than 0 of the 34 other live ones, and was the 6th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
PrECOG, LLC. · Sites in United States
Ages 18–79
GlaxoSmithKline · Sites in United States, Argentina, Australia and 21 more countries
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 18+
By country, each count listing its studies:
belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 29 · Phase 3 9
First in 2014; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 325 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 49 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 49 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
42 studies in Multiple Myeloma by GlaxoSmithKline: 6 open now, 20 under way, 7 of them phase 3. Of 19 finished, 16 (84%) have results posted.
Among the 42 studies in Multiple Myeloma by GlaxoSmithKline, this one is the 4th largest by enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2020, is one of 8 in phase 3, reaches primary completion later than 0 of the 19 other live ones, and was the 19th registered.
GlaxoSmithKline’s Multiple Myeloma studies by the year they started, since 2006.
4 of the studies testing belantamab mafodotin in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05853965Universitätsklinikum Hamburg-EppendorfCombination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma | 2027-04 |
| NCT03715478Canadian Myeloma Research GroupMulti-Center Study of GSK2857916 in Combination With Pomalidomide and Dex | 2027-06-01 |
| NCT05556798Memorial Sloan Kettering Cancer CenterA Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment | 2027-10 |
| NCT05208307Emory UniversityBelantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma | 2027-10-21 |
Add all 4 to your calendar (.ics) → With an account.
Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, from their registry updates:
Among GlaxoSmithKline’s 42 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participants with RRMM. Participants will be randomized in a 2:1 ratio to receive either single agent belantamab mafodotin or pom/dex. Belantamab mafodotin will be administered on Day 1 (D1) at every 3 weeks (Q3W) schedule. Pomalidomide will be administered daily on Days 1 to 21 of each 28-day cycle, with dexamethasone administered once weekly (Days 1, 8, 15, and 22). Participants in both arms will be treated until disease progression, death, unacceptable toxicity, withdrawal of consent, and lost to follow-up or end of study, whichever comes first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive belantamab mafodotin single agent dose on Day 1 of Q3W
Drug: Belantamab mafodotin
Participants will receive pomalidomide daily on Days 1 to 21 of each 28-day cycle, with dexamethasone once weekly on Days 1, 8, 15 and 22.
Drug: Pom/dex (Pomalidomide plus low dose Dexamethasone)
Belantamab mafodotin will be administered.
Pomalidomide and Dexamethasone will be administered.
Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG)
PFS is time from randomization until earliest date of progressive disease (PD), or death due to any cause per investigator-assessed response per IMWG. PD is ≥25% increase from nadir in any of following: serum M-protein (absolute increase ≥0.5 gram per deciliter \[g/dL\]),urine M-protein(absolute increase ≥200 mg/24hr),difference between involved/uninvolved FLC levels (absolute increase \>10 mg/dL) in patients without measurable serum and urine M-protein levels, or bone marrow plasma-cell percentage irrespective of baseline status (absolute increase ≥10%) in patients without measurable serum and urine M-protein levels and without measurable involved FLC levels; appearance of new lesion,≥50% increase in longest diameter of a lesion previously measured \>1cm in short axis, or ≥50% increase from nadir in sum of products of two longest perpendicular diameters of more than 1 lesion; ≥50% increase in circulating plasma cells (minimum of 200 cells/microliter) if this is only measure of disease.
Time frame: Up to 27 months
Overall Survival (OS)
OS is defined as the time from randomization until death due to any cause.
Time frame: Up to approximately 263 weeks
Overall Response Rate (ORR)
Overall Response Rate is defined as the percentage of participants with a confirmed partial response (PR) or better (i.e., PR, very good partial response \[VGPR\], complete response \[CR\] and stringent complete response \[sCR\]), according to the International Myeloma Working Group (IMWG) Response Criteria. PR: ≥50% reduction of serum M-protein and reduction in 24-hour (h) urinary M-protein by ≥90% or to \<200 mg/24-h; VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24-h; CR:negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR:stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.
Time frame: Up to approximately 263 weeks
Clinical Benefit Rate (CBR)
Clinical benefit rate is defined as the percentage of participants with a confirmed minimal response (MR) or better according to the IMWG Response Criteria. MR is \>= 25% but \< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%.
Time frame: Up to approximately 263 weeks
Duration of Response (DoR)
Duration of response is defined as the time from first documented evidence of PR or better, to the time when disease progression (PD) is documented per IMWG response criteria; or death due to PD occurs among participants who achieve an overall response, i.e. confirmed PR or better. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 h). PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \<200 mg/24 h.
Time frame: Up to approximately 263 weeks
Time to Response (TTR)
TTR is defined as the time between the date of randomization and the first documented evidence of response (PR or better) among participants who achieve confirmed PR or better. PR: \>=50% reduction of serum M-protein \& reduction in 24h urinary M-protein by \>=90%/\<200mg/24 h.
Time frame: Up to approximately 263 weeks
Time to Progression (TTP)
TTP is defined as the time from the date of randomization until the earliest date of documented PD (per IMWG Response Criteria) or death due to PD. PD: increase of \>=25% from lowest confirmed value in any 1 of following criteria: serum M-protein (absolute increase must be \>=0.5 g/dL), serum M-protein increase \>=1g/dL if lowest M component was \>=5g/dL; urine M-component (absolute increase must be \>=200mg/24 hour),appearance of new lesion(s), \>=50% increase from nadir in Sum of the Products of the maximal perpendicular Diameters of measured lesions (SPD) of \>1 lesion, or \>=50% increase in the longest diameter of previous lesion \>1 cm in short axis.
Time frame: Up to approximately 263 weeks
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. TEAE is an event that emerged during treatment having been absent pre-treatment or worsened relative to the pre-treatment state. AEs were to be coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
Time frame: Up to approximately 263 weeks
Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-baseline Relative to Baseline
Blood samples were collected for evaluation of hematology parameters. The summaries of worst-case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE v5.0. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. \[Basophils (Baso), Mean Corpuscular Hemoglobin Concentration (MCHC), Mean Corpuscular Hemoglobin (MCH), Mean Corpuscular Volume (MCV), Erythrocytes (Ery), Hematocrit (Hct), Monocytes (Mono), Reticulocytes (Ret), Leukocytes (Leu), Eosinophils (Eosi), Lymphocytes (Lym), Neutrophils (Neu)\]
Time frame: Baseline (Day 1) and up to approximately 263 weeks
Number of Participants With Maximum Grade Increase Post-Baseline Relative to Baseline in Hematology
Blood samples were collected for evaluation of hematology parameters. The summaries of maximum grade increase from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE version 5.0. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. \[White Blood Cells (WBC)\]
Time frame: Baseline (Day 1) and up to approximately 263 weeks
Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range Post-baseline Relative to Baseline
Blood samples were collected for evaluation of clinical chemistry parameters. The summaries of worst-case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE v5.0. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. \[Kappa Light (K Lt), Lambda (λ),Monoclonal (Mc), Protein (P), Change (Cge), Alpha (α), Beta (β), Creatine Kinase (CK), Gamma (γ) ,Immunoglobulin (I-Globulin), Indirect (In.)\]
Time frame: Baseline (Day 1) and up to approximately 263 weeks
Number of Participants With Maximum Grade Increase Post-Baseline Relative to Baseline in Clinical Chemistry
Blood samples were collected for evaluation of clinical chemistry parameters. The summaries of maximum grade increase from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. \[Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Aspartate Aminotransferase (AST), Creatine Kinase (CPK), Gamma Glutamyl Transferase (GGT)\]
Time frame: Baseline (Day 1) and Up to approximately 263 weeks
Number of Participants With Shift in Urine Albumin Creatinine Ratio From Baseline to Worst Post-Baseline
Urine samples were analyzed for spot urine albumin/creatinine ratio (UACR)\[milligrams/grams (mg/g)\]. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. The "worst post-baseline value" is defined as the highest UACR measurement recorded for a participant after the baseline assessment and up to the end of the study observation period. The "shift" will be calculated as the difference between this worst post-baseline UACR value and the baseline UACR value (Worst Post-Baseline UACR - Baseline UACR). Each category is reported as "Baseline category, Worst post-baseline category." Ranges are inclusive and expressed as \[lower-upper\].
Time frame: Baseline (Day 1) and Up to approximately 263 weeks
Number of Participants With Maximum Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores
BCVA score was assessed individually for each eye. BCVA score was calculated based on the Logarithm of the Minimum Angle of Resolution (logMAR score). Any worst-case change from baseline categories are presented for right and left eyes. BCVA test scores were categorized as no change/improved vision, possible worsened vision and definite worsened vision. No change/improved vision was defined as a change from baseline \<0.12 logMAR score; a possible worsened vision was defined as a change from baseline \>=0.12 to \<0.3 logMAR score; a definite worsened vision was defined as a change from baseline \>=0.3 logMAR score. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline (Day 1) and up to approximately 263 weeks
Observed Plasma Concentrations of Belantamab Mafodotin- Antibody-drug Conjugate (ADC)
Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin
Time frame: Pre-dose on Day (D)1 of Cycles(C)1,2,3,4,6,9,12,18,24,30,36,42; End of Infusion (EOI) on D1 of C1,2,3,4&6; Start of infusion (SOI) + 2 hours(h) on D1,SOI + 24 h on D1; D4,D8-15,D22 of C1&C3; D1 of C2,3,4&6; C3D2; & End of Treatment(EOT) (~242 weeks)
Observed Plasma Concentrations of Belantamab Mafodotin- Total Monoclonal Antibody (mAb)
Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin
Time frame: Pre-dose on Day (D)1 of Cycles (C)1,2,3,4,6,9,12,18,24,30,36,42; EOI on D1 of C1,2,3, 4 & 6; SOI + 24h on D1&2 of C1&3; D4, D8-15, D22 of C1&3; D1of C2,3,4 & 6; D2 of C3; and EOT (~242 weeks)
Observed Plasma Concentrations of Belantamab Mafodotin-Cys-mc Microtubular Inhibitor Monomethyl Auristatin-F (MMAF)
Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin
Time frame: Pre-dose on Day (D)1 of Cycles (C)1,2,3,4,6,9,12,18,24,30,36,42; EOI on D1 of C1,2,3, 4 & 6; D1 SOI + 2 h of C1&3; D2 SOI + 24h of C1&3; D4, D8-15, D22 of C1&3; D1 of C2,3,4,6,9,12,18,24 & 30; D2 of C3; and EOT (~242 weeks)
Number of Participants With Post-baseline Positive Anti-Drug Antibody (ADAs) Against Belantamab Mafodotin
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers.
Time frame: Upto approximately 263 weeks
Titers of ADAs Against Belantamab Mafodotin
Serum samples were collected and tested for the presence of antibodies against belantamab mafodotin . Confirmed positive ADA samples were further analyzed to obtain the titer of the antibodies. Titers of anti-drug antibodies against belantamab mafodotin is presented.
Time frame: Up to approximately 263 weeks
Number of Participants With Symptomatic Adverse Effects as Measured by the Patient Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE. It includes symptomatic toxicities drawn from the CTCAE like blurred vision, chills, constipation, decreased appetite, fatigue, general pain, mouth/throat sores, nausea, nosebleed, shortness of breath, vomiting, watery eyes, cough, itchy, loose/watery stools, Numb/Tingling Hands/Feet (N/T H/F), Pain/Burning (P/B) and Problems Tasting Food/Drink (Prob Tasting F/D) . Items are scored individually on a 0 to 4 scale for severity, frequency and interference. A score of 0 indicates no symptom or interference, while higher score of 4 signify increasing severity, frequency, and interference with daily activities.
Time frame: Up to approximately 263 weeks
Change From Baseline (CFB) in Ocular Surface Disease Index (OSDI) Total Score
OSDI is 12-item patient-reported outcomes questionnaire designed to provide rapid assessment of range of ocular surface symptoms, including symptoms related to chronic dry eye, severity, and impact on patient's ability to function. In addition to an overall score, there are three subscales of OSDI: ocular symptoms, vision-related function, and environmental triggers. OSDI items are scored on a 0 to 4 Likert-type scale, where 0 = None of the time and 4 = All of the time. Total OSDI score = (\[sum of scores for all questions answered×100\]/\[total number of questions answered×4\]). Subscale scores are computed similarly with only questions from each subscale used to generate its own score. Any subscales analyzed separately would also have a maximum possible score of 100. A score of 100=to complete disability, while a score of 0=to no disability. Decrease in score from baseline means improvement
Time frame: Baseline (Day 1) and Up to approximately 263 weeks
Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score.
The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning \[PF\], role functioning \[RF\], emotional functioning \[EF\] cognitive functioning \[CF\] and social functioning \[SF\]), three symptom scales (fatigue, nausea/vomiting \[N/V\] and pain), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (dyspnea, insomnia, appetite loss \[AL\], constipation, diarrhea and financial difficulties \[FD\]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1), every three weeks(Q3W) starting from week 4 until week 238, End of Treatment (~242 weeks) and Follow up (~ 263 weeks)
Change From Baseline (CFB) in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score
The EORTC QLQ-MY20 is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. The module comprised of 20 questions that addressed four myeloma-specific HRQoL domains: disease symptoms (DS), side effects of treatment (SET), future perspective (FP) and body image (BI). Responses are 1 to 4. Scores were averaged and scales were transformed to 0 to 100 scale. A high score for disease symptoms and side effects of treatment represented a high level of symptomatology or problems, whereas a high score for future perspective and body image represented better outcomes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1), every three weeks(Q3W) starting from week 4 until week 238, End of Treatment (~242 weeks) and Follow up (~263 weeks)
Change From Baseline (CFB) in EORTC IL52 Score
European Organization for Research and Treatment of Cancer Item Library 52 (EORTC-QLQ-IL52) is disease symptoms domain from EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module) (EORTC QLQ-MY20). Disease symptoms domain of IL52 contain 6 items covering following concepts: bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. IL52 items are scored on 1 to 4 Likert-type scale, where 1 = Not at all, 2 = A little, 3 = Quite a bit, and 4 = Very much. A raw score is then calculated as mean of completed item responses across 6 disease symptom items. For symptom scales, this raw score is linearly transformed to a 0 to 100 scale using the formula: \[(raw score - 1) / 3\] × 100. Under this approach, a score of 0 indicates no symptoms across items, while a score of 100 indicates the highest level of symptom burden. Accordingly, higher scores indicate greater symptom burden or worse disease symptoms
Time frame: Baseline (Day 1), every three weeks(Q3W) starting from week 4 until week 238
Number of Participants With Minimal Residual Disease (MRD) Negativity Rate
MRD negativity rate is defined as the percentage of participants who are MRD negative by Next generation sequencing (NGS) method. The number of participants with MRD negativity has been presented
Time frame: Up to approximately 263 weeks
| Milestone | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone |
|---|---|---|
| Started | 218 | 107 |
| Safety population | 217 | 102 |
| Completed | 126 | 68 |
| Not completed | 92 | 39 |
| Withdrew: Lost to follow-up | 4 | 1 |
| Withdrew: Physician decision | 51 | 26 |
| Withdrew: Withdrawal by subject | 22 | 9 |
| Withdrew: Ongoing at the time of analysis | 15 | 3 |
OS is defined as the time from randomization until death due to any cause.
| Months | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone |
|---|---|---|
| Overall Survival (OS) | 24.0 (19.4 to 33.2) | 22.9 (16.0 to 29.3) |
Overall Response Rate is defined as the percentage of participants with a confirmed partial response (PR) or better (i.e., PR, very good partial response \[VGPR\], complete response \[CR\] and stringent complete response \[sCR\]), according to the International Myeloma Working Group (IMWG) Response Criteria. PR: ≥50% reduction of serum M-protein and reduction in 24-hour (h) urinary M-protein by ≥90% or to \<200 mg/24-h; VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24-h; CR:negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR:stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.
| Percentage of Participants | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone |
|---|---|---|
| Overall Response Rate (ORR) | 41 (34.7 to 48.1) | 36 (26.5 to 45.4) |
Clinical benefit rate is defined as the percentage of participants with a confirmed minimal response (MR) or better according to the IMWG Response Criteria. MR is \>= 25% but \< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%.
| Percentage of Participants | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone |
|---|---|---|
| Clinical Benefit Rate (CBR) | 47 (40.5 to 54.1) | 47 (37.0 to 56.6) |
Duration of response is defined as the time from first documented evidence of PR or better, to the time when disease progression (PD) is documented per IMWG response criteria; or death due to PD occurs among participants who achieve an overall response, i.e. confirmed PR or better. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 h). PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \<200 mg/24 h.
| Months | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone |
|---|---|---|
| Duration of Response (DoR) | 25.3 (20.7 to 31.8) | 9.9 (7.6 to 20.2) |
TTR is defined as the time between the date of randomization and the first documented evidence of response (PR or better) among participants who achieve confirmed PR or better. PR: \>=50% reduction of serum M-protein \& reduction in 24h urinary M-protein by \>=90%/\<200mg/24 h.
| Months | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone |
|---|---|---|
| Time to Response (TTR) | 2.10 (0.89 to 3.52) | 1.53 (0.89 to 2.33) |
TTP is defined as the time from the date of randomization until the earliest date of documented PD (per IMWG Response Criteria) or death due to PD. PD: increase of \>=25% from lowest confirmed value in any 1 of following criteria: serum M-protein (absolute increase must be \>=0.5 g/dL), serum M-protein increase \>=1g/dL if lowest M component was \>=5g/dL; urine M-component (absolute increase must be \>=200mg/24 hour),appearance of new lesion(s), \>=50% increase from nadir in Sum of the Products of the maximal perpendicular Diameters of measured lesions (SPD) of \>1 lesion, or \>=50% increase in the longest diameter of previous lesion \>1 cm in short axis.
| Months | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone |
|---|---|---|
| Time to Progression (TTP) | 11.3 (7.0 to 14.6) | 8.6 (5.7 to 11.8) |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. TEAE is an event that emerged during treatment having been absent pre-treatment or worsened relative to the pre-treatment state. AEs were to be coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
| Participants | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 212 | 98 |
Blood samples were collected for evaluation of hematology parameters. The summaries of worst-case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE v5.0. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. \[Basophils (Baso), Mean Corpuscular Hemoglobin Concentration (MCHC), Mean Corpuscular Hemoglobin (MCH), Mean Corpuscular Volume (MCV), Erythrocytes (Ery), Hematocrit (Hct), Monocytes (Mono), Reticulocytes (Ret), Leukocytes (Leu), Eosinophils (Eosi), Lymphocytes (Lym), Neutrophils (Neu)\]
| Participants | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone |
|---|---|---|
| Baso, Decrease to Low | 8 | 4 |
| Baso, Change to Normal or No Change | 147 | 47 |
| Baso, Increase to High | 14 | 19 |
| MCHC, Decrease to Low | 69 | 30 |
| MCHC, Change to Normal or No Change | 129 | 59 |
| MCHC, Increase to High | 19 | 9 |
| MCH, Decrease to Low | 56 | 13 |
| MCH, Change to Normal or No Change | 142 | 68 |
| MCH, Increase to High | 23 | 24 |
| MCV, Decrease to Low | 44 | 10 |
| MCV, Change to Normal or No Change | 151 | 65 |
| MCV, Increase to High | 25 | 25 |
| Ery, Decrease to Low | 18 | 10 |
| Ery, Change to Normal or No Change | 165 | 79 |
| Ery, Increase to High | 27 | 5 |
| Hct, Decrease to Low | 23 | 19 |
| Hct, Change to Normal or No Change | 182 | 78 |
| Hct, Increase to High | 13 | 2 |
| Mono, Decrease to Low | 20 | 25 |
| Mono, Change to Normal or No Change | 103 | 20 |
| Mono, Increase to High | 51 | 39 |
| Ret, Decrease to Low | 23 | 14 |
| Ret, Change to Normal or No Change | 55 | 22 |
| Ret, Increase to High | 41 | 13 |
| Baso/Leu, Decrease to Low | 0 | 0 |
| Baso/Leu, Change to Normal or No Change | 36 | 10 |
| Baso/Leu, Increase to High | 2 | 12 |
| Eosi/Leu, Decrease to Low | 11 | 3 |
| Eosi/Leu, Change to Normal or No Change | 23 | 7 |
| Eosi/Leu, Increase to High | 7 | 13 |
| Lym/Leu, Decrease to Low | 14 | 8 |
| Lym/Leu, Change to Normal or No Change | 18 | 4 |
| Lym/Leu, Increase to High | 7 | 11 |
| Mono/Leu, Decrease to Low | 8 | 4 |
| Mono/Leu, Change to Normal or No Change | 21 | 9 |
| Mono/Leu, Increase to High | 13 | 10 |
| Neu/Leu, Decrease to Low | 8 | 11 |
| Neu/Leu, Change to Normal or No Change | 17 | 4 |
| Neu/Leu, Increase to High | 11 | 9 |
Blood samples were collected for evaluation of hematology parameters. The summaries of maximum grade increase from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE version 5.0. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. \[White Blood Cells (WBC)\]
| Participants | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone |
|---|---|---|
| Anemia, Increase (Inc) G1-G4 | 87 | 57 |
| Anemia, Inc G2-G4 | 73 | 39 |
| Anemia, Inc G3-G4 | 39 | 21 |
| Hemoglobin increased, Inc G1-G4 | 6 | 0 |
| Hemoglobin increased, Inc G2-G4 | 1 | 0 |
| Hemoglobin increased, Inc G3-G4 | 1 | 0 |
| Lymphocyte count decreased, Inc G1-G4 | 105 | 71 |
| Lymphocyte count decreased, Inc G2-G4 | 77 | 55 |
| Lymphocyte count decreased, Inc G3-G4 | 43 | 27 |
| Lymphocyte count increased, Inc G1-G4 | 8 | 4 |
| Lymphocyte count increased, Inc G2-G4 | 8 | 4 |
| Lymphocyte count increased, Inc G3-G4 | 0 | 0 |
| Neutrophil count decreased, Inc G1-G4 | 96 | 83 |
| Neutrophil count decreased, Inc G2-G4 | 71 | 76 |
| Neutrophil count decreased, Inc G3-G4 | 32 | 58 |
| Platelet count decreased, Inc G1-G4 | 145 | 62 |
| Platelet count decreased, Inc G2-G4 | 98 | 38 |
| Platelet count decreased, Inc G3-G4 | 67 | 21 |
| Eosi, Inc G1-G4 | 33 | 34 |
| WBC decreased, Inc G1-G4 | 91 | 83 |
| WBC decreased, Inc G2-G4 | 61 | 69 |
| WBC decreased, Inc G3-G4 | 24 | 34 |
Blood samples were collected for evaluation of clinical chemistry parameters. The summaries of worst-case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE v5.0. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. \[Kappa Light (K Lt), Lambda (λ),Monoclonal (Mc), Protein (P), Change (Cge), Alpha (α), Beta (β), Creatine Kinase (CK), Gamma (γ) ,Immunoglobulin (I-Globulin), Indirect (In.)\]
| Participants | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone |
|---|---|---|
| Calcium, Decrease to Low | 42 | 40 |
| Calcium, Change to Normal (N) or No Change | 138 | 49 |
| Calcium, Increase to High | 39 | 10 |
| Carbon Dioxide, Decrease to Low | 61 | 28 |
| Carbon Dioxide, Change to N or No Change | 93 | 44 |
| Carbon Dioxide, Increase to High | 31 | 12 |
| Chloride, Decrease to Low | 30 | 12 |
| Chloride, Change to N or No Change | 132 | 56 |
| Chloride, Increase to High | 54 | 31 |
| Protein, Decrease to Low | 63 | 42 |
| Protein, Change to N or No Change | 135 | 51 |
| Protein, Increase to High | 19 | 6 |
| K Lt C (Chain), Decrease to Low | 30 | 7 |
| K Lt C, Change to N or No Change | 169 | 78 |
| K Lt C, Increase to High | 9 | 13 |
| K Lt C,Free, Decrease to Low | 3 | 3 |
| K Lt C, Free, Change to N or No Change | 18 | 4 |
| K Lt C, Free, Increase to High | 9 | 4 |
| K Lt C,Free/λ Lt C, Decrease to Low | 4 | 1 |
| K Lt C,Free/λ Lt C, Change to N or No Change | 10 | 5 |
| K Lt C,Free/λ Lt C, Increase to High | 13 | 5 |
| λ Lt C, Decrease to Low | 46 | 2 |
| λ Lt C, Change to N or No Change | 159 | 83 |
| λ Lt C, Increase to High | 5 | 13 |
| λ Lt C, Free, Decrease to Low | 12 | 3 |
| λ Lt C, Free, Change to N or No Change | 12 | 7 |
| λ Lt C, Free, Increase to High | 5 | 1 |
| Mc Protein, Change to N or No Change | 11 | 6 |
| Mc Protein, Increase to High | 18 | 3 |
| Mc Protein Spike, Change to N or No Change | 193 | 88 |
| Mc Protein Spike, Increase to High | 7 | 1 |
| Mc P Spike/Total P, Cge to N or No Cge | 193 | 88 |
| Mc P Spike/Total P, Increase to High | 7 | 1 |
| No. of Mc P Spikes, Cge to N or No Cge | 193 | 88 |
| No. of Mc P Spikes, Increase to High | 7 | 1 |
| α -1 Globulin/Total P, Decrease to Low | 6 | 1 |
| α -1 Globulin/Total P,Cge to N or No Cge | 103 | 41 |
| α -1 Globulin/Total P, Increase to High | 104 | 57 |
| α -2 Globulin/Total P, Decrease to Low | 14 | 3 |
| α -2 Globulin/Total P, Cge to N or No Cge | 127 | 47 |
| α -2 Globulin/Total P, Increase to High | 72 | 49 |
| β -2 microglobulin, Cge to N or No Cge | 41 | 18 |
| β -2 microglobulin, Increase to High | 1 | 1 |
| CK , Increase to High | 0 | 1 |
| Direct Bilirubin, Decrease to Low | 2 | 1 |
| Direct Bilirubin, Cge to N or No Cge | 143 | 60 |
| Direct Bilirubin, Increase to High | 46 | 30 |
| γ Globulin/Total P, Decrease to Low | 50 | 17 |
| γ Globulin/Total P, Cge to N or No Cge | 157 | 77 |
| γ Globulin/Total P, Increase to High | 6 | 5 |
| I-Globulin A, Decrease to Low | 2 | 0 |
| I-Globulin A, Cge to N or No Cge | 13 | 0 |
| I-Globulin A,, Increase to High | 0 | 1 |
| I-Globulin G, Decrease to Low | 2 | 0 |
| I-Globulin G, Change to Normal or No Change | 7 | 0 |
| I-Globulin G, Increase to High | 1 | 1 |
| I-Globulin M, Decrease to Low | 4 | 2 |
| I-Globulin M, Cge to N or No Cge | 12 | 2 |
| In. Bilirubin, Decrease to Low | 1 | 0 |
| In. Bilirubin, Cge to N or No Cge | 0 | 1 |
| In. Bilirubin, Increase to High | 1 | 1 |
| Phosphate, Decrease to Low | 56 | 42 |
| Phosphate, Cge to N or No Cge | 123 | 43 |
| Phosphate, Increase to High | 39 | 12 |
| Thyrotropin, Decrease to Low | 6 | 2 |
| Thyrotropin, Cge to N or No Cge | 42 | 13 |
| Thyrotropin, Increase to High | 18 | 7 |
| Thyroxine, Decrease to Low | 10 | 6 |
| Thyroxine, Cge to N or No Cge | 42 | 12 |
| Thyroxine, Increase to High | 13 | 3 |
| Troponin I, Increase to High | 1 | 1 |
| Urate, Decrease to Low | 46 | 14 |
| Urate, Cge to N or No Cge | 128 | 67 |
| Urate, Increase to High | 44 | 17 |
| Urea Nitrogen, Decrease to Low | 10 | 4 |
| Urea Nitrogen, Cge to N or No Cge | 40 | 19 |
| Urea Nitrogen, Increase to High | 37 | 17 |
Blood samples were collected for evaluation of clinical chemistry parameters. The summaries of maximum grade increase from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. \[Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Aspartate Aminotransferase (AST), Creatine Kinase (CPK), Gamma Glutamyl Transferase (GGT)\]
| Participants | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone |
|---|---|---|
| ALT Inc,G1-G4 | 84 | 25 |
| ALT Inc, G2-G4 | 13 | 5 |
| ALT Inc, G3-G4 | 3 | 2 |
| ALP Inc, G1-G4 | 93 | 17 |
| ALP Inc, G2-G4 | 18 | 2 |
| ALP Inc, G3-G4 | 2 | 0 |
| AST Inc, G1-G4 | 153 | 15 |
| AST Inc, G2-G4 | 21 | 2 |
| AST Inc, G3-G4 | 4 | 1 |
| Blood bilirubin Inc, G1-G4 | 37 | 18 |
| Blood bilirubin Inc, G2-G4 | 11 | 3 |
| Blood bilirubin Inc, G3-G4 | 2 | 0 |
| CPK increased, Inc to G1-G4 | 57 | 5 |
| CPK increased, Inc to G2-G4 | 14 | 1 |
| CPK increased, Inc to G3-G4 | 3 | 1 |
| Creatinine increased, G1-G4 | 91 | 40 |
| Creatinine increased, G2-G4 | 40 | 15 |
| Creatinine increased, G3-G4 | 6 | 2 |
| GGT increased, G1-G4 | 113 | 23 |
| GGT increased, G2-G4 | 51 | 8 |
| GGT increased, G3-G4 | 22 | 4 |
| Hyperkalemia, Inc to G1-G4 | 18 | 10 |
| Hyperkalemia, Inc to G2-G4 | 6 | 5 |
| Hyperkalemia, Inc to G3-G4 | 2 | 2 |
| Hypermagnesemia, Inc to G1-G4 | 20 | 7 |
| Hypermagnesemia, Inc to G2-G4 | 2 | 1 |
| Hypermagnesemia, Inc to G3-G4 | 2 | 1 |
| Hypernatremia, Inc to G1-G4 | 19 | 10 |
| Hypernatremia, Inc to G2-G4 | 3 | 1 |
| Hypernatremia, Inc to G3-G4 | 2 | 1 |
| Hypoalbuminemia, Inc to G1-G4 | 74 | 41 |
| Hypoalbuminemia, Inc to G2-G4 | 33 | 14 |
| Hypoalbuminemia, Inc to G3-G4 | 4 | 2 |
| Hypoglycemia, Inc to G1-G4 | 21 | 6 |
| Hypoglycemia, Inc to G2-G4 | 3 | 1 |
| Hypoglycemia, Inc to G3-G4 | 0 | 0 |
| Hypomagnesemia, Inc to G1- G4 | 39 | 26 |
| Hypomagnesemia, Inc to G2-G4 | 8 | 3 |
| Hypomagnesemia, Inc to G3-G4 | 3 | 0 |
| Hypercalcemia, Inc to G1- G4 | 58 | 17 |
| Hypercalcemia, Inc to G2- G4 | 12 | 5 |
| Hypercalcemia, Inc to G3- G4 | 7 | 2 |
| Hypocalcemia, Inc to G1- G4 | 47 | 44 |
| Hypocalcemia, Inc to G2- G4 | 8 | 6 |
| Hypocalcemia, Inc to G3- G4 | 2 | 0 |
| Chronic Kidney Disease (CKD), Inc to G1- G4 | 60 | 26 |
| CKD, Inc to G2- G4 | 54 | 25 |
| CKD, Inc to G3- G4 | 10 | 11 |
| Lactate dehydrogenase(LDH),Inc to G1- G4 | 132 | 24 |
Urine samples were analyzed for spot urine albumin/creatinine ratio (UACR)\[milligrams/grams (mg/g)\]. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. The "worst post-baseline value" is defined as the highest UACR measurement recorded for a participant after the baseline assessment and up to the end of the study observation period. The "shift" will be calculated as the difference between this worst post-baseline UACR value and the baseline UACR value (Worst Post-Baseline UACR - Baseline UACR). Each category is reported as "Baseline category, Worst post-baseline category." Ranges are inclusive and expressed as \[lower-upper\].
| Participants | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone |
|---|---|---|
| Baseline [< 500, < 500] | 129 | 57 |
| Worst post-baseline [< 500, (500, 2000)] | 25 | 2 |
| Worst post-baseline [< 500, > 2000] | 5 | 0 |
| Worst post-baseline [< 500, Missing] | 23 | 16 |
| Worst post-baseline [(500, 2000), < 500] | 2 | 1 |
| Worst post-baseline [(500, 2000), (500, 2000)] | 2 | 0 |
| Worst post-baseline [(500, 2000), > 2000] | 1 | 0 |
| Worst post-baseline [(500, 2000), Missing] | 0 | 0 |
| Worst post-baseline [> 2000, < 500] | 0 | 0 |
| Worst post-baseline [> 2000, (500, 2000)] | 0 | 0 |
| Worst post-baseline [> 2000, > 2000] | 1 | 0 |
| Worst post-baseline [> 2000, Missing] | 0 | 0 |
| Worst post-baseline [Missing, < 500] | 21 | 17 |
| Worst post-baseline [Missing, (500, 2000)] | 2 | 0 |
| Worst post-baseline [Missing, > 2000] | 1 | 0 |
| Worst post-baseline [Missing, Missing] | 5 | 9 |
BCVA score was assessed individually for each eye. BCVA score was calculated based on the Logarithm of the Minimum Angle of Resolution (logMAR score). Any worst-case change from baseline categories are presented for right and left eyes. BCVA test scores were categorized as no change/improved vision, possible worsened vision and definite worsened vision. No change/improved vision was defined as a change from baseline \<0.12 logMAR score; a possible worsened vision was defined as a change from baseline \>=0.12 to \<0.3 logMAR score; a definite worsened vision was defined as a change from baseline \>=0.3 logMAR score. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
| Participants | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone |
|---|---|---|
| Left Eye — >=3 line decrease | 78 | 5 |
| Left Eye — >=2 but < 3 line decrease | 29 | 6 |
| Left Eye — >=1 but < 2 line decrease | 28 | 10 |
| Left Eye — <1 line decrease or any increase | 68 | 41 |
| Right Eye — >=3 line decrease | 84 | 5 |
| Right Eye — >=2 but < 3 line decrease | 26 | 4 |
| Right Eye — >=1 but < 2 line decrease | 29 | 8 |
| Right Eye — <1 line decrease or any increase | 64 | 45 |
| Worst Eye — >=3 line decrease | 98 | 7 |
| Worst Eye — >=2 but < 3 line decrease | 25 | 7 |
| Worst Eye — >=1 but < 2 line decrease | 30 | 15 |
| Worst Eye — <1 line decrease or any increase | 50 | 33 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin
| Micrograms per milliliter (ug/mL) | Belantamab Mafodotin |
|---|---|
| C1 D1, Pre-dose | 0.3692 ± 4.95969 |
| C1 D1, EOI | 47.3332 ± 16.96867 |
| C1 D1, SOI + 2 hours | 41.5745 ± 16.93490 |
| C1 D2, SOI + 24 hours | 27.6062 ± 9.78065 |
| C1 D4 | 14.0901 ± 6.98060 |
| C1 D8-15 | 5.3548 ± 3.73879 |
| C1 D22 | 1.7940 ± 1.49303 |
| C2 D1 | 34.8667 ± 33.36770 |
| C2 D1, Pre-dose | 2.4459 ± 5.19465 |
| C2 D1, EOI | 50.3281 ± 19.73235 |
| C3 D1 | 24.6770 ± 23.95059 |
| C3 D1, Pre-dose | 3.2534 ± 4.96069 |
| C3 D1, EOI | 48.0512 ± 21.57493 |
| C3 D1, SOI + 2 hours | 42.4683 ± 18.02709 |
| C3 D2 | 35.2500 ± 2.33345 |
| C3 D2, SOI + 24 hours | 32.8751 ± 12.45517 |
| C3 D4 | 21.5897 ± 12.95046 |
| C3 D8-15 | 8.9996 ± 4.50886 |
| C3 D22 | 3.2830 ± 1.95202 |
| C4 D1 | 36.3300 ± 44.22246 |
| C4 D1, Pre-dose | 3.7620 ± 5.53119 |
| C4 D1, EOI | 49.9998 ± 17.69286 |
| C6 D1 | 68.6000 ± NA |
| C6 D1, Pre-dose | 3.4671 ± 2.09208 |
| C6 D1, EOI | 47.2153 ± 22.86249 |
| C9 D1, Pre-dose | 3.9596 ± 2.61261 |
| C12 D1, Pre-dose | 5.6298 ± 6.30104 |
| C18 D1, Pre-dose | 4.7952 ± 2.38870 |
| C24 D1, Pre-dose | 4.9518 ± 2.60878 |
| C30 D1, Pre-dose | 4.5167 ± 3.14142 |
| C36 D1, Pre-dose | 5.3687 ± 4.47411 |
| C42 D1, Pre-dose | 1.2400 ± NA |
| EOT (~242 weeks) | 2.9678 ± 7.67752 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin
| ug/mL | Belantamab Mafodotin |
|---|---|
| C1 D1, Pre-dose | 0.5379 ± 5.58667 |
| C1 D1, EOI | 44.2483 ± 14.91713 |
| C1 D1, SOI + 24 hours | 41.2999 ± 14.01003 |
| C1 D2, SOI+ 24 hours | 32.7096 ± 11.17415 |
| C1 D4 | 20.9259 ± 8.82782 |
| C1 D8-15 | 12.2688 ± 6.20180 |
| C1 D22 | 5.9391 ± 4.89415 |
| C2 D1 | 32.0000 ± 28.37622 |
| C2 D1, Pre-dose | 6.2446 ± 5.39820 |
| C2 D1, EOI | 51.3993 ± 21.28458 |
| C3 D1 | 29.8917 ± 25.68839 |
| C3 D1, Pre-dose | 10.4384 ± 8.69143 |
| C3 D1, EOI | 54.5050 ± 22.63257 |
| C3 D1, SOI + 24 hours | 48.7361 ± 20.09005 |
| C3 D2 | 50.3500 ± 0.49497 |
| C3 D2, SOI + 24 hours | 44.6118 ± 15.68169 |
| C3 D4 | 33.1541 ± 14.83313 |
| C3 D8-15 | 23.7107 ± 11.14934 |
| C3 D22 | 13.0207 ± 8.94586 |
| C4 D1 | 41.2000 ± 31.11270 |
| C4 D1, Pre-dose | 13.1691 ± 10.19527 |
| C4 D1, EOI | 57.9805 ± 20.36662 |
| C6 D1 | 77.3000 ± NA |
| C6 D1, Pre-dose | 14.8742 ± 9.94411 |
| C6 D1, EOI | 57.0211 ± 32.13534 |
| C9 D1, Pre-dose | 16.1902 ± 10.42646 |
| C12 D1, Pre-dose | 18.3373 ± 12.66464 |
| C18 D1, Pre-dose | 24.4376 ± 15.48838 |
| C24 D1, Pre-dose | 21.7079 ± 12.62491 |
| C30 D1, Pre-dose | 19.8650 ± 14.43844 |
| C36 D1, Pre-dose | 24.3000 ± 21.96383 |
| C42 D1, Pre-dose | 4.5600 ± NA |
| EOT (~242 weeks) | 8.3097 ± 9.58575 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin
| ug/mL | Belantamab Mafodotin |
|---|---|
| C1 D1, Pre-dose | 0.00482 ± 0.048935 |
| C1 D1, EOI | 0.50257 ± 0.385958 |
| C1 D1, SOI + 2 hours | 0.52993 ± 0.308119 |
| C1 D2, SOI + 24 hours | 1.24435 ± 0.944185 |
| C1 D4 | 0.75975 ± 0.499179 |
| C1 D8-15 | 0.16905 ± 0.163228 |
| C1 D22 | 0.00236 ± 0.011322 |
| C2 D1 | 0.27226 ± 0.372987 |
| C2 D1, Pre-dose | 0.00314 ± 0.025276 |
| C2 D1, EOI | 0.52055 ± 0.431549 |
| C3 D1 | 0.24057 ± 0.283128 |
| C3 D1, Pre-dose | 0.01507 ± 0.091695 |
| C3 D1, EOI | 0.50649 ± 0.396744 |
| C3 D1, SOI+ 2 hours | 0.50982 ± 0.338394 |
| C3 D2 | 0.61414 ± 0.552990 |
| C3 D2, SOI + 24 hours | 0.80486 ± 0.477242 |
| C3 D4 | 0.55168 ± 0.279372 |
| C3 D8-15 | 0.15658 ± 0.109425 |
| C3 D22 | 0.00000 ± 0.000000 |
| C4 D1 | 0.44550 ± 0.676984 |
| C4 D1, Pre-dose | 0.01072 ± 0.046683 |
| C4 D1, EOI | 0.48903 ± 0.313553 |
| C6 D1 | 0.20500 ± 0.222222 |
| C6 D1, Pre-dose | 0.00247 ± 0.011594 |
| C6 D1, EOI | 0.44992 ± 0.272831 |
| C9 D1 | 0.08611 ± 0.258333 |
| C9 D1, Pre-dose | 0.04322 ± 0.289200 |
| C12 D1 | 0.00000 ± 0.000000 |
| C12 D1, Pre-dose | 0.01859 ± 0.080759 |
| C18 D1 | 0.000000 ± 0.000000 |
| C18 D1, Pre-dose | 0.00884 ± 0.025477 |
| C24 D1 | 0.000000 ± NA |
| C24 D1, Pre-dose | 0.00000 ± 0.000000 |
| C30 D1 | 0.000000 ± NA |
| C30 D1, Pre-dose | 0.00000 ± 0.000000 |
| C36 D1, Pre-dose | 0.00000 ± 0.000000 |
| C42 D1, Pre-dose | 0.00000 ± 0.00000 |
| EOT (~242 weeks) | 0.03551 ± 0.114319 |
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers.
| Participants | Belantamab Mafodotin |
|---|---|
| Number of Participants With Post-baseline Positive Anti-Drug Antibody (ADAs) Against Belantamab Mafodotin | 1 |
Serum samples were collected and tested for the presence of antibodies against belantamab mafodotin . Confirmed positive ADA samples were further analyzed to obtain the titer of the antibodies. Titers of anti-drug antibodies against belantamab mafodotin is presented.
| Titer | Belantamab Mafodotin |
|---|---|
| Titers of ADAs Against Belantamab Mafodotin | 200 (NA to NA) |
PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE. It includes symptomatic toxicities drawn from the CTCAE like blurred vision, chills, constipation, decreased appetite, fatigue, general pain, mouth/throat sores, nausea, nosebleed, shortness of breath, vomiting, watery eyes, cough, itchy, loose/watery stools, Numb/Tingling Hands/Feet (N/T H/F), Pain/Burning (P/B) and Problems Tasting Food/Drink (Prob Tasting F/D) . Items are scored individually on a 0 to 4 scale for severity, frequency and interference. A score of 0 indicates no symptom or interference, while higher score of 4 signify increasing severity, frequency, and interference with daily activities.
| Participants | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone |
|---|---|---|
| Blurred Vision, Severity, 0 | 40 | 31 |
| Blurred Vision, Severity, 1 | 50 | 32 |
| Blurred Vision, Severity, 2 | 50 | 21 |
| Blurred Vision, Severity, 3 | 43 | 8 |
| Blurred Vision, Severity, 4 | 24 | 2 |
| Blurred Vision, Severity, 3+4 | 67 | 10 |
| Blurred Vision, Severity, Any Scale >0 | 167 | 63 |
| Blurred Vision, Interference, 0 | 14 | 7 |
| Blurred Vision, Interference, 1 | 46 | 31 |
| Blurred Vision, Interference, 2 | 38 | 15 |
| Blurred Vision, Interference, 3 | 40 | 7 |
| Blurred Vision, Interference, 4 | 29 | 3 |
| Blurred Vision, Interference, 3+4 | 69 | 10 |
| Blurred Vision, Interference, Any Scale >0 | 153 | 56 |
| Constipation, Severity, 0 | 87 | 38 |
| Constipation, Severity, 1 | 62 | 22 |
| Constipation, Severity, 2 | 26 | 17 |
| Constipation, Severity, 3 | 20 | 14 |
| Constipation, Severity, 4 | 12 | 3 |
| Constipation, Severity, 3+4 | 32 | 17 |
| Constipation, Severity, Any Scale >0 | 120 | 56 |
| Decreased Appetite, Severity, 0 | 57 | 36 |
| Decreased Appetite, Severity, 1 | 75 | 34 |
| Decreased Appetite, Severity, 2 | 44 | 15 |
| Decreased Appetite, Severity, 3 | 23 | 5 |
| Decreased Appetite, Severity, 4 | 8 | 4 |
| Decreased Appetite, Severity, 3+4 | 31 | 9 |
| Decreased Appetite, Severity, Any Scale >0 | 150 | 58 |
| Decreased Appetite, Interference, 0 | 43 | 17 |
| Decreased Appetite, Interference, 1 | 51 | 20 |
| Decreased Appetite, Interference, 2 | 29 | 13 |
| Decreased Appetite, Interference, 3 | 19 | 5 |
| Decreased Appetite, Interference, 4 | 8 | 3 |
| Decreased Appetite, Interference, 3+4 | 27 | 8 |
| Decreased Appetite, Interference, Any Scale >0 | 107 | 41 |
| Fatigue, Severity, 0 | 19 | 8 |
| Fatigue, Severity, 1 | 50 | 21 |
| Fatigue, Severity, 2 | 77 | 35 |
| Fatigue, Severity, 3 | 42 | 19 |
| Fatigue, Severity, 4 | 19 | 11 |
| Fatigue, Severity, 3+4 | 61 | 30 |
| Fatigue, Severity, Any Scale >0 | 188 | 86 |
| Fatigue, Interference, 0 | 9 | 4 |
| Fatigue, Interference, 1 | 46 | 26 |
| Fatigue, Interference, 2 | 64 | 25 |
| Fatigue, Interference, 3 | 44 | 17 |
| Fatigue, Interference, 4 | 25 | 14 |
| Fatigue, Interference, 3+4 | 69 | 31 |
| Fatigue, Interference, Any Scale >0 | 179 | 82 |
| General Pain, Frequency, 0 | 85 | 46 |
| General Pain, Frequency, 1 | 61 | 26 |
| General Pain, Frequency, 2 | 35 | 16 |
| General Pain, Frequency, 3 | 17 | 5 |
| General Pain, Frequency, 4 | 9 | 1 |
| General Pain, Frequency, 3+4 | 26 | 6 |
| General Pain, Frequency, Any Scale >0 | 122 | 48 |
| General Pain, Severity, 0 | 14 | 3 |
| General Pain, Severity, 1 | 59 | 26 |
| General Pain, Severity, 2 | 28 | 15 |
| General Pain, Severity, 3 | 18 | 3 |
| General Pain, Severity, 4 | 3 | 1 |
| General Pain, Severity, 3+4 | 21 | 4 |
| General Pain, Severity, Any Scale >0 | 108 | 45 |
| General Pain, Interference, 0 | 22 | 15 |
| General Pain, Interference, 1 | 50 | 18 |
| General Pain, Interference, 2 | 19 | 10 |
| General Pain, Interference, 3 | 14 | 1 |
| General Pain, Interference, 4 | 3 | 1 |
| General Pain, Interference, 3+4 | 17 | 2 |
| General Pain, Interference, Any Scale >0 | 86 | 30 |
| Mouth/Throat Sores, Severity, 0 | 132 | 58 |
| Mouth/Throat Sores, Severity, 1 | 44 | 20 |
| Mouth/Throat Sores, Severity, 2 | 22 | 11 |
| Mouth/Throat Sores, Severity, 3 | 6 | 4 |
| Mouth/Throat Sores, Severity, 4 | 3 | 1 |
| Mouth/Throat Sores, Severity, 3+4 | 9 | 5 |
| Mouth/Throat Sores, Severity, Any Scale >0 | 75 | 36 |
| Mouth/Throat Sores, Interference, 0 | 23 | 15 |
| Mouth/Throat Sores, Interference, 1 | 33 | 14 |
| Mouth/Throat Sores, Interference, 2 | 10 | 2 |
| Mouth/Throat Sores, Interference, 3 | 5 | 3 |
| Mouth/Throat Sores, Interference, 4 | 4 | 2 |
| Mouth/Throat Sores, Interference, 3+4 | 9 | 5 |
| Mouth/Throat Sores, Interference, Any Scale >0 | 52 | 21 |
| Nausea, Frequency, 0 | 97 | 54 |
| Nausea, Frequency, 1 | 54 | 23 |
| Nausea, Frequency, 2 | 32 | 13 |
| Nausea, Frequency, 3 | 17 | 4 |
| Nausea, Frequency, 4 | 7 | 0 |
| Nausea, Frequency, 3+4 | 24 | 4 |
| Nausea, Frequency, Any Scale >0 | 110 | 40 |
| Nausea, Severity, 0 | 10 | 8 |
| Nausea, Severity, 1 | 55 | 19 |
| Nausea, Severity, 2 | 26 | 9 |
| Nausea, Severity, 3 | 17 | 4 |
| Nausea, Severity, 4 | 2 | 0 |
| Nausea, Severity, 3+4 | 19 | 4 |
| Nausea, Severity, Any Scale >0 | 100 | 32 |
| Nosebleeds, Frequency, 0 | 127 | 74 |
| Nosebleeds, Frequency, 1 | 51 | 15 |
| Nosebleeds, Frequency, 2 | 20 | 3 |
| Nosebleeds, Frequency, 3 | 6 | 1 |
| Nosebleeds, Frequency, 4 | 3 | 1 |
| Nosebleeds, Frequency, 3+4 | 9 | 2 |
| Nosebleeds, Frequency, Any Scale >0 | 80 | 20 |
| Nosebleeds, Severity, 0 | 12 | 6 |
| Nosebleeds, Severity, 1 | 46 | 12 |
| Nosebleeds, Severity, 2 | 14 | 1 |
| Nosebleeds, Severity, 3 | 5 | 1 |
| Nosebleeds, Severity, 4 | 3 | 0 |
| Nosebleeds, Severity, 3+4 | 8 | 1 |
| Nosebleeds, Severity, Any Scale >0 | 68 | 14 |
| Shivering/Shaking Chills, Frequency, 0 | 102 | 43 |
| Shivering/Shaking Chills, Frequency, 1 | 52 | 25 |
| Shivering/Shaking Chills, Frequency, 2 | 34 | 12 |
| Shivering/Shaking Chills, Frequency, 3 | 17 | 13 |
| Shivering/Shaking Chills, Frequency, 4 | 2 | 1 |
| Shivering/Shaking Chills, Frequency, 3+4 | 19 | 14 |
| Shivering/Shaking Chills, Frequency, Any Scale >0 | 105 | 51 |
| Shivering/Shaking Chills, Severity, 0 | 11 | 6 |
| Shivering/Shaking Chills, Severity, 1 | 59 | 23 |
| Shivering/Shaking Chills, Severity, 2 | 25 | 11 |
| Shivering/Shaking Chills, Severity, 3 | 9 | 10 |
| Shivering/Shaking Chills, Severity, 4 | 1 | 1 |
| Shivering/Shaking Chills, Severity, 3+4 | 10 | 11 |
| Shivering/Shaking Chills, Severity, Any Scale >0 | 94 | 45 |
| Shortness of Breath, Severity, 0 | 66 | 24 |
| Shortness of Breath, Severity, 1 | 68 | 32 |
| Shortness of Breath, Severity, 2 | 45 | 22 |
| Shortness of Breath, Severity, 3 | 20 | 9 |
| Shortness of Breath, Severity, 4 | 8 | 7 |
| Shortness of Breath, Severity, 3+4 | 28 | 16 |
| Shortness of Breath, Severity, Any Scale >0 | 141 | 70 |
| Vomiting, Frequency, 0 | 158 | 81 |
| Vomiting, Frequency, 1 | 27 | 7 |
| Vomiting, Frequency, 2 | 12 | 4 |
| Vomiting, Frequency, 3 | 10 | 2 |
| Vomiting, Frequency, 4 | 0 | 0 |
| Vomiting, Frequency, 3+4 | 10 | 2 |
| Vomiting, Frequency, Any Scale >0 | 49 | 13 |
| Vomiting, Severity, 0 | 5 | 1 |
| Vomiting, Severity, 1 | 23 | 6 |
| Vomiting, Severity, 2 | 14 | 5 |
| Vomiting, Severity, 3 | 6 | 1 |
| Vomiting, Severity, 4 | 1 | 0 |
| Vomiting, Severity, 3+4 | 7 | 1 |
| Vomiting, Severity, Any Scale >0 | 44 | 12 |
| Watery Eyes, Severity, 0 | 76 | 41 |
| Watery Eyes, Severity, 1 | 60 | 39 |
| Watery Eyes, Severity, 2 | 42 | 11 |
| Watery Eyes, Severity, 3 | 27 | 3 |
| Watery Eyes, Severity, 4 | 2 | 0 |
| Watery Eyes, Severity, 3+4 | 29 | 3 |
| Watery Eyes, Severity, Any Scale >0 | 131 | 53 |
| Watery Eyes, Interference, 0 | 15 | 16 |
| Watery Eyes, Interference, 1 | 61 | 27 |
| Watery Eyes, Interference, 2 | 32 | 7 |
| Watery Eyes, Interference, 3 | 18 | 2 |
| Watery Eyes, Interference, 4 | 5 | 1 |
| Watery Eyes, Interference, 3+4 | 23 | 3 |
| Watery Eyes, Interference, Any Scale >0 | 116 | 37 |
| Cough, Severity, 0 | 103 | 43 |
| Cough, Severity, 1 | 69 | 28 |
| Cough, Severity, 2 | 17 | 16 |
| Cough, Severity, 3 | 15 | 6 |
| Cough, Severity, 4 | 3 | 1 |
| Cough, Severity, 3+4 | 18 | 7 |
| Cough, Severity, Any Scale >0 | 104 | 51 |
| Cough, Interference, 0 | 32 | 16 |
| Cough, Interference, 1 | 44 | 18 |
| Cough, Interference, 2 | 20 | 10 |
| Cough, Interference, 3 | 4 | 7 |
| Cough, Interference, 4 | 4 | 0 |
| Cough, Interference, 3+4 | 8 | 7 |
| Cough, Interference, Any Scale >0 | 72 | 35 |
| Itchy, Severity, 0 | 98 | 52 |
| Itchy, Severity, 1 | 75 | 24 |
| Itchy, Severity, 2 | 24 | 15 |
| Itchy, Severity, 3 | 6 | 3 |
| Itchy, Severity, 4 | 4 | 0 |
| Itchy, Severity, 3+4 | 10 | 3 |
| Itchy, Severity, Any Scale >0 | 109 | 42 |
| Loose/Watery Stools, Frequency, 0 | 86 | 40 |
| Loose/Watery Stools, Frequency, 1 | 48 | 27 |
| Loose/Watery Stools, Frequency, 2 | 37 | 14 |
| Loose/Watery Stools, Frequency, 3 | 22 | 9 |
| Loose/Watery Stools, Frequency, 4 | 14 | 4 |
| Loose/Watery Stools, Frequency, 3+4 | 36 | 13 |
| Loose/Watery Stools, Freq., Any Scale >0 | 121 | 54 |
| N/T H/F, Severity, 0 | 50 | 26 |
| N/T H/F, Severity, 1 | 70 | 25 |
| N/T H/F, Severity, 2 | 54 | 31 |
| N/T H/F, Severity, 3 | 23 | 11 |
| N/T H/F, Severity, 4 | 10 | 1 |
| N/T H/F, Severity, 3+4 | 33 | 12 |
| N/T H/F, Severity, Any Scale >0 | 157 | 68 |
| N/T H/F, Interference, 0 | 34 | 12 |
| N/T H/F, Interference, 1 | 57 | 27 |
| N/T H/F, Interference, 2 | 43 | 20 |
| N/T H/F, Interference, 3 | 13 | 5 |
| N/T H/F, Interference, 4 | 10 | 4 |
| N/T H/F, Interference, 3+4 | 23 | 9 |
| N/T H/F, Interference, Any Scale >0 | 123 | 56 |
| P/B Urination, Severity, 0 | 135 | 68 |
| P/B Urination, Severity, 1 | 49 | 17 |
| P/B Urination, Severity, 2 | 18 | 6 |
| P/B Urination, Severity, 3 | 4 | 2 |
| P/B Urination, Severity, 4 | 1 | 1 |
| P/B Urination, Severity, 3+4 | 5 | 3 |
| P/B Urination, Severity, Any Scale >0 | 72 | 26 |
| Prob Tasting F/D, Severity, 0 | 108 | 51 |
| Prob Tasting F/D, Severity, 1 | 57 | 24 |
| Prob Tasting F/D, Severity, 2 | 24 | 9 |
| Prob Tasting F/D, Severity, 3 | 15 | 6 |
| Prob Tasting F/D, Severity, 4 | 3 | 4 |
| Prob Tasting F/D, Severity, 3+4 | 18 | 10 |
| Prob Tasting F/D, Severity, Any Scale >0 | 99 | 43 |
OSDI is 12-item patient-reported outcomes questionnaire designed to provide rapid assessment of range of ocular surface symptoms, including symptoms related to chronic dry eye, severity, and impact on patient's ability to function. In addition to an overall score, there are three subscales of OSDI: ocular symptoms, vision-related function, and environmental triggers. OSDI items are scored on a 0 to 4 Likert-type scale, where 0 = None of the time and 4 = All of the time. Total OSDI score = (\[sum of scores for all questions answered×100\]/\[total number of questions answered×4\]). Subscale scores are computed similarly with only questions from each subscale used to generate its own score. Any subscales analyzed separately would also have a maximum possible score of 100. A score of 100=to complete disability, while a score of 0=to no disability. Decrease in score from baseline means improvement
| Scores on Scale | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone |
|---|---|---|
| CFB to Week 4 | 2.59 ± 17.476 | 1.41 ± 12.547 |
| CFB to Week 7 | 13.07 ± 25.989 | 1.66 ± 14.990 |
| CFB to Week 10 | 15.29 ± 27.843 | 2.66 ± 19.075 |
| CFB to Week 13 | 13.38 ± 26.089 | 4.19 ± 16.918 |
| CFB to Week 16 | 13.26 ± 26.184 | 3.11 ± 18.073 |
| CFB to Week 19 | 10.80 ± 26.948 | 3.40 ± 20.072 |
| CFB to Week 22 | 11.90 ± 25.844 | 5.07 ± 20.162 |
| CFB to Week 25 | 10.80 ± 22.411 | 3.04 ± 15.127 |
| CFB to Week 28 | 10.00 ± 24.292 | 2.42 ± 16.637 |
| CFB to Week 31 | 11.59 ± 24.217 | 0.10 ± 14.473 |
| CFB to Week 34 | 12.78 ± 24.293 | -3.77 ± 16.175 |
| CFB to Week 37 | 11.12 ± 25.434 | -4.01 ± 13.960 |
| CFB to Week 40 | 11.94 ± 29.680 | 6.25 ± 30.021 |
| CFB to Week 43 | 9.94 ± 26.511 | -2.57 ± 13.078 |
| CFB to Week 46 | 13.39 ± 23.682 | -1.05 ± 10.973 |
| CFB to Week 49 | 9.43 ± 23.900 | -1.58 ± 10.344 |
| CFB to Week 52 | 8.50 ± 23.103 | -3.39 ± 11.210 |
| CFB to Week 55 | 6.71 ± 23.217 | -2.40 ± 11.789 |
| CFB to Week 58 | 8.06 ± 27.288 | -1.71 ± 11.305 |
| CFB to Week 61 | 9.86 ± 24.993 | -1.46 ± 13.508 |
| CFB to Week 64 | 11.15 ± 27.558 | -0.90 ± 11.579 |
| CFB to Week 67 | 8.72 ± 25.841 | -1.08 ± 12.042 |
| CFB to Week 70 | 5.82 ± 25.580 | 2.21 ± 7.068 |
| CFB to Week 73 | 10.00 ± 27.506 | 0.42 ± 12.045 |
| CFB to Week 76 | 13.64 ± 25.404 | 4.93 ± 10.105 |
| CFB to Week 79 | 11.45 ± 29.293 | 0.33 ± 10.061 |
| CFB to Week 82 | 7.54 ± 27.703 | -1.60 ± 10.799 |
| CFB to Week 85 | 9.21 ± 30.044 | -1.45 ± 14.926 |
| CFB to Week 88 | 8.16 ± 29.508 | -1.09 ± 12.537 |
| CFB to Week 91 | 14.39 ± 35.202 | -1.40 ± 15.058 |
| CFB to Week 94 | 7.34 ± 28.796 | -1.92 ± 17.782 |
| CFB to Week 97 | 12.80 ± 19.992 | 0.98 ± 15.164 |
| CFB to Week 100 | 11.67 ± 28.130 | 1.21 ± 14.782 |
| CFB to Week 103 | 7.19 ± 26.707 | -0.09 ± 18.537 |
| CFB to Week 106 | 5.40 ± 26.244 | -0.90 ± 20.060 |
| CFB to Week 109 | 4.79 ± 25.159 | 3.11 ± 15.098 |
| CFB to Week 112 | 3.31 ± 23.345 | -0.70 ± 18.898 |
| CFB to Week 115 | 3.20 ± 23.763 | 5.18 ± 14.995 |
| CFB to Week 118 | 6.93 ± 28.876 | 3.78 ± 22.276 |
| CFB to Week 121 | 4.59 ± 30.664 | 0.83 ± 21.583 |
| CFB to Week 124 | 6.22 ± 30.072 | 2.71 ± 25.931 |
| CFB to Week 127 | 0.62 ± 27.862 | 3.59 ± 20.142 |
| CFB to Week 130 | -0.38 ± 26.198 | -0.76 ± 26.377 |
| CFB to Week 133 | 4.17 ± 31.724 | 3.31 ± 27.578 |
| CFB to Week 136 | 4.67 ± 30.314 | -1.76 ± 28.117 |
| CFB to Week 139 | 12.31 ± 24.985 | 0.47 ± 26.057 |
| CFB to Week 142 | 1.71 ± 28.995 | -0.21 ± 37.083 |
| CFB to Week 145 | 10.39 ± 20.291 | -4.03 ± 25.715 |
| CFB to Week 151 | 6.42 ± 29.284 | -0.25 ± 30.276 |
| CFB to Week 154 | 5.96 ± 31.273 | 0.93 ± 28.401 |
| CFB to Week 157 | 1.62 ± 30.352 | -5.42 ± 35.933 |
| CFB to Week 160 | 5.59 ± 34.252 | -7.85 ± 32.500 |
| CFB to Week 163 | 2.02 ± 31.500 | -1.94 ± 42.950 |
| CFB to Week 166 | 7.78 ± 12.660 | 3.89 ± 29.360 |
| CFB to Week 169 | 2.43 ± 32.178 | -2.78 ± 39.240 |
| CFB to Week 172 | -5.88 ± 33.448 | -11.57 ± 30.185 |
| CFB to Week 175 | 6.06 ± 19.269 | 5.28 ± 37.364 |
| CFB to Week 178 | 2.83 ± 41.101 | 1.62 ± 30.108 |
| CFB to Week 181 | -6.07 ± 32.570 | 1.99 ± 42.043 |
| CFB to Week 184 | -1.11 ± 44.766 | 0.19 ± 32.223 |
| CFB to Week 187 | 0.73 ± 16.111 | 43.33 ± 15.321 |
| CFB to Week 193 | -16.07 ± 43.956 | 4.93 ± 37.846 |
| CFB to Week 196 | -9.58 ± 38.655 | 9.44 ± 44.098 |
| CFB to Week 199 | -6.96 ± 20.187 | -5.97 ± 23.810 |
| CFB to Week 202 | -11.72 ± 40.286 | -3.01 ± 9.857 |
| CFB to Week 208 | -14.13 ± 40.965 | 11.25 ± 15.910 |
| CFB to Week 211 | -19.11 ± 47.990 | 8.75 ± 12.374 |
| CFB to Week 214 | 13.61 ± 16.881 | 5.00 ± 7.071 |
| CFB to Week 217 | -48.96 ± 69.238 | 7.50 ± 10.607 |
| CFB to Week 220 | -9.29 ± 17.071 | 11.11 ± 15.713 |
| CFB to Week 223 | -31.84 ± 47.569 | 8.75 ± 12.374 |
| CFB to Week 226 | -42.79 ± 50.110 | 7.50 ± NA |
| CFB to Week 229 | -14.38 ± 20.329 | 15.00 ± NA |
| CFB to Week 232 | -42.10 ± 48.966 | 10.00 ± NA |
| CFB to Week 235 | -50.00 ± 70.711 | 20.00 ± NA |
| CFB to Week 238 | — | 15.00 ± NA |
| CFB to LFU (~263 weeks) | 2.81 ± 21.245 | 15.74 ± 9.755 |
| CFB to EOT (~242 weeks) | 11.77 ± 25.264 | 6.08 ± 18.132 |
The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning \[PF\], role functioning \[RF\], emotional functioning \[EF\] cognitive functioning \[CF\] and social functioning \[SF\]), three symptom scales (fatigue, nausea/vomiting \[N/V\] and pain), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (dyspnea, insomnia, appetite loss \[AL\], constipation, diarrhea and financial difficulties \[FD\]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Scores on Scale | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone |
|---|---|---|
| GHS, CFB to Week 4 | 0.47 ± 20.619 | -3.11 ± 23.198 |
| GHS, CFB to Week 7 | 0.57 ± 20.052 | -2.14 ± 23.279 |
| GHS, CFB to Week 10 | 1.95 ± 20.585 | -2.18 ± 24.794 |
| GHS, CFB to Week 13 | 0.98 ± 19.935 | -3.30 ± 27.034 |
| GHS, CFB to Week 16 | 1.73 ± 23.337 | -3.40 ± 26.870 |
| GHS, CFB to Week 19 | 4.55 ± 23.231 | 1.50 ± 25.627 |
| GHS, CFB to Week 22 | 2.52 ± 23.605 | 1.79 ± 25.868 |
| GHS, CFB to Week 25 | 2.99 ± 25.276 | -1.23 ± 25.470 |
| GHS, CFB to Week 28 | 5.10 ± 24.670 | 0.00 ± 23.570 |
| GHS, CFB to Week 31 | 5.02 ± 24.150 | 0.51 ± 24.379 |
| GHS, CFB to Week 34 | 7.31 ± 23.321 | 6.00 ± 24.594 |
| GHS, CFB to Week 37 | 7.00 ± 27.882 | 3.00 ± 24.400 |
| GHS, CFB to Week 40 | 8.33 ± 24.696 | 3.67 ± 29.372 |
| GHS, CFB to Week 43 | 7.50 ± 29.833 | 6.35 ± 25.400 |
| GHS, CFB to Week 46 | 7.55 ± 26.130 | 10.94 ± 28.661 |
| GHS, CFB to Week 49 | 10.03 ± 24.270 | 11.84 ± 25.657 |
| GHS, CFB to Week 52 | 12.70 ± 24.541 | 6.25 ± 26.196 |
| GHS, CFB to Week 55 | 9.17 ± 26.473 | 3.51 ± 29.307 |
| GHS, CFB to Week 58 | 8.77 ± 30.105 | 6.48 ± 27.350 |
| GHS, CFB to Week 61 | 11.93 ± 27.247 | 8.33 ± 29.149 |
| GHS, CFB to Week 64 | 10.46 ± 26.711 | 10.00 ± 30.732 |
| GHS, CFB to Week 67 | 10.17 ± 25.493 | 13.54 ± 25.797 |
| GHS, CFB to Week 70 | 9.67 ± 26.156 | 8.97 ± 25.563 |
| GHS, CFB to Week 73 | 9.76 ± 29.042 | 8.33 ± 27.095 |
| GHS, CFB to Week 76 | 13.69 ± 24.681 | 11.11 ± 30.807 |
| GHS, CFB to Week 79 | 11.51 ± 25.764 | 10.56 ± 25.289 |
| GHS, CFB to Week 82 | 10.66 ± 26.684 | 11.67 ± 27.960 |
| GHS, CFB to Week 85 | 8.56 ± 29.820 | 6.41 ± 27.879 |
| GHS, CFB to Week 88 | 11.34 ± 25.210 | 9.62 ± 28.635 |
| GHS, CFB to Week 91 | 9.68 ± 27.883 | 3.57 ± 33.923 |
| GHS, CFB to Week 94 | 11.34 ± 28.602 | 4.17 ± 36.670 |
| GHS, CFB to Week 97 | 12.22 ± 27.831 | 9.85 ± 29.302 |
| GHS, CFB to Week 100 | 9.76 ± 27.303 | 0.00 ± 29.397 |
| GHS, CFB to Week 103 | 14.22 ± 27.641 | 2.78 ± 29.756 |
| GHS, CFB to Week 106 | 15.40 ± 26.197 | 4.76 ± 29.603 |
| GHS, CFB to Week 109 | 13.97 ± 27.883 | 7.29 ± 29.017 |
| GHS, CFB to Week 115 | 11.39 ± 25.189 | 3.13 ± 32.409 |
| GHS, CFB to Week 118 | 9.17 ± 25.460 | 8.33 ± 26.352 |
| GHS, CFB to Week 121 | 8.67 ± 22.111 | 6.25 ± 26.633 |
| GHS, CFB to Week 124 | 10.58 ± 24.671 | 13.89 ± 26.176 |
| GHS, CFB to Week 127 | 11.22 ± 26.661 | 12.50 ± 29.698 |
| GHS, CFB to Week 130 | 13.00 ± 26.251 | 15.00 ± 27.889 |
| GHS, CFB to Week 133 | 10.76 ± 27.636 | 11.11 ± 28.219 |
| GHS, CFB to Week 139 | 13.10 ± 27.710 | 11.11 ± 30.581 |
| GHS, CFB to Week 142 | 9.85 ± 23.519 | 18.75 ± 30.713 |
| GHS, CFB to Week 148 | 6.14 ± 29.768 | 18.75 ± 30.713 |
| GHS, CFB to Week 151 | 7.94 ± 25.204 | 18.75 ± 30.713 |
| GHS, CFB to Week 154 | 9.21 ± 29.252 | 20.83 ± 30.807 |
| GHS, CFB to Week 157 | 4.41 ± 29.333 | 16.67 ± 41.667 |
| GHS, CFB to Week 160 | 7.87 ± 22.410 | 19.44 ± 37.577 |
| GHS, CFB to Week 163 | 11.57 ± 23.767 | 16.67 ± 41.667 |
| GHS, CFB to Week 166 | 12.78 ± 27.434 | 16.67 ± 41.667 |
| GHS, CFB to Week 169 | 12.25 ± 29.627 | 16.67 ± 46.398 |
| GHS, CFB to Week 172 | 12.82 ± 32.206 | 19.44 ± 37.577 |
| GHS, CFB to Week 175 | 16.67 ± 30.360 | 13.89 ± 45.896 |
| GHS, CFB to Week 178 | 10.71 ± 32.263 | 25.00 ± 33.333 |
| GHS, CFB to Week 181 | 13.10 ± 35.463 | 16.67 ± 41.667 |
| GHS, CFB to Week 184 | 9.09 ± 30.834 | 16.67 ± 41.667 |
| GHS, CFB to Week 187 | 2.78 ± 31.458 | 12.50 ± 64.818 |
| GHS, CFB to Week 193 | 5.95 ± 28.347 | 16.67 ± 41.667 |
| GHS, CFB to Week 196 | 27.08 ± 30.456 | 13.89 ± 45.896 |
| GHS, CFB to Week 199 | 5.95 ± 34.263 | 8.33 ± 54.645 |
| GHS, CFB to Week 202 | 18.52 ± 29.100 | 19.44 ± 37.577 |
| GHS, CFB to Week 208 | 19.05 ± 36.233 | 0.00 ± 23.570 |
| GHS, CFB to Week 211 | 11.67 ± 38.006 | -4.17 ± 29.463 |
| GHS, CFB to Week 214 | 22.22 ± 45.896 | 0.00 ± 23.570 |
| GHS, CFB to Week 217 | 0.00 ± 0.000 | 0.00 ± 23.570 |
| GHS, CFB to Week 220 | -4.17 ± 29.463 | -8.33 ± 35.355 |
| GHS, CFB to Week 223 | -4.17 ± 19.837 | 0.00 ± 23.570 |
| GHS, CFB to Week 226 | 2.78 ± 17.347 | -16.67 ± NA |
| GHS, CFB to Week 229 | 16.67 ± 23.570 | -25.00 ± NA |
| GHS, CFB to Week 232 | 5.56 ± 25.459 | -33.33 ± NA |
| GHS, CFB to Week 235 | -8.33 ± 11.785 | -33.33 ± NA |
| GHS, CFB to Week 238 | — | -33.33 ± NA |
| GHS, CFB to EOT (~242 weeks) | -7.35 ± 27.192 | -12.88 ± 24.468 |
| GHS, CFB to LFU (~263 weeks) | -0.60 ± 26.749 | -0.83 ± 22.114 |
| PF, CFB to Week 4 | 0.68 ± 17.972 | 0.78 ± 14.129 |
| PF, CFB to Week 7 | 3.04 ± 19.097 | -0.60 ± 18.460 |
| PF, CFB to Week 10 | 1.59 ± 18.011 | 0.00 ± 19.437 |
| PF, CFB to Week 13 | 2.84 ± 17.088 | -3.22 ± 16.004 |
| PF, CFB to Week 16 | 1.95 ± 19.751 | -0.74 ± 15.790 |
| PF, CFB to Week 19 | 3.07 ± 21.029 | 1.36 ± 16.264 |
| PF, CFB to Week 22 | 2.32 ± 19.075 | 0.63 ± 16.969 |
| PF, CFB to Week 25 | 3.36 ± 18.097 | 0.59 ± 12.322 |
| PF, CFB to Week 28 | 4.58 ± 18.390 | 1.52 ± 18.371 |
| PF, CFB to Week 31 | 5.93 ± 17.434 | 3.84 ± 16.752 |
| PF, CFB to Week 34 | 4.63 ± 20.081 | 2.67 ± 9.623 |
| PF, CFB to Week 37 | 5.28 ± 20.310 | 0.80 ± 10.597 |
| PF, CFB to Week 40 | 8.38 ± 18.361 | -0.80 ± 10.941 |
| PF, CFB to Week 43 | 7.21 ± 20.266 | -0.32 ± 15.126 |
| PF, CFB to Week 46 | 7.60 ± 20.481 | 2.22 ± 16.330 |
| PF, CFB to Week 49 | 8.82 ± 19.478 | 3.33 ± 9.750 |
| PF, CFB to Week 52 | 10.55 ± 17.144 | 3.92 ± 12.203 |
| PF, CFB to Week 55 | 6.19 ± 20.449 | 5.26 ± 10.081 |
| PF, CFB to Week 58 | 6.28 ± 21.460 | 0.99 ± 11.285 |
| PF, CFB to Week 61 | 9.37 ± 19.552 | -2.59 ± 15.700 |
| PF, CFB to Week 64 | 9.40 ± 21.539 | 2.67 ± 12.293 |
| PF, CFB to Week 67 | 7.82 ± 23.113 | 6.25 ± 13.437 |
| PF, CFB to Week 70 | 7.02 ± 21.131 | 4.10 ± 17.541 |
| PF, CFB to Week 73 | 8.83 ± 21.364 | 4.44 ± 12.258 |
| PF, CFB to Week 76 | 6.88 ± 19.241 | 5.33 ± 18.379 |
| PF, CFB to Week 79 | 10.32 ± 19.735 | 6.19 ± 19.649 |
| PF, CFB to Week 82 | 8.78 ± 20.893 | 6.67 ± 15.327 |
| PF, CFB to Week 85 | 11.83 ± 19.528 | 4.10 ± 17.114 |
| PF, CFB to Week 88 | 10.00 ± 21.822 | 6.15 ± 13.183 |
| PF, CFB to Week 91 | 9.19 ± 21.906 | -0.95 ± 17.899 |
| PF, CFB to Week 94 | 11.11 ± 23.798 | -6.67 ± 36.670 |
| PF, CFB to Week 97 | 9.11 ± 15.211 | 0.61 ± 15.335 |
| PF, CFB to Week 106 | 14.34 ± 22.981 | 1.90 ± 22.015 |
| PF, CFB to Week 100 | 11.62 ± 21.834 | 1.33 ± 21.728 |
| PF, CFB to Week 103 | 9.80 ± 18.071 | 3.70 ± 17.985 |
| PF, CFB to Week 109 | 14.31 ± 21.657 | 5.83 ± 17.973 |
| PF, CFB to Week 112 | 13.95 ± 21.683 | 4.76 ± 17.518 |
| PF, CFB to Week 115 | 11.33 ± 19.586 | 1.67 ± 11.127 |
| PF, CFB to Week 118 | 7.78 ± 21.873 | -0.83 ± 21.510 |
| PF, CFB to Week 121 | 7.47 ± 19.467 | 6.67 ± 17.457 |
| PF, CFB to Week 124 | 11.54 ± 22.435 | 10.00 ± 22.211 |
| PF, CFB to Week 127 | 11.28 ± 21.231 | 4.44 ± 18.698 |
| PF, CFB to Week 130 | 14.13 ± 22.470 | 4.00 ± 24.766 |
| PF, CFB to Week 133 | 12.50 ± 21.830 | 4.44 ± 23.727 |
| PF, CFB to Week 136 | 15.56 ± 24.795 | 6.67 ± 20.000 |
| PF, CFB to Week 139 | 16.19 ± 23.624 | 6.67 ± 23.851 |
| PF, CFB to Week 142 | 12.42 ± 20.398 | 8.33 ± 26.317 |
| PF, CFB to Week 145 | 4.07 ± 25.985 | 9.33 ± 22.901 |
| PF, CFB to Week 148 | 11.23 ± 25.536 | 8.33 ± 21.344 |
| PF, CFB to Week 151 | 6.35 ± 25.164 | 10.00 ± 22.771 |
| PF, CFB to Week 154 | 8.77 ± 23.836 | 8.33 ± 22.690 |
| PF, CFB to Week 157 | 6.67 ± 24.833 | 2.22 ± 23.413 |
| PF, CFB to Week 160 | 2.96 ± 15.377 | 6.67 ± 30.551 |
| PF, CFB to Week 163 | 6.30 ± 26.019 | 13.33 ± 23.094 |
| PF, CFB to Week 166 | 9.78 ± 27.702 | 13.33 ± 29.059 |
| PF, CFB to Week 169 | 5.88 ± 29.710 | 11.11 ± 25.240 |
| PF, CFB to Week 172 | 11.79 ± 32.677 | 13.33 ± 23.094 |
| PF, CFB to Week 175 | 17.22 ± 29.876 | 13.33 ± 23.094 |
| PF, CFB to Week 178 | 8.10 ± 32.257 | 15.56 ± 26.943 |
| PF, CFB to Week 181 | 11.90 ± 30.063 | 8.89 ± 21.430 |
| PF, CFB to Week 184 | 11.52 ± 31.565 | 13.33 ± 35.277 |
| PF, CFB to Week 187 | 8.15 ± 37.827 | 20.00 ± 47.140 |
| PF, CFB to Week 190 | 12.00 ± 33.672 | 13.33 ± 35.277 |
| PF, CFB to Week 193 | 0.95 ± 11.819 | 13.33 ± 35.277 |
| PF, CFB to Week 196 | 19.17 ± 38.121 | 16.11 ± 32.332 |
| PF, CFB to Week 199 | 7.62 ± 40.812 | 11.11 ± 37.908 |
| PF, CFB to Week 202 | 18.52 ± 36.633 | 11.11 ± 31.505 |
| PF, CFB to Week 205 | 25.71 ± 40.264 | -2.50 ± 3.536 |
| PF, CFB to Week 208 | 22.86 ± 39.974 | -6.67 ± 9.428 |
| PF, CFB to Week 211 | 10.67 ± 29.288 | -10.00 ± 14.142 |
| PF, CFB to Week 214 | 11.11 ± 31.505 | -6.67 ± 9.428 |
| PF, CFB to Week 217 | 0.00 ± 0.000 | -6.67 ± 9.428 |
| PF, CFB to Week 220 | 0.00 ± 28.284 | -6.67 ± 9.428 |
| PF, CFB to Week 223 | 3.33 ± 22.111 | 0.00 ± 0.000 |
| PF, CFB to Week 226 | 6.67 ± 11.547 | -6.67 ± NA |
| PF, CFB to Week 229 | 16.67 ± 23.570 | -6.67 ± NA |
| PF, CFB to Week 232 | 11.11 ± 19.245 | -13.33 ± NA |
| PF, CFB to Week 235 | 0.00 ± 0.000 | -20.00 ± NA |
| PF, CFB to Week 238 | — | -6.67 ± NA |
| PF, CFB to EOT (~242 weeks) | -9.34 ± 25.270 | -9.80 ± 23.453 |
| PF, CFB to LFU (~263 weeks) | -6.96 ± 27.711 | 3.00 ± 26.796 |
| RF, CFB to Week 4 | 0.85 ± 24.770 | -4.42 ± 26.555 |
| RF, CFB to Week 7 | -0.11 ± 26.078 | -1.08 ± 27.880 |
| RF, CFB to Week 10 | -0.91 ± 25.897 | -3.59 ± 28.941 |
| RF, CFB to Week 13 | -0.61 ± 22.681 | -5.46 ± 28.337 |
| RF, CFB to Week 16 | -1.27 ± 31.069 | -1.23 ± 24.412 |
| RF, CFB to Week 19 | -0.35 ± 28.095 | 1.67 ± 25.028 |
| RF, CFB to Week 22 | -1.23 ± 27.531 | -1.59 ± 26.496 |
| RF, CFB to Week 25 | 3.33 ± 27.844 | -3.65 ± 29.248 |
| RF, CFB to Week 28 | 3.37 ± 29.131 | 0.00 ± 27.116 |
| RF, CFB to Week 31 | 3.63 ± 28.382 | -1.01 ± 25.324 |
| RF, CFB to Week 34 | 1.60 ± 30.828 | 3.33 ± 23.074 |
| RF, CFB to Week 37 | 2.90 ± 33.450 | 0.00 ± 23.074 |
| RF, CFB to Week 40 | 5.48 ± 31.434 | 0.00 ± 25.909 |
| RF, CFB to Week 43 | 5.00 ± 32.272 | -4.76 ± 30.342 |
| RF, CFB to Week 46 | 5.99 ± 30.192 | 1.04 ± 33.593 |
| RF, CFB to Week 49 | 9.38 ± 28.464 | -0.88 ± 20.393 |
| RF, CFB to Week 52 | 9.68 ± 26.747 | 3.33 ± 25.706 |
| RF, CFB to Week 55 | 5.65 ± 29.460 | -0.88 ± 20.393 |
| RF, CFB to Week 58 | 6.14 ± 30.150 | -10.19 ± 28.087 |
| RF, CFB to Week 61 | 7.19 ± 28.530 | -2.78 ± 25.082 |
| RF, CFB to Week 64 | 6.86 ± 29.283 | -1.11 ± 22.242 |
| RF, CFB to Week 67 | 8.67 ± 29.401 | 1.04 ± 25.436 |
| RF, CFB to Week 70 | 7.67 ± 27.605 | -1.28 ± 24.019 |
| RF, CFB to Week 73 | 3.66 ± 30.621 | -5.56 ± 27.936 |
| RF, CFB to Week 76 | 4.37 ± 26.560 | -7.78 ± 28.776 |
| RF, CFB to Week 79 | 8.73 ± 27.358 | -3.33 ± 27.603 |
| RF, CFB to Week 82 | 11.63 ± 28.990 | 1.11 ± 31.159 |
| RF, CFB to Week 85 | 9.91 ± 24.677 | 2.56 ± 20.237 |
| RF, CFB to Week 88 | 9.72 ± 27.131 | 2.56 ± 25.318 |
| RF, CFB to Week 91 | 6.76 ± 26.487 | -8.33 ± 35.656 |
| RF, CFB to Week 94 | 7.87 ± 29.677 | -9.72 ± 40.488 |
| RF, CFB to Week 97 | 13.33 ± 24.914 | 3.03 ± 33.181 |
| RF, CFB to Week 100 | 13.81 ± 26.961 | -10.00 ± 35.312 |
| RF, CFB to Week 103 | 12.25 ± 29.102 | -5.56 ± 28.868 |
| RF, CFB to Week 106 | 16.16 ± 29.013 | -7.14 ± 37.090 |
| RF, CFB to Week 109 | 17.65 ± 25.604 | -4.17 ± 24.801 |
| RF, CFB to Week 112 | 17.22 ± 31.405 | -2.38 ± 17.817 |
| RF, CFB to Week 115 | 13.33 ± 29.814 | 0.00 ± 25.198 |
| RF, CFB to Week 118 | 10.00 ± 29.556 | -2.08 ± 25.877 |
| RF, CFB to Week 121 | 8.00 ± 31.593 | -4.17 ± 24.801 |
| RF, CFB to Week 124 | 14.74 ± 33.442 | 11.11 ± 36.004 |
| RF, CFB to Week 127 | 12.18 ± 31.112 | 8.33 ± 27.386 |
| RF, CFB to Week 130 | 15.33 ± 30.015 | 12.50 ± 36.956 |
| RF, CFB to Week 133 | 12.50 ± 31.565 | 8.33 ± 29.345 |
| RF, CFB to Week 136 | 10.32 ± 32.265 | 16.67 ± 33.333 |
| RF, CFB to Week 139 | 10.32 ± 30.494 | 11.11 ± 34.427 |
| RF, CFB to Week 142 | 12.12 ± 30.071 | 12.50 ± 36.956 |
| RF, CFB to Week 145 | 7.41 ± 28.135 | 13.33 ± 27.386 |
| RF, CFB to Week 148 | 10.53 ± 27.336 | 20.83 ± 36.956 |
| RF, CFB to Week 151 | 7.94 ± 35.986 | 12.50 ± 28.464 |
| RF, CFB to Week 154 | 10.53 ± 35.229 | 16.67 ± 30.429 |
| RF, CFB to Week 157 | 2.94 ± 30.182 | 11.11 ± 34.694 |
| RF, CFB to Week 160 | -1.85 ± 24.845 | 22.22 ± 53.576 |
| RF, CFB to Week 163 | 4.63 ± 33.726 | 11.11 ± 34.694 |
| RF, CFB to Week 166 | 8.89 ± 33.845 | 25.00 ± 35.355 |
| RF, CFB to Week 169 | 13.73 ± 32.933 | 16.67 ± 28.868 |
| RF, CFB to Week 172 | 17.95 ± 28.432 | 16.67 ± 44.096 |
| RF, CFB to Week 175 | 15.28 ± 37.240 | 22.22 ± 53.576 |
| RF, CFB to Week 178 | 5.95 ± 35.571 | 16.67 ± 28.868 |
| RF, CFB to Week 181 | 14.29 ± 33.242 | 11.11 ± 34.694 |
| RF, CFB to Week 184 | 10.61 ± 39.632 | 16.67 ± 44.096 |
| RF, CFB to Week 187 | 7.41 ± 50.077 | 33.33 ± 70.711 |
| RF, CFB to Week 190 | 10.00 ± 37.843 | 22.22 ± 53.576 |
| RF, CFB to Week 193 | 4.76 ± 24.934 | 22.22 ± 53.576 |
| RF, CFB to Week 196 | 25.00 ± 37.796 | 22.22 ± 53.576 |
| RF, CFB to Week 199 | 9.52 ± 46.004 | 44.096 ± 16.67 |
| RF, CFB to Week 202 | 16.67 ± 37.268 | 22.22 ± 53.576 |
| RF, CFB to Week 205 | 28.57 ± 48.795 | -16.67 ± 23.570 |
| RF, CFB to Week 208 | 26.19 ± 47.000 | -8.33 ± 11.785 |
| RF, CFB to Week 211 | 20.00 ± 44.721 | -8.33 ± 11.785 |
| RF, CFB to Week 214 | 16.67 ± 44.096 | -8.33 ± 11.785 |
| RF, CFB to Week 217 | 0.00 ± 0.000 | -8.33 ± 11.785 |
| RF, CFB to Week 220 | 0.00 ± 47.140 | -8.33 ± 11.785 |
| RF, CFB to Week 223 | 8.33 ± 41.944 | -8.33 ± 11.785 |
| RF, CFB to Week 226 | 16.67 ± 28.868 | 16.67 ± NA |
| RF, CFB to Week 229 | 33.33 ± 47.140 | -16.67 ± NA |
| RF, CFB to Week 232 | 16.67 ± 28.868 | -16.67 ± NA |
| RF, CFB to Week 235 | 0.00 ± 0.000 | -16.67 ± NA |
| RF, CFB to Week 238 | — | -16.67 ± NA |
| RF, CFB to EOT (~242 weeks) | -12.57 ± 32.169 | -11.11 ± 33.119 |
| RF, CFB to LFU (~263 weeks) | -7.60 ± 31.072 | -1.67 ± 36.635 |
| EF, CFB to Week 4 | 0.28 ± 17.941 | -0.10 ± 17.543 |
| EF, CFB to Week 7 | 0.25 ± 20.123 | 3.31 ± 17.733 |
| EF, CFB to Week 10 | 1.29 ± 17.351 | 2.31 ± 17.709 |
| EF, CFB to Week 13 | 2.85 ± 19.119 | 0.86 ± 20.808 |
| EF, CFB to Week 16 | 1.35 ± 22.142 | 2.47 ± 17.853 |
| EF, CFB to Week 19 | 2.66 ± 21.468 | 6.17 ± 20.119 |
| EF, CFB to Week 22 | 0.26 ± 18.572 | 2.78 ± 17.718 |
| EF, CFB to Week 25 | 1.09 ± 17.784 | -2.21 ± 19.817 |
| EF, CFB to Week 28 | -1.18 ± 17.638 | 1.67 ± 21.936 |
| EF, CFB to Week 31 | -0.21 ± 15.661 | 2.27 ± 18.549 |
| EF, CFB to Week 34 | 1.07 ± 15.106 | 1.33 ± 12.883 |
| EF, CFB to Week 37 | 0.85 ± 17.858 | -2.00 ± 15.077 |
| EF, CFB to Week 40 | 0.60 ± 15.883 | -3.00 ± 17.821 |
| EF, CFB to Week 43 | 2.74 ± 20.000 | -1.19 ± 19.236 |
| EF, CFB to Week 46 | 3.52 ± 17.556 | -1.04 ± 16.066 |
| EF, CFB to Week 49 | 3.78 ± 17.247 | 0.15 ± 12.846 |
| EF, CFB to Week 52 | 2.91 ± 17.719 | 2.08 ± 2.08 |
| EF, CFB to Week 55 | 2.36 ± 16.098 | 0.00 ± 15.466 |
| EF, CFB to Week 58 | 1.90 ± 20.775 | 0.46 ± 18.846 |
| EF, CFB to Week 61 | 5.39 ± 13.927 | -3.70 ± 11.862 |
| EF, CFB to Week 64 | 4.08 ± 15.668 | 5.00 ± 9.860 |
| EF, CFB to Week 67 | 1.33 ± 13.295 | -1.04 ± 16.066 |
| EF, CFB to Week 70 | 3.50 ± 14.686 | 1.92 ± 11.860 |
| EF, CFB to Week 73 | 1.22 ± 14.856 | 1.11 ± 16.627 |
| EF, CFB to Week 76 | 2.38 ± 16.696 | 0.56 ± 14.929 |
| EF, CFB to Week 79 | 2.78 ± 16.220 | 2.22 ± 14.929 |
| EF, CFB to Week 82 | 2.38 ± 17.097 | 0.56 ± 14.929 |
| EF, CFB to Week 85 | 2.93 ± 15.862 | -4.49 ± 16.533 |
| EF, CFB to Week 88 | -2.39 ± 20.338 | 2.56 ± 7.124 |
| EF, CFB to Week 91 | 2.70 ± 16.673 | -3.57 ± 20.338 |
| EF, CFB to Week 94 | 2.78 ± 14.226 | 0.69 ± 9.704 |
| EF, CFB to Week 97 | 1.94 ± 18.529 | 0.00 ± 15.811 |
| EF, CFB to Week 100 | 4.05 ± 15.175 | -0.83 ± 10.722 |
| EF, CFB to Week 103 | 2.70 ± 18.994 | 2.78 ± 9.317 |
| EF, CFB to Week 106 | 1.77 ± 16.372 | 3.57 ± 8.133 |
| EF, CFB to Week 109 | 2.94 ± 18.336 | 4.17 ± 8.909 |
| EF, CFB to Week 112 | 4.02 ± 14.368 | 5.95 ± 6.299 |
| EF, CFB to Week 115 | 5.56 ± 14.070 | 2.08 ± 15.905 |
| EF, CFB to Week 118 | 1.67 ± 17.008 | 2.08 ± 9.708 |
| EF, CFB to Week 121 | 1.67 ± 15.590 | 5.21 ± 8.839 |
| EF, CFB to Week 124 | 1.60 ± 17.483 | 8.33 ± 13.944 |
| EF, CFB to Week 127 | 2.24 ± 15.376 | 0.00 ± 10.541 |
| EF, CFB to Week 130 | 3.67 ± 13.625 | 8.33 ± 8.333 |
| EF, CFB to Week 133 | -1.04 ± 17.430 | -1.39 ± 11.076 |
| EF, CFB to Week 136 | 0.79 ± 15.569 | 0.00 ± 11.785 |
| EF, CFB to Week 139 | 1.98 ± 14.885 | 0.00 ± 9.129 |
| EF, CFB to Week 142 | 1.52 ± 14.915 | 6.25 ± 7.979 |
| EF, CFB to Week 145 | 3.24 ± 16.204 | 1.67 ± 9.129 |
| EF, CFB to Week 148 | 0.00 ± 14.164 | 6.25 ± 7.979 |
| EF, CFB to Week 151 | 0.00 ± 17.480 | 2.08 ± 10.486 |
| EF, CFB to Week 154 | -2.19 ± 19.213 | 4.17 ± 8.333 |
| EF, CFB to Week 157 | -4.90 ± 13.838 | 5.56 ± 9.623 |
| EF, CFB to Week 160 | -5.56 ± 17.620 | 11.11 ± 9.623 |
| EF, CFB to Week 163 | -1.85 ± 16.802 | 5.56 ± 9.623 |
| EF, CFB to Week 166 | 2.22 ± 15.895 | 5.56 ± 9.623 |
| EF, CFB to Week 169 | 1.47 ± 15.091 | 5.56 ± 9.623 |
| EF, CFB to Week 172 | 3.21 ± 13.835 | 8.33 ± 8.333 |
| EF, CFB to Week 175 | 5.56 ± 14.794 | 5.56 ± 9.623 |
| EF, CFB to Week 178 | -1.79 ± 17.351 | 11.11 ± 9.623 |
| EF, CFB to Week 181 | 2.38 ± 17.732 | 0.00 ± 16.667 |
| EF, CFB to Week 184 | 1.52 ± 17.802 | 8.33 ± 8.333 |
| EF, CFB to Week 187 | -6.48 ± 19.444 | 4.17 ± 5.893 |
| EF, CFB to Week 190 | -11.11 ± 28.868 | 5.56 ± 9.623 |
| EF, CFB to Week 193 | 5.95 ± 9.272 | 8.33 ± 8.333 |
| EF, CFB to Week 196 | 8.33 ± 7.715 | 11.11 ± 9.623 |
| EF, CFB to Week 199 | -2.38 ± 10.446 | 5.56 ± 9.623 |
| EF, CFB to Week 202 | 6.48 ± 12.345 | 8.33 ± 8.333 |
| EF, CFB to Week 205 | 11.90 ± 15.105 | 8.33 ± 11.785 |
| EF, CFB to Week 208 | 11.90 ± 14.319 | 12.50 ± 5.893 |
| EF, CFB to Week 211 | 0.00 ± 11.785 | 8.33 ± 11.785 |
| EF, CFB to Week 214 | 0.00 ± 8.333 | 12.50 ± 5.893 |
| EF, CFB to Week 217 | 0.00 ± 0.000 | 4.17 ± 17.678 |
| EF, CFB to Week 220 | 4.17 ± 5.893 | 8.33 ± 11.785 |
| EF, CFB to Week 223 | 4.17 ± 10.758 | 12.50 ± 5.893 |
| EF, CFB to Week 226 | 5.56 ± 9.623 | 0.00 ± NA |
| EF, CFB to Week 229 | 8.33 ± 11.785 | 8.33 ± NA |
| EF, CFB to Week 232 | 0.00 ± 16.667 | 8.33 ± NA |
| EF, CFB to Week 235 | -4.17 ± 5.893 | 0.00 ± NA |
| EF, CFB to Week 238 | — | 8.33 ± NA |
| EF, CFB to EOT (~242 weeks) | -5.53 ± 23.677 | -6.19 ± 21.098 |
| EF, CFB to LFU (~263 weeks) | -0.60 ± 20.328 | 10.83 ± 26.366 |
| CF, CFB to Week 4 | 0.75 ± 17.391 | -1.61 ± 16.175 |
| CF, CFB to Week 7 | 0.68 ± 16.538 | -1.28 ± 20.766 |
| CF, CFB to Week 10 | -0.13 ± 16.204 | -0.51 ± 22.042 |
| CF, CFB to Week 13 | -0.75 ± 16.110 | -1.72 ± 21.332 |
| CF, CFB to Week 16 | -4.09 ± 21.920 | -3.70 ± 19.870 |
| CF, CFB to Week 19 | -1.55 ± 20.706 | -3.00 ± 18.347 |
| CF, CFB to Week 22 | -1.91 ± 17.749 | -7.54 ± 20.889 |
| CF, CFB to Week 25 | -1.99 ± 17.444 | -10.29 ± 25.955 |
| CF, CFB to Week 28 | -2.55 ± 15.958 | -3.81 ± 17.191 |
| CF, CFB to Week 31 | -0.64 ± 15.991 | -3.54 ± 14.882 |
| CF, CFB to Week 34 | -2.05 ± 16.184 | -0.67 ± 14.814 |
| CF, CFB to Week 37 | -1.45 ± 15.054 | -4.00 ± 12.981 |
| CF, CFB to Week 40 | -1.67 ± 15.320 | -2.67 ± 12.435 |
| CF, CFB to Week 43 | -0.48 ± 15.007 | -3.17 ± 22.123 |
| CF, CFB to Week 46 | -0.26 ± 16.127 | -1.04 ± 14.232 |
| CF, CFB to Week 49 | 2.60 ± 14.614 | 0.88 ± 10.354 |
| CF, CFB to Week 52 | 1.85 ± 15.000 | 4.17 ± 13.107 |
| CF, CFB to Week 55 | 3.06 ± 14.873 | 2.63 ± 11.471 |
| CF, CFB to Week 58 | 0.29 ± 18.498 | 4.63 ± 15.971 |
| CF, CFB to Week 61 | 1.31 ± 12.842 | -2.78 ± 17.386 |
| CF, CFB to Week 64 | 0.00 ± 15.635 | 0.00 ± 17.817 |
| CF, CFB to Week 67 | 1.33 ± 14.998 | 3.13 ± 16.351 |
| CF, CFB to Week 70 | -0.67 ± 18.120 | 5.13 ± 10.507 |
| CF, CFB to Week 73 | -2.03 ± 13.538 | 3.33 ± 12.910 |
| CF, CFB to Week 76 | -0.79 ± 24.125 | 1.11 ± 13.313 |
| CF, CFB to Week 79 | 0.00 ± 17.266 | 2.22 ± 15.258 |
| CF, CFB to Week 82 | 3.49 ± 14.346 | 4.44 ± 16.019 |
| CF, CFB to Week 85 | 4.05 ± 16.389 | 0.00 ± 18.002 |
| CF, CFB to Week 88 | -1.39 ± 17.537 | 2.56 ± 13.344 |
| CF, CFB to Week 91 | 1.80 ± 17.909 | -3.57 ± 21.857 |
| CF, CFB to Week 94 | 1.85 ± 15.825 | 0.00 ± 7.107 |
| CF, CFB to Week 97 | -1.67 ± 18.231 | 3.03 ± 10.050 |
| CF, CFB to Week 100 | 1.90 ± 18.423 | 1.67 ± 12.298 |
| CF, CFB to Week 103 | -1.47 ± 18.517 | 3.70 ± 11.111 |
| CF, CFB to Week 106 | -4.55 ± 18.761 | 2.38 ± 17.817 |
| CF, CFB to Week 109 | -0.49 ± 15.067 | -2.08 ± 10.681 |
| CF, CFB to Week 112 | 0.56 ± 17.223 | 0.00 ± 13.608 |
| CF, CFB to Week 115 | -2.22 ± 17.904 | 0.00 ± 12.599 |
| CF, CFB to Week 118 | -2.78 ± 19.120 | -2.08 ± 13.909 |
| CF, CFB to Week 121 | -2.00 ± 18.207 | -2.08 ± 10.681 |
| CF, CFB to Week 124 | -5.13 ± 19.304 | 2.78 ± 6.804 |
| CF, CFB to Week 127 | -5.13 ± 15.470 | -5.56 ± 8.607 |
| CF, CFB to Week 130 | -1.33 ± 15.899 | -6.67 ± 9.129 |
| CF, CFB to Week 133 | 0.00 ± 13.901 | -2.78 ± 6.804 |
| CF, CFB to Week 136 | -2.38 ± 12.117 | 3.33 ± 7.454 |
| CF, CFB to Week 139 | -1.59 ± 11.672 | 0.00 ± 0.000 |
| CF, CFB to Week 142 | -2.27 ± 12.905 | 0.00 ± 0.000 |
| CF, CFB to Week 145 | -9.26 ± 16.392 | 0.00 ± 0.000 |
| CF, CFB to Week 148 | -3.51 ± 11.888 | 0.00 ± 0.000 |
| CF, CFB to Week 151 | -3.97 ± 15.728 | 0.00 ± 0.000 |
| CF, CFB to Week 154 | -1.75 ± 12.291 | 0.00 ± 0.000 |
| CF, CFB to Week 157 | -9.80 ± 16.728 | 0.00 ± 0.000 |
| CF, CFB to Week 160 | -11.11 ± 16.169 | 5.56 ± 9.623 |
| CF, CFB to Week 163 | -9.26 ± 15.363 | 0.00 ± 0.000 |
| CF, CFB to Week 166 | -6.67 ± 12.280 | 5.56 ± 9.623 |
| CF, CFB to Week 169 | -11.76 ± 18.413 | -5.56 ± 9.623 |
| CF, CFB to Week 172 | -8.97 ± 17.501 | 0.00 ± 0.000 |
| CF, CFB to Week 175 | 0.00 ± 7.107 | 0.00 ± 0.000 |
| CF, CFB to Week 178 | -1.19 ± 7.911 | 5.56 ± 9.623 |
| CF, CFB to Week 181 | -8.33 ± 14.248 | -5.56 ± 9.623 |
| CF, CFB to Week 184 | -1.52 ± 5.025 | -5.56 ± 9.623 |
| CF, CFB to Week 187 | -1.85 ± 13.029 | 0.00 ± 0.000 |
| CF, CFB to Week 190 | 1.85 ± 15.466 | 0.00 ± 0.000 |
| CF, CFB to Week 193 | 0.00 ± 9.623 | 0.00 ± 0.000 |
| CF, CFB to Week 196 | 2.08 ± 10.681 | 0.00 ± 16.667 |
| CF, CFB to Week 199 | -11.90 ± 24.934 | 0.00 ± 0.000 |
| CF, CFB to Week 202 | 1.85 ± 10.015 | 0.00 ± 0.000 |
| CF, CFB to Week 205 | 0.00 ± 9.623 | 8.33 ± 11.785 |
| CF, CFB to Week 208 | 4.76 ± 8.133 | 0.00 ± 0.000 |
| CF, CFB to Week 211 | 3.33 ± 7.454 | 8.33 ± 11.785 |
| CF, CFB to Week 214 | 0.00 ± 0.000 | 8.33 ± 11.785 |
| CF, CFB to Week 217 | 0.00 ± 0.000 | 8.33 ± 11.785 |
| CF, CFB to Week 220 | 8.33 ± 11.785 | 8.33 ± 11.785 |
| CF, CFB to Week 223 | 4.17 ± 8.333 | 8.33 ± 11.785 |
| CF, CFB to Week 226 | 0.00 ± 16.667 | 16.67 ± NA |
| CF, CFB to Week 229 | 8.33 ± 8.33 | 16.67 ± NA |
| CF, CFB to Week 232 | 5.56 ± 9.623 | 16.67 ± NA |
| CF, CFB to Week 235 | 0.00 ± 0.000 | 16.67 ± NA |
| CF, CFB to Week 238 | — | 0.00 ± NA |
| CF, CFB to EOT (~242 weeks) | -5.18 ± 21.452 | -7.58 ± 21.520 |
| CF, CFB to LFU (~263 weeks) | -5.31 ± 23.308 | -2.50 ± 21.134 |
| SF, CFB to Week 4 | 1.99 ± 23.111 | -0.60 ± 21.376 |
| SF, CFB to Week 7 | -0.46 ± 25.667 | 0.00 ± 23.570 |
| SF, CFB to Week 10 | 0.65 ± 23.608 | -0.26 ± 23.843 |
| SF, CFB to Week 13 | 1.53 ± 25.614 | -1.72 ± 22.445 |
| SF, CFB to Week 16 | 0.00 ± 26.069 | -0.64 ± 26.806 |
| SF, CFB to Week 19 | 1.91 ± 27.346 | -1.00 ± 26.813 |
| SF, CFB to Week 22 | -1.58 ± 29.180 | -4.37 ± 27.065 |
| SF, CFB to Week 25 | 4.21 ± 28.284 | -2.45 ± 26.947 |
| SF, CFB to Week 28 | 1.79 ± 29.614 | 1.43 ± 26.926 |
| SF, CFB to Week 31 | 4.11 ± 25.385 | 2.53 ± 23.615 |
| SF, CFB to Week 34 | 4.17 ± 26.940 | -0.67 ± 23.805 |
| SF, CFB to Week 37 | 5.39 ± 28.425 | -1.33 ± 17.951 |
| SF, CFB to Week 40 | 5.48 ± 27.762 | -2.67 ± 23.902 |
| SF, CFB to Week 43 | 3.14 ± 26.703 | 3.97 ± 24.667 |
| SF, CFB to Week 46 | 4.50 ± 28.273 | 2.08 ± 29.736 |
| SF, CFB to Week 49 | 8.47 ± 23.162 | 7.02 ± 26.244 |
| SF, CFB to Week 52 | 11.29 ± 23.527 | 6.67 ± 25.015 |
| SF, CFB to Week 55 | 3.39 ± 22.270 | 7.02 ± 19.497 |
| SF, CFB to Week 58 | 2.38 ± 29.030 | 3.70 ± 25.918 |
| SF, CFB to Week 61 | 5.00 ± 29.595 | 7.41 ± 22.304 |
| SF, CFB to Week 64 | 8.16 ± 28.285 | 4.44 ± 27.070 |
| SF, CFB to Week 67 | 4.42 ± 25.634 | 7.29 ± 21.054 |
| SF, CFB to Week 70 | 6.46 ± 27.390 | 5.13 ± 21.926 |
| SF, CFB to Week 73 | -0.41 ± 27.761 | 4.44 ± 23.960 |
| SF, CFB to Week 76 | 2.44 ± 27.275 | 6.67 ± 22.537 |
| SF, CFB to Week 79 | 6.91 ± 30.041 | 8.89 ± 26.627 |
| SF, CFB to Week 82 | 8.33 ± 28.809 | 11.11 ± 17.442 |
| SF, CFB to Week 85 | 9.26 ± 29.932 | 3.85 ± 26.487 |
| SF, CFB to Week 88 | 7.87 ± 30.469 | 11.54 ± 25.806 |
| SF, CFB to Week 91 | 11.26 ± 27.793 | 5.95 ± 31.082 |
| SF, CFB to Week 94 | 7.41 ± 31.983 | 5.56 ± 35.056 |
| SF, CFB to Week 97 | 2.78 ± 28.054 | 13.64 ± 27.707 |
| SF, CFB to Week 100 | 5.24 ± 27.047 | 10.00 ± 36.175 |
| SF, CFB to Week 103 | 6.86 ± 26.310 | 1.85 ± 25.610 |
| SF, CFB to Week 106 | 8.08 ± 30.935 | 7.14 ± 31.706 |
| SF, CFB to Week 109 | 11.27 ± 28.932 | 8.33 ± 28.172 |
| SF, CFB to Week 112 | 11.67 ± 28.416 | 7.14 ± 33.134 |
| SF, CFB to Week 115 | 8.33 ± 25.801 | 8.33 ± 30.861 |
| SF, CFB to Week 118 | 6.67 ± 32.636 | 8.33 ± 28.172 |
| SF, CFB to Week 121 | 4.67 ± 27.855 | 10.42 ± 25.099 |
| SF, CFB to Week 124 | 8.33 ± 27.183 | 11.11 ± 41.722 |
| SF, CFB to Week 127 | 7.05 ± 33.057 | 13.89 ± 30.581 |
| SF, CFB to Week 130 | 9.33 ± 30.077 | 6.67 ± 25.276 |
| SF, CFB to Week 133 | 7.64 ± 37.744 | 19.44 ± 30.581 |
| SF, CFB to Week 136 | 7.14 ± 29.141 | 20.00 ± 21.731 |
| SF, CFB to Week 139 | 8.73 ± 28.195 | 13.89 ± 30.581 |
| SF, CFB to Week 142 | 12.12 ± 26.816 | 25.00 ± 31.914 |
| SF, CFB to Week 145 | 2.78 ± 34.419 | 16.67 ± 23.570 |
| SF, CFB to Week 148 | 8.77 ± 29.064 | 16.67 ± 33.333 |
| SF, CFB to Week 151 | 6.35 ± 35.931 | 25.00 ± 21.517 |
| SF, CFB to Week 154 | -1.75 ± 33.285 | 20.83 ± 25.000 |
| SF, CFB to Week 157 | 3.92 ± 30.917 | 22.22 ± 38.490 |
| SF, CFB to Week 160 | -7.41 ± 30.903 | 27.78 ± 25.459 |
| SF, CFB to Week 163 | -1.85 ± 40.378 | 27.78 ± 25.459 |
| SF, CFB to Week 166 | 2.22 ± 39.272 | 16.67 ± 28.868 |
| SF, CFB to Week 169 | 1.96 ± 42.033 | 27.78 ± 25.459 |
| SF, CFB to Week 172 | 8.97 ± 37.028 | 16.67 ± 28.868 |
| SF, CFB to Week 175 | 12.50 ± 41.515 | 27.78 ± 25.459 |
| SF, CFB to Week 178 | 1.19 ± 39.475 | 16.67 ± 28.868 |
| SF, CFB to Week 181 | 7.14 ± 40.146 | 27.78 ± 25.459 |
| SF, CFB to Week 184 | 1.52 ± 41.133 | 27.78 ± 25.459 |
| SF, CFB to Week 187 | 11.11 ± 47.871 | 41.67 ± 58.926 |
| SF, CFB to Week 190 | 9.26 ± 47.952 | 38.89 ± 41.944 |
| SF, CFB to Week 193 | 9.52 ± 26.972 | 27.78 ± 25.459 |
| SF, CFB to Week 196 | 27.08 ± 33.259 | 38.89 ± 41.944 |
| SF, CFB to Week 199 | 11.90 ± 46.859 | 27.78 ± 25.459 |
| SF, CFB to Week 202 | 12.96 ± 40.635 | 27.78 ± 27.78 |
| SF, CFB to Week 205 | 26.19 ± 42.879 | 16.67 ± 23.570 |
| SF, CFB to Week 208 | 21.43 ± 46.859 | 16.67 ± 23.570 |
| SF, CFB to Week 211 | 10.00 ± 43.461 | 16.67 ± 23.570 |
| SF, CFB to Week 214 | 0.00 ± 33.333 | 16.67 ± 23.570 |
| SF, CFB to Week 217 | 16.67 ± 23.570 | 16.67 ± 23.570 |
| SF, CFB to Week 220 | 0.00 ± 47.140 | 16.67 ± 23.570 |
| SF, CFB to Week 223 | 8.33 ± 28.868 | 16.67 ± 23.570 |
| SF, CFB to Week 226 | 16.67 ± 28.868 | 0.00 ± NA |
| SF, CFB to Week 229 | 33.33 ± 47.140 | 0.00 ± NA |
| SF, CFB to Week 232 | 16.67 ± 28.868 | 0.00 ± NA |
| SF, CFB to Week 235 | 0.00 ± 0.000 | 0.00 ± NA |
| SF, CFB to Week 238 | — | 0.00 ± NA |
| SF, CFB to EOT (~242 weeks) | -9.46 ± 29.995 | -6.57 ± 32.407 |
| SF, CFB to LFU (~263 weeks) | -3.92 ± 29.241 | 10.00 ± 41.323 |
| Fatigue, CFB to Week 4 | -3.66 ± 18.691 | 0.95 ± 22.711 |
| Fatigue, CFB to Week 7 | -3.91 ± 21.587 | 0.00 ± 26.735 |
| Fatigue, CFB to Week 10 | -4.82 ± 21.684 | 0.53 ± 24.799 |
| Fatigue, CFB to Week 13 | -7.51 ± 19.753 | 4.09 ± 23.629 |
| Fatigue, CFB to Week 16 | -5.77 ± 22.274 | -2.10 ± 22.335 |
| Fatigue, CFB to Week 19 | -7.06 ± 19.505 | 2.27 ± 23.238 |
| Fatigue, CFB to Week 22 | -5.61 ± 19.117 | 0.00 ± 21.373 |
| Fatigue, CFB to Week 25 | -5.37 ± 22.030 | 3.70 ± 24.637 |
| Fatigue, CFB to Week 28 | -6.02 ± 21.529 | -0.98 ± 22.451 |
| Fatigue, CFB to Week 31 | -3.97 ± 19.179 | -0.35 ± 21.583 |
| Fatigue, CFB to Week 34 | -4.03 ± 21.936 | -2.31 ± 20.456 |
| Fatigue, CFB to Week 37 | -5.96 ± 20.436 | 3.24 ± 16.860 |
| Fatigue, CFB to Week 40 | -8.97 ± 20.358 | 4.63 ± 22.443 |
| Fatigue, CFB to Week 43 | -8.65 ± 21.268 | 1.11 ± 15.672 |
| Fatigue, CFB to Week 46 | -10.07 ± 24.704 | -4.17 ± 21.033 |
| Fatigue, CFB to Week 49 | -9.64 ± 21.419 | -2.92 ± 21.225 |
| Fatigue, CFB to Week 52 | -10.22 ± 23.228 | -5.00 ± 17.090 |
| Fatigue, CFB to Week 55 | -10.19 ± 19.970 | 0.58 ± 17.163 |
| Fatigue, CFB to Week 58 | -7.41 ± 23.414 | 0.62 ± 19.975 |
| Fatigue, CFB to Week 61 | -11.78 ± 22.717 | 1.85 ± 27.016 |
| Fatigue, CFB to Week 64 | -13.29 ± 22.773 | -0.74 ± 17.042 |
| Fatigue, CFB to Week 67 | -9.22 ± 22.040 | -2.78 ± 22.407 |
| Fatigue, CFB to Week 70 | -12.00 ± 24.471 | 0.85 ± 16.013 |
| Fatigue, CFB to Week 73 | -6.11 ± 25.899 | 3.70 ± 24.727 |
| Fatigue, CFB to Week 76 | -7.41 ± 23.623 | -2.96 ± 26.047 |
| Fatigue, CFB to Week 79 | -13.76 ± 18.659 | -6.67 ± 22.537 |
| Fatigue, CFB to Week 82 | -11.11 ± 25.738 | -2.96 ± 18.999 |
| Fatigue, CFB to Week 85 | -14.11 ± 23.226 | -2.56 ± 21.827 |
| Fatigue, CFB to Week 88 | -10.19 ± 25.528 | -2.56 ± 19.852 |
| Fatigue, CFB to Week 91 | -9.61 ± 27.363 | -0.79 ± 26.675 |
| Fatigue, CFB to Week 94 | -12.96 ± 22.925 | 7.41 ± 34.274 |
| Fatigue, CFB to Week 97 | -12.78 ± 27.105 | -2.02 ± 21.556 |
| Fatigue, CFB to Week 100 | -12.38 ± 25.816 | 1.11 ± 28.903 |
| Fatigue, CFB to Week 103 | -12.75 ± 23.710 | 0.00 ± 29.918 |
| Fatigue, CFB to Week 106 | -13.47 ± 24.652 | 3.17 ± 30.574 |
| Fatigue, CFB to Week 109 | -12.75 ± 23.232 | 0.00 ± 38.029 |
| Fatigue, CFB to Week 112 | -15.08 ± 26.573 | -4.76 ± 26.338 |
| Fatigue, CFB to Week 115 | -8.89 ± 26.648 | 0.00 ± 19.698 |
| Fatigue, CFB to Week 118 | -11.11 ± 27.373 | -1.39 ± 25.502 |
| Fatigue, CFB to Week 121 | -12.89 ± 23.058 | -5.56 ± 23.002 |
| Fatigue, CFB to Week 124 | -8.55 ± 30.519 | -9.26 ± 29.327 |
| Fatigue, CFB to Week 127 | -6.84 ± 26.865 | -7.41 ± 24.003 |
| Fatigue, CFB to Week 130 | -13.78 ± 26.309 | -6.67 ± 28.974 |
| Fatigue, CFB to Week 133 | -12.96 ± 25.520 | -7.41 ± 30.361 |
| Fatigue, CFB to Week 136 | -15.87 ± 27.119 | -8.89 ± 33.702 |
| Fatigue, CFB to Week 139 | -8.99 ± 23.206 | -7.41 ± 30.361 |
| Fatigue, CFB to Week 142 | -9.09 ± 23.666 | -11.11 ± 38.490 |
| Fatigue, CFB to Week 145 | -3.70 ± 22.222 | -8.89 ± 33.702 |
| Fatigue, CFB to Week 148 | -6.14 ± 23.196 | -16.67 ± 33.333 |
| Fatigue, CFB to Week 151 | -3.17 ± 21.700 | -13.89 ± 35.573 |
| Fatigue, CFB to Week 154 | -11.11 ± 26.189 | -11.11 ± 38.490 |
| Fatigue, CFB to Week 157 | -5.23 ± 23.609 | -11.11 ± 50.918 |
| Fatigue, CFB to Week 160 | -3.09 ± 23.741 | -14.81 ± 46.259 |
| Fatigue, CFB to Week 163 | -6.79 ± 26.986 | -14.81 ± 35.717 |
| Fatigue, CFB to Week 166 | -8.15 ± 25.010 | -14.81 ± 46.259 |
| Fatigue, CFB to Week 169 | -7.84 ± 26.283 | -14.81 ± 35.717 |
| Fatigue, CFB to Week 172 | -10.26 ± 27.764 | -11.11 ± 40.062 |
| Fatigue, CFB to Week 175 | -14.81 ± 27.354 | -18.52 ± 42.066 |
| Fatigue, CFB to Week 178 | -8.73 ± 27.279 | -18.52 ± 32.075 |
| Fatigue, CFB to Week 181 | -6.35 ± 26.045 | -7.41 ± 44.905 |
| Fatigue, CFB to Week 184 | -7.07 ± 24.481 | -18.52 ± 42.066 |
| Fatigue, CFB to Week 187 | -6.17 ± 29.975 | -22.22 ± 62.854 |
| Fatigue, CFB to Week 190 | -7.78 ± 28.713 | -14.81 ± 46.259 |
| Fatigue, CFB to Week 193 | -1.59 ± 26.001 | -18.52 ± 42.066 |
| Fatigue, CFB to Week 196 | -15.28 ± 32.496 | -18.52 ± 42.066 |
| Fatigue, CFB to Week 199 | -1.59 ± 33.597 | -11.11 ± 40.062 |
| Fatigue, CFB to Week 202 | -14.81 ± 30.429 | -18.52 ± 42.066 |
| Fatigue, CFB to Week 205 | -12.70 ± 36.531 | 16.67 ± 23.570 |
| Fatigue, CFB to Week 208 | -9.52 ± 35.963 | 11.11 ± 15.713 |
| Fatigue, CFB to Week 211 | -8.89 ± 32.773 | 11.11 ± 15.713 |
| Fatigue, CFB to Week 214 | -3.70 ± 39.021 | 11.11 ± 15.713 |
| Fatigue, CFB to Week 217 | 0.00 ± 0.000 | 11.11 ± 15.713 |
| Fatigue, CFB to Week 220 | 11.11 ± 31.427 | 16.67 ± 23.570 |
| Fatigue, CFB to Week 223 | 2.78 ± 22.906 | 5.56 ± 7.857 |
| Fatigue, CFB to Week 226 | -3.70 ± 16.973 | 22.22 ± NA |
| Fatigue, CFB to Week 229 | 0.00 ± 31.427 | 0.00 ± NA |
| Fatigue, CFB to Week 232 | -3.70 ± 16.973 | 11.11 ± NA |
| Fatigue, CFB to Week 235 | 0.00 ± 0.000 | 22.22 ± NA |
| Fatigue, CFB to Week 238 | — | 0.00 ± NA |
| Fatigue, CFB to EOT (~242 weeks) | 1.77 ± 27.301 | 7.12 ± 26.440 |
| Fatigue, CFB to LFU (~263 weeks) | 0.25 ± 28.835 | -6.11 ± 30.263 |
| N/V, CFB to Week 4 | 3.52 ± 17.470 | -0.20 ± 10.309 |
| N/V, CFB to Week 7 | 1.49 ± 16.887 | 2.35 ± 16.055 |
| N/V, CFB to Week 10 | -0.79 ± 14.677 | -0.78 ± 8.622 |
| N/V, CFB to Week 13 | -1.83 ± 17.174 | 1.15 ± 15.877 |
| N/V, CFB to Week 16 | -1.92 ± 15.633 | -0.93 ± 13.118 |
| N/V, CFB to Week 19 | -2.51 ± 14.527 | 0.33 ± 11.414 |
| N/V, CFB to Week 22 | -1.25 ± 20.150 | 2.44 ± 13.724 |
| N/V, CFB to Week 25 | -2.75 ± 15.369 | 2.45 ± 13.061 |
| N/V, CFB to Week 28 | -0.60 ± 13.882 | 0.95 ± 12.088 |
| N/V, CFB to Week 31 | -1.08 ± 14.393 | 0.51 ± 12.137 |
| N/V, CFB to Week 34 | 1.85 ± 15.462 | -1.33 ± 10.672 |
| N/V, CFB to Week 37 | -0.98 ± 11.832 | 1.33 ± 10.672 |
| N/V, CFB to Week 40 | -1.67 ± 13.050 | 0.00 ± 8.333 |
| N/V, CFB to Week 43 | -0.48 ± 14.844 | -1.59 ± 11.672 |
| N/V, CFB to Week 46 | -2.65 ± 11.673 | -1.04 ± 9.562 |
| N/V, CFB to Week 49 | -2.38 ± 10.733 | -0.93 ± 8.988 |
| N/V, CFB to Week 52 | -2.19 ± 12.351 | -1.67 ± 7.454 |
| N/V, CFB to Week 55 | -1.72 ± 11.121 | -1.75 ± 7.647 |
| N/V, CFB to Week 58 | 0.30 ± 13.292 | -0.93 ± 8.988 |
| N/V, CFB to Week 61 | -3.67 ± 13.166 | 0.00 ± 11.433 |
| N/V, CFB to Week 64 | -3.74 ± 11.915 | -1.11 ± 16.019 |
| N/V, CFB to Week 67 | -3.82 ± 13.422 | 0.00 ± 10.541 |
| N/V, CFB to Week 70 | -4.08 ± 12.043 | -3.85 ± 13.868 |
| N/V, CFB to Week 73 | -3.25 ± 10.685 | -2.22 ± 13.897 |
| N/V, CFB to Week 76 | -3.66 ± 7.916 | -1.11 ± 9.894 |
| N/V, CFB to Week 79 | -3.25 ± 10.685 | -1.11 ± 9.894 |
| N/V, CFB to Week 82 | -3.57 ± 12.502 | -2.22 ± 13.897 |
| N/V, CFB to Week 85 | -4.17 ± 12.199 | -3.85 ± 13.868 |
| N/V, CFB to Week 88 | -1.85 ± 15.825 | -3.85 ± 13.868 |
| N/V, CFB to Week 91 | -3.24 ± 11.832 | -2.38 ± 14.407 |
| N/V, CFB to Week 94 | -4.17 ± 10.059 | -1.39 ± 11.143 |
| N/V, CFB to Week 97 | -1.11 ± 11.525 | -1.52 ± 11.677 |
| N/V, CFB to Week 100 | -1.43 ± 10.203 | -1.67 ± 12.298 |
| N/V, CFB to Week 103 | -2.45 ± 10.958 | -4.17 ± 11.785 |
| N/V, CFB to Week 106 | -2.02 ± 13.015 | -4.76 ± 20.893 |
| N/V, CFB to Week 109 | -3.92 ± 9.229 | -2.08 ± 22.603 |
| N/V, CFB to Week 112 | -4.60 ± 9.857 | -2.38 ± 14.996 |
| N/V, CFB to Week 115 | -2.22 ± 11.357 | 0.00 ± 17.817 |
| N/V, CFB to Week 118 | -3.33 ± 10.171 | -4.17 ± 11.785 |
| N/V, CFB to Week 121 | -3.47 ± 12.984 | -6.25 ± 17.678 |
| N/V, CFB to Week 124 | -1.28 ± 11.473 | -8.33 ± 20.412 |
| N/V, CFB to Week 127 | -0.64 ± 12.893 | -8.33 ± 20.412 |
| N/V, CFB to Week 130 | -0.67 ± 13.159 | -6.67 ± 14.907 |
| N/V, CFB to Week 133 | -1.39 ± 13.828 | 0.00 ± 0.000 |
| N/V, CFB to Week 136 | -3.97 ± 8.983 | 0.00 ± 0.000 |
| N/V, CFB to Week 139 | -4.76 ± 9.344 | 0.00 ± 0.000 |
| N/V, CFB to Week 142 | -1.52 ± 8.773 | 0.00 ± 0.000 |
| N/V, CFB to Week 145 | 0.00 ± 9.901 | 0.00 ± 0.000 |
| N/V, CFB to Week 148 | -2.63 ± 10.036 | 0.00 ± 0.000 |
| N/V, CFB to Week 151 | -3.97 ± 8.983 | 0.00 ± 0.000 |
| N/V, CFB to Week 154 | -4.39 ± 10.890 | 0.00 ± 0.000 |
| N/V, CFB to Week 157 | -4.90 ± 12.862 | 0.00 ± 0.000 |
| N/V, CFB to Week 160 | -3.70 ± 12.201 | 8.33 ± 11.785 |
| N/V, CFB to Week 163 | -6.48 ± 11.630 | 0.00 ± 0.000 |
| N/V, CFB to Week 166 | -5.56 ± 12.062 | 0.00 ± 0.000 |
| N/V, CFB to Week 169 | -5.88 ± 11.698 | 0.00 ± 0.000 |
| N/V, CFB to Week 172 | -7.69 ± 12.938 | 0.00 ± 0.000 |
| N/V, CFB to Week 175 | -4.17 ± 10.360 | 0.00 ± 0.000 |
| N/V, CFB to Week 178 | -2.38 ± 11.050 | 0.00 ± 0.000 |
| N/V, CFB to Week 181 | -1.19 ± 13.812 | 0.00 ± 0.000 |
| N/V, CFB to Week 184 | 0.00 ± 12.910 | 0.00 ± 0.000 |
| N/V, CFB to Week 187 | -3.70 ± 11.111 | 0.00 ± 0.000 |
| N/V, CFB to Week 190 | -8.33 ± 14.164 | 0.00 ± 0.000 |
| N/V, CFB to Week 193 | -4.76 ± 12.599 | 0.00 ± 0.000 |
| N/V, CFB to Week 196 | -6.25 ± 12.400 | 0.00 ± 0.000 |
| N/V, CFB to Week 199 | 0.00 ± 0.000 | 0.00 ± 0.000 |
| N/V, CFB to Week 202 | -5.56 ± 11.785 | 0.00 ± 0.000 |
| N/V, CFB to Week 205 | -7.14 ± 13.113 | 0.00 ± 0.000 |
| N/V, CFB to Week 208 | -7.14 ± 13.113 | 0.00 ± 0.000 |
| N/V, CFB to Week 211 | -10.00 ± 14.907 | 0.00 ± 0.000 |
| N/V, CFB to Week 214 | -5.56 ± 9.623 | 0.00 ± 0.000 |
| N/V, CFB to Week 217 | 0.00 ± 0.000 | 0.00 ± 0.000 |
| N/V, CFB to Week 220 | -16.67 ± 23.570 | 0.00 ± 0.000 |
| N/V, CFB to Week 223 | -8.33 ± 16.667 | 0.00 ± 0.000 |
| N/V, CFB to Week 226 | -11.11 ± 19.245 | 0.00 ± NA |
| N/V, CFB to Week 229 | -16.67 ± 23.570 | 0.00 ± NA |
| N/V, CFB to Week 232 | -11.11 ± 19.245 | 0.00 ± NA |
| N/V, CFB to Week 235 | 0.00 ± 0.000 | 0.00 ± NA |
| N/V, CFB to Week 238 | — | 0.00 ± NA |
| N/V, CFB to EOT (~242 weeks) | 1.99 ± 23.587 | 3.08 ± 12.109 |
| N/V, CFB to LFU (~263 weeks) | 1.93 ± 19.075 | 6.67 ± 21.898 |
| Pain, CFB to Week 4 | -1.51 ± 23.589 | -1.41 ± 26.571 |
| Pain, CFB to Week 7 | -3.17 ± 24.546 | -4.27 ± 30.441 |
| Pain, CFB to Week 10 | -2.31 ± 24.445 | -6.41 ± 30.146 |
| Pain, CFB to Week 13 | -5.56 ± 24.856 | -8.05 ± 22.780 |
| Pain, CFB to Week 16 | -6.29 ± 27.454 | -7.41 ± 31.667 |
| Pain, CFB to Week 19 | -6.36 ± 29.012 | -2.67 ± 27.013 |
| Pain, CFB to Week 22 | -4.34 ± 29.044 | -4.37 ± 30.144 |
| Pain, CFB to Week 25 | -7.97 ± 25.616 | -5.88 ± 26.869 |
| Pain, CFB to Week 28 | -4.96 ± 24.514 | -6.19 ± 24.617 |
| Pain, CFB to Week 31 | -6.62 ± 24.374 | -7.58 ± 21.687 |
| Pain, CFB to Week 34 | -3.88 ± 24.771 | -6.00 ± 21.452 |
| Pain, CFB to Week 37 | -8.70 ± 25.663 | 0.67 ± 17.665 |
| Pain, CFB to Week 40 | -7.86 ± 25.494 | -1.33 ± 11.706 |
| Pain, CFB to Week 43 | -7.86 ± 27.323 | 0.00 ± 21.082 |
| Pain, CFB to Week 46 | -7.29 ± 27.519 | 0.00 ± 16.102 |
| Pain, CFB to Week 49 | -6.51 ± 26.497 | 0.00 ± 13.608 |
| Pain, CFB to Week 52 | -10.32 ± 26.846 | -4.17 ± 13.107 |
| Pain, CFB to Week 55 | -3.89 ± 28.846 | 0.88 ± 20.393 |
| Pain, CFB to Week 58 | -9.65 ± 29.370 | -1.85 ± 17.977 |
| Pain, CFB to Week 61 | -9.67 ± 25.218 | 2.78 ± 21.580 |
| Pain, CFB to Week 64 | -10.13 ± 28.300 | -2.22 ± 12.387 |
| Pain, CFB to Week 67 | -12.00 ± 26.735 | -8.33 ± 17.213 |
| Pain, CFB to Week 70 | -12.00 ± 26.522 | -5.13 ± 18.490 |
| Pain, CFB to Week 73 | -10.16 ± 24.403 | 4.44 ± 14.729 |
| Pain, CFB to Week 7615 | -8.33 ± 25.833 | -3.33 ± 22.003 |
| Pain, CFB to Week 79 | -9.52 ± 27.826 | -3.33 ± 18.039 |
| Pain, CFB to Week 82 | -10.47 ± 29.327 | -8.89 ± 18.758 |
| Pain, CFB to Week 85 | -12.16 ± 31.829 | -2.56 ± 19.059 |
| Pain, CFB to Week 88 | -12.96 ± 29.307 | -1.28 ± 25.875 |
| Pain, CFB to Week 91 | -11.71 ± 31.639 | 1.19 ± 33.630 |
| Pain, CFB to Week 94 | -11.11 ± 30.079 | 6.94 ± 35.146 |
| Pain, CFB to Week 97 | -10.56 ± 24.559 | -6.06 ± 15.407 |
| Pain, CFB to Week 100 | -11.90 ± 27.288 | -1.67 ± 41.907 |
| Pain, CFB to Week 103 | -10.78 ± 26.235 | -5.56 ± 31.180 |
| Pain, CFB to Week 106 | -12.12 ± 27.724 | -7.14 ± 26.972 |
| Pain, CFB to Week 109 | -12.75 ± 29.319 | 4.17 ± 37.533 |
| Pain, CFB to Week 112 | -13.33 ± 30.134 | 0.00 ± 34.694 |
| Pain, CFB to Week 115 | -8.89 ± 29.274 | 0.00 ± 19.920 |
| Pain, CFB to Week 118 | -9.44 ± 24.637 | 2.08 ± 32.657 |
| Pain, CFB to Week 121 | -10.00 ± 27.639 | -4.17 ± 19.416 |
| Pain, CFB to Week 124 | -12.82 ± 29.555 | -11.11 ± 29.187 |
| Pain, CFB to Week 127 | -12.82 ± 26.795 | -11.11 ± 27.217 |
| Pain, CFB to Week 130 | -14.00 ± 23.902 | -6.67 ± 25.276 |
| Pain, CFB to Week 133 | -11.81 ± 29.684 | -8.33 ± 22.973 |
| Pain, CFB to Week 136 | -11.11 ± 25.999 | -13.33 ± 29.814 |
| Pain, CFB to Week 139 | -9.52 ± 25.588 | -5.56 ± 34.427 |
| Pain, CFB to Week 142 | -12.12 ± 31.782 | -12.50 ± 36.956 |
| Pain, CFB to Week 145 | -3.70 ± 25.918 | -10.00 ± 22.361 |
| Pain, CFB to Week 148 | -14.04 ± 29.008 | -8.33 ± 28.868 |
| Pain, CFB to Week 151 | -8.73 ± 25.614 | -8.33 ± 28.868 |
| Pain, CFB to Week 154 | -8.77 ± 27.425 | -4.17 ± 8.333 |
| Pain, CFB to Week 157 | -2.94 ± 30.182 | -16.67 ± 44.096 |
| Pain, CFB to Week 160 | -4.63 ± 25.441 | -16.67 ± 44.096 |
| Pain, CFB to Week 163 | -10.19 ± 30.324 | -16.67 ± 44.096 |
| Pain, CFB to Week 166 | -12.22 ± 27.070 | -16.67 ± 44.096 |
| Pain, CFB to Week 169 | -7.84 ± 24.380 | -22.22 ± 38.490 |
| Pain, CFB to Week 172 | -11.54 ± 32.192 | -16.67 ± 28.868 |
| Pain, CFB to Week 175 | -16.67 ± 27.524 | -16.67 ± 44.096 |
| Pain, CFB to Week 178 | -7.14 ± 33.150 | -33.33 ± 33.333 |
| Pain, CFB to Week 181 | -2.38 ± 40.222 | -5.56 ± 41.944 |
| Pain, CFB to Week 184 | -3.03 ± 35.604 | -22.22 ± 38.490 |
| Pain, CFB to Week 187 | 0.00 ± 44.876 | -25.00 ± 58.926 |
| Pain, CFB to Week 190 | -8.33 ± 41.759 | -11.11 ± 50.918 |
| Pain, CFB to Week 193 | -7.14 ± 30.211 | -5.56 ± 41.944 |
| Pain, CFB to Week 196 | -22.92 ± 29.463 | -16.67 ± 44.096 |
| Pain, CFB to Week 199 | -7.14 ± 30.211 | -16.67 ± 44.096 |
| Pain, CFB to Week 202 | -18.52 ± 34.805 | -16.67 ± 44.096 |
| Pain, CFB to Week 205 | -19.05 ± 36.551 | 16.67 ± 23.570 |
| Pain, CFB to Week 208 | -16.67 ± 34.694 | 16.67 ± 23.570 |
| Pain, CFB to Week 211 | -16.67 ± 40.825 | 8.33 ± 11.785 |
| Pain, CFB to Week 214 | -11.11 ± 34.694 | 0.00 ± 0.000 |
| Pain, CFB to Week 217 | 0.00 ± 0.000 | 8.33 ± 11.785 |
| Pain, CFB to Week 220 | 0.00 ± 47.140 | 16.67 ± 23.570 |
| Pain, CFB to Week 223 | -4.17 ± 34.359 | 0.00 ± 0.000 |
| Pain, CFB to Week 226 | -11.11 ± 19.245 | 0.00 ± NA |
| Pain, CFB to Week 229 | -33.33 ± 47.140 | -16.67 ± NA |
| Pain, CFB to Week 232 | -5.56 ± 41.944 | 0.00 ± NA |
| Pain, CFB to Week 235 | 0.00 ± 0.000 | 16.67 ± NA |
| Pain, CFB to Week 238 | — | 0.00 ± NA |
| Pain, CFB to EOT (~242 weeks) | 4.24 ± 30.051 | 3.28 ± 27.303 |
| Pain, CFB to LFU (~263 weeks) | 1.21 ± 32.252 | -10.00 ± 29.814 |
| Dyspnea, CFB to Week 4 | 1.13 ± 23.810 | 4.82 ± 24.491 |
| Dyspnea, CFB to Week 7 | 0.46 ± 21.792 | 2.16 ± 25.557 |
| Dyspnea, CFB to Week 10 | 2.07 ± 23.479 | 6.15 ± 27.571 |
| Dyspnea, CFB to Week 13 | -1.52 ± 24.057 | 6.90 ± 26.312 |
| Dyspnea, CFB to Week 16 | -4.44 ± 26.176 | 9.26 ± 24.586 |
| Dyspnea, CFB to Week 19 | -3.13 ± 23.732 | 8.67 ± 26.777 |
| Dyspnea, CFB to Week 22 | -2.13 ± 24.347 | 7.94 ± 24.205 |
| Dyspnea, CFB to Week 25 | -2.22 ± 23.331 | 11.46 ± 26.246 |
| Dyspnea, CFB to Week 28 | 0.00 ± 23.281 | 6.67 ± 26.568 |
| Dyspnea, CFB to Week 31 | -0.43 ± 21.284 | 6.06 ± 25.624 |
| Dyspnea, CFB to Week 34 | 0.93 ± 20.150 | 5.33 ± 22.933 |
| Dyspnea, CFB to Week 37 | -3.92 ± 23.415 | 8.00 ± 19.907 |
| Dyspnea, CFB to Week 40 | -1.45 ± 25.202 | 9.33 ± 20.458 |
| Dyspnea, CFB to Week 43 | 0.48 ± 23.909 | 7.94 ± 27.698 |
| Dyspnea, CFB to Week 46 | -4.76 ± 25.998 | 2.08 ± 25.730 |
| Dyspnea, CFB to Week 49 | -1.59 ± 25.701 | 1.75 ± 25.995 |
| Dyspnea, CFB to Week 52 | -1.64 ± 26.124 | 8.33 ± 30.349 |
| Dyspnea, CFB to Week 55 | -1.15 ± 25.718 | 3.51 ± 15.294 |
| Dyspnea, CFB to Week 58 | 2.38 ± 25.312 | 9.26 ± 27.548 |
| Dyspnea, CFB to Week 61 | -6.00 ± 22.018 | 9.26 ± 19.150 |
| Dyspnea, CFB to Week 64 | -0.67 ± 23.800 | 8.89 ± 19.787 |
| Dyspnea, CFB to Week 67 | -3.40 ± 24.763 | 8.33 ± 19.245 |
| Dyspnea, CFB to Week 70 | -1.36 ± 27.182 | 7.69 ± 24.167 |
| Dyspnea, CFB to Week 73 | -3.33 ± 29.040 | 8.89 ± 23.458 |
| Dyspnea, CFB to Week 76 | 1.63 ± 25.767 | 8.89 ± 23.458 |
| Dyspnea, CFB to Week 79 | -1.63 ± 22.300 | 11.11 ± 32.530 |
| Dyspnea, CFB to Week 82 | -4.88 ± 20.495 | 8.89 ± 32.038 |
| Dyspnea, CFB to Week 85 | -5.41 ± 22.924 | 5.13 ± 18.490 |
| Dyspnea, CFB to Week 88 | -2.78 ± 24.398 | 7.69 ± 19.971 |
| Dyspnea, CFB to Week 91 | 0.00 ± 23.570 | 11.90 ± 28.063 |
| Dyspnea, CFB to Week 94 | -3.70 ± 19.153 | 5.56 ± 23.925 |
| Dyspnea, CFB to Week 97 | -2.22 ± 21.323 | 6.06 ± 20.101 |
| Dyspnea, CFB to Week 100 | -0.95 ± 24.899 | 6.67 ± 14.055 |
| Dyspnea, CFB to Week 103 | -1.96 ± 21.620 | 11.11 ± 16.667 |
| Dyspnea, CFB to Week 106 | -2.02 ± 24.916 | 9.52 ± 25.198 |
| Dyspnea, CFB to Week 109 | -5.88 ± 22.429 | 8.33 ± 15.430 |
| Dyspnea, CFB to Week 112 | -1.15 ± 30.188 | -4.76 ± 12.599 |
| Dyspnea, CFB to Week 115 | -1.11 ± 23.947 | 4.17 ± 21.362 |
| Dyspnea, CFB to Week 118 | -2.22 ± 23.050 | 8.33 ± 23.570 |
| Dyspnea, CFB to Week 121 | -4.00 ± 29.376 | 4.17 ± 11.785 |
| Dyspnea, CFB to Week 124 | -8.97 ± 22.226 | 5.56 ± 13.608 |
| Dyspnea, CFB to Week 127 | -5.13 ± 20.423 | 11.11 ± 17.213 |
| Dyspnea, CFB to Week 130 | -9.33 ± 22.608 | 0.00 ± 27.217 |
| Dyspnea, CFB to Week 133 | -12.50 ± 25.656 | 11.11 ± 17.213 |
| Dyspnea, CFB to Week 136 | -9.52 ± 26.125 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 139 | -6.35 ± 20.053 | 5.56 ± 13.608 |
| Dyspnea, CFB to Week 142 | -13.64 ± 19.678 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 145 | -5.56 ± 26.197 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 148 | -8.77 ± 21.779 | 8.33 ± 16.667 |
| Dyspnea, CFB to Week 151 | -9.52 ± 23.905 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 154 | -7.02 ± 21.020 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 157 | -5.88 ± 13.098 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 160 | -5.56 ± 17.150 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 163 | -11.11 ± 19.803 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 166 | -4.44 ± 17.213 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 169 | -7.84 ± 22.140 | -11.11 ± 19.245 |
| Dyspnea, CFB to Week 172 | -10.26 ± 25.036 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 175 | -11.11 ± 25.950 | -11.11 ± 19.245 |
| Dyspnea, CFB to Week 178 | -4.76 ± 22.100 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 181 | -11.90 ± 21.111 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 184 | -9.09 ± 21.556 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 187 | -14.81 ± 24.216 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 190 | -6.67 ± 26.294 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 193 | -9.52 ± 16.265 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 196 | -12.50 ± 24.801 | -11.11 ± 19.245 |
| Dyspnea, CFB to Week 199 | -9.52 ± 25.198 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 202 | -11.11 ± 23.570 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 205 | -14.29 ± 26.227 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 208 | -19.05 ± 26.227 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 211 | -6.67 ± 14.907 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 214 | -11.11 ± 19.245 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 217 | 0.00 ± 0.000 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 220 | -16.67 ± 23.570 | 0.00 ± 0.000 |
| Dyspnea, CFB to Week 223 | -8.33 ± 16.667 | 0.00 ± 0.00 |
| Dyspnea, CFB to Week 226 | -11.11 ± 19.245 | 0.00 ± NA |
| Dyspnea, CFB to Week 229 | -16.67 ± 23.570 | -33.33 ± NA |
| Dyspnea, CFB to Week 232 | -11.11 ± 19.245 | 0.00 ± NA |
| Dyspnea, CFB to Week 235 | 0.00 ± 0.000 | 0.00 ± NA |
| Dyspnea, CFB to Week 238 | — | 0.00 ± NA |
| Dyspnea, CFB to EOT (~242 weeks) | 0.00 ± 24.549 | 9.60 ± 21.693 |
| Dyspnea, CFB to LFU (~263 weeks) | 1.96 ± 35.911 | 8.33 ± 33.985 |
| Insomnia, CFB to Week 4 | -2.12 ± 27.644 | -2.44 ± 29.528 |
| Insomnia, CFB to Week 7 | -2.55 ± 26.760 | -3.03 ± 32.973 |
| Insomnia, CFB to Week 10 | -6.25 ± 26.373 | -1.59 ± 29.590 |
| Insomnia, CFB to Week 13 | -2.80 ± 28.270 | -4.68 ± 27.774 |
| Insomnia, CFB to Week 16 | -2.86 ± 32.395 | -4.40 ± 26.983 |
| Insomnia, CFB to Week 19 | -10.53 ± 30.466 | -5.44 ± 30.692 |
| Insomnia, CFB to Week 22 | -7.09 ± 26.717 | -0.81 ± 31.170 |
| Insomnia, CFB to Week 25 | -9.06 ± 28.432 | 4.04 ± 40.618 |
| Insomnia, CFB to Week 28 | -5.95 ± 24.902 | 2.94 ± 27.668 |
| Insomnia, CFB to Week 31 | -5.19 ± 27.072 | -5.21 ± 26.920 |
| Insomnia, CFB to Week 34 | -3.65 ± 30.713 | -4.17 ± 29.996 |
| Insomnia, CFB to Week 37 | -4.90 ± 25.925 | -4.17 ± 29.996 |
| Insomnia, CFB to Week 40 | -5.24 ± 28.734 | -2.78 ± 33.932 |
| Insomnia, CFB to Week 43 | -8.57 ± 32.938 | 1.67 ± 36.635 |
| Insomnia, CFB to Week 46 | -9.38 ± 26.206 | -6.25 ± 34.894 |
| Insomnia, CFB to Week 49 | -8.85 ± 26.721 | -1.75 ± 30.376 |
| Insomnia, CFB to Week 52 | -9.14 ± 28.419 | -5.00 ± 27.091 |
| Insomnia, CFB to Week 55 | -8.89 ± 24.446 | -3.51 ± 24.582 |
| Insomnia, CFB to Week 58 | -7.74 ± 33.630 | 0.00 ± 32.338 |
| Insomnia, CFB to Week 61 | -12.00 ± 24.981 | -3.70 ± 22.547 |
| Insomnia, CFB to Week 64 | -10.46 ± 24.486 | -8.89 ± 23.458 |
| Insomnia, CFB to Week 67 | -7.33 ± 27.180 | -2.08 ± 35.421 |
| Insomnia, CFB to Week 70 | -10.00 ± 26.298 | -7.69 ± 30.894 |
| Insomnia, CFB to Week 73 | -4.17 ± 26.352 | -4.44 ± 30.516 |
| Insomnia, CFB to Week 76 | -6.35 ± 25.755 | 0.00 ± 33.333 |
| Insomnia, CFB to Week 79 | -7.14 ± 27.086 | -6.67 ± 31.371 |
| Insomnia, CFB to Week 82 | -10.32 ± 27.038 | -2.22 ± 26.627 |
| Insomnia, CFB to Week 85 | -12.61 ± 31.770 | -10.26 ± 36.980 |
| Insomnia, CFB to Week 88 | -7.41 ± 26.561 | -2.56 ± 31.802 |
| Insomnia, CFB to Week 91 | -2.70 ± 31.796 | -11.90 ± 33.607 |
| Insomnia, CFB to Week 94 | -11.11 ± 30.861 | -11.11 ± 21.711 |
| Insomnia, CFB to Week 97 | -13.33 ± 32.282 | 3.03 ± 34.816 |
| Insomnia, CFB to Week 100 | -8.57 ± 31.667 | -10.00 ± 27.442 |
| Insomnia, CFB to Week 103 | -17.65 ± 29.854 | -11.11 ± 28.868 |
| Insomnia, CFB to Week 106 | -13.13 ± 28.795 | -14.29 ± 26.227 |
| Insomnia, CFB to Week 109 | -13.73 ± 27.362 | -16.67 ± 25.198 |
| Insomnia, CFB to Week 112 | -14.29 ± 29.297 | -14.29 ± 17.817 |
| Insomnia, CFB to Week 115 | -6.67 ± 28.230 | 0.00 ± 25.198 |
| Insomnia, CFB to Week 118 | -8.89 ± 32.676 | -12.50 ± 24.801 |
| Insomnia, CFB to Week 121 | -10.67 ± 28.415 | -4.17 ± 21.362 |
| Insomnia, CFB to Week 124 | -2.56 ± 32.555 | -5.56 ± 25.092 |
| Insomnia, CFB to Week 127 | -7.69 ± 23.679 | -11.11 ± 17.213 |
| Insomnia, CFB to Week 130 | 0.00 ± 30.429 | -6.67 ± 14.907 |
| Insomnia, CFB to Week 133 | -6.94 ± 25.968 | 5.56 ± 25.092 |
| Insomnia, CFB to Week 136 | -3.17 ± 25.614 | 0.00 ± 23.570 |
| Insomnia, CFB to Week 139 | -4.76 ± 30.342 | -5.56 ± 13.608 |
| Insomnia, CFB to Week 142 | -3.03 ± 27.039 | -8.33 ± 16.667 |
| Insomnia, CFB to Week 145 | -3.70 ± 32.113 | 6.67 ± 14.907 |
| Insomnia, CFB to Week 148 | -5.26 ± 22.942 | -8.33 ± 16.667 |
| Insomnia, CFB to Week 151 | -3.17 ± 23.345 | 0.00 ± 27.217 |
| Insomnia, CFB to Week 154 | -5.26 ± 27.807 | -8.33 ± 16.667 |
| Insomnia, CFB to Week 157 | -1.96 ± 29.978 | 0.00 ± 33.333 |
| Insomnia, CFB to Week 160 | 1.85 ± 26.746 | -11.11 ± 19.245 |
| Insomnia, CFB to Week 163 | -3.70 ± 27.745 | 0.00 ± 0.000 |
| Insomnia, CFB to Week 166 | -2.22 ± 23.458 | -11.11 ± 19.245 |
| Insomnia, CFB to Week 169 | -7.84 ± 27.712 | -11.11 ± 19.245 |
| Insomnia, CFB to Week 172 | -10.26 ± 34.385 | -11.11 ± 19.245 |
| Insomnia, CFB to Week 175 | -11.11 ± 29.588 | -11.11 ± 19.245 |
| Insomnia, CFB to Week 178 | -4.76 ± 34.237 | -11.11 ± 19.245 |
| Insomnia, CFB to Week 181 | -4.76 ± 36.648 | 0.00 ± 33.333 |
| Insomnia, CFB to Week 184 | -9.09 ± 30.151 | 0.00 ± 33.333 |
| Insomnia, CFB to Week 187 | 11.11 ± 47.140 | 0.00 ± 47.140 |
| Insomnia, CFB to Week 190 | -3.33 ± 50.796 | 0.00 ± 33.333 |
| Insomnia, CFB to Week 193 | -19.05 ± 26.227 | -11.11 ± 19.245 |
| Insomnia, CFB to Week 196 | -20.83 ± 30.538 | -11.11 ± 19.245 |
| Insomnia, CFB to Week 199 | -4.76 ± 23.002 | -11.11 ± 19.245 |
| Insomnia, CFB to Week 202 | -3.70 ± 38.889 | -11.11 ± 19.245 |
| Insomnia, CFB to Week 205 | -14.29 ± 42.414 | 16.67 ± 23.570 |
| Insomnia, CFB to Week 208 | -19.05 ± 32.530 | 0.00 ± 0.000 |
| Insomnia, CFB to Week 211 | -26.67 ± 27.889 | 0.00 ± 0.000 |
| Insomnia, CFB to Week 214 | -22.22 ± 19.245 | 0.00 ± 0.000 |
| Insomnia, CFB to Week 217 | 0.00 ± 0.000 | 0.00 ± 0.000 |
| Insomnia, CFB to Week 220 | -50.00 ± 23.570 | 16.67 ± 23.570 |
| Insomnia, CFB to Week 223 | -25.00 ± 31.914 | 16.67 ± 23.570 |
| Insomnia, CFB to Week 226 | -22.22 ± 38.490 | 33.33 ± NA |
| Insomnia, CFB to Week 229 | -33.33 ± 47.140 | 0.00 ± NA |
| Insomnia, CFB to Week 232 | -22.22 ± 38.490 | 33.33 ± NA |
| Insomnia, CFB to Week 235 | 0.00 ± 0.000 | 0.00 ± NA |
| Insomnia, CFB to Week 238 | — | 0.00 ± NA |
| Insomnia, CFB to EOT (~242 weeks) | -2.56 ± 30.686 | 1.04 ± 34.615 |
| Insomnia, CFB to LFU (~263 weeks) | -2.42 ± 28.191 | -16.67 ± 25.363 |
| AL, CFB to Week 4 | 1.71 ± 24.570 | 1.23 ± 22.635 |
| AL, CFB to Week 7 | -2.55 ± 26.760 | -0.43 ± 24.320 |
| AL, CFB to Week 10 | -1.85 ± 25.753 | 2.08 ± 28.406 |
| AL, CFB to Week 13 | -1.83 ± 29.339 | 0.57 ± 22.934 |
| AL, CFB to Week 16 | -2.56 ± 29.992 | -3.09 ± 21.736 |
| AL, CFB to Week 19 | -4.71 ± 31.480 | -2.67 ± 21.125 |
| AL, CFB to Week 22 | -1.08 ± 30.077 | 0.81 ± 17.461 |
| AL, CFB to Week 25 | -1.83 ± 28.701 | 3.92 ± 15.922 |
| AL, CFB to Week 28 | -2.81 ± 22.212 | 0.95 ± 18.935 |
| AL, CFB to Week 31 | -2.16 ± 22.516 | 3.03 ± 15.284 |
| AL, CFB to Week 34 | 1.39 ± 26.500 | 4.00 ± 11.055 |
| AL, CFB to Week 37 | -3.43 ± 28.296 | 6.67 ± 13.608 |
| AL, CFB to Week 40 | -4.29 ± 25.958 | 9.33 ± 20.458 |
| AL, CFB to Week 43 | -4.83 ± 26.368 | 3.17 ± 10.026 |
| AL, CFB to Week 46 | -5.82 ± 26.464 | 4.17 ± 11.386 |
| AL, CFB to Week 49 | -4.76 ± 27.342 | 5.56 ± 12.783 |
| AL, CFB to Week 52 | -7.65 ± 25.381 | 3.33 ± 10.260 |
| AL, CFB to Week 55 | -9.77 ± 22.520 | 3.51 ± 10.510 |
| AL, CFB to Week 58 | -5.95 ± 27.785 | 7.41 ± 18.277 |
| AL, CFB to Week 61 | -8.00 ± 24.799 | 3.70 ± 10.779 |
| AL, CFB to Week 64 | -8.84 ± 26.154 | 8.89 ± 19.787 |
| AL, CFB to Week 67 | -7.64 ± 26.843 | 2.08 ± 8.333 |
| AL, CFB to Week 70 | -6.80 ± 26.334 | 2.56 ± 9.245 |
| AL, CFB to Week 73 | -3.25 ± 25.609 | 6.67 ± 13.801 |
| AL, CFB to Week 76 | -4.88 ± 29.402 | 2.22 ± 8.607 |
| AL, CFB to Week 79 | -5.69 ± 28.773 | 4.44 ± 11.729 |
| AL, CFB to Week 82 | -5.56 ± 29.372 | 4.44 ± 11.729 |
| AL, CFB to Week 85 | -9.26 ± 29.397 | 7.69 ± 14.618 |
| AL, CFB to Week 88 | -9.26 ± 25.956 | 5.13 ± 12.518 |
| AL, CFB to Week 91 | -6.48 ± 30.674 | 11.90 ± 21.111 |
| AL, CFB to Week 94 | -4.63 ± 26.610 | 2.78 ± 9.623 |
| AL, CFB to Week 97 | -4.44 ± 28.679 | 3.03 ± 10.050 |
| AL, CFB to Week 100 | -4.76 ± 21.607 | 3.33 ± 10.541 |
| AL, CFB to Week 103 | -6.86 ± 24.315 | 0.00 ± 0.000 |
| AL, CFB to Week 106 | -7.07 ± 24.661 | 4.76 ± 12.599 |
| AL, CFB to Week 109 | -5.88 ± 20.874 | 8.33 ± 23.570 |
| AL, CFB to Week 112 | -11.11 ± 22.030 | 4.76 ± 12.599 |
| AL, CFB to Week 115 | -8.89 ± 21.323 | 8.33 ± 15.430 |
| AL, CFB to Week 118 | -3.33 ± 20.248 | 0.00 ± 0.000 |
| AL, CFB to Week 121 | -5.56 ± 27.217 | 4.17 ± 11.785 |
| AL, CFB to Week 124 | -3.85 ± 21.760 | 5.56 ± 13.608 |
| AL, CFB to Week 127 | -1.28 ± 17.590 | 5.56 ± 13.608 |
| AL, CFB to Week 130 | -5.33 ± 15.753 | 0.00 ± 0.000 |
| AL, CFB to Week 133 | -2.78 ± 16.787 | 5.56 ± 13.608 |
| AL, CFB to Week 136 | 0.00 ± 18.257 | 6.67 ± 14.907 |
| AL, CFB to Week 139 | 0.00 ± 14.907 | 5.56 ± 13.608 |
| AL, CFB to Week 142 | -6.06 ± 16.703 | 8.33 ± 16.667 |
| AL, CFB to Week 145 | 3.70 ± 15.713 | 6.67 ± 14.907 |
| AL, CFB to Week 148 | -3.51 ± 18.904 | 8.33 ± 16.667 |
| AL, CFB to Week 151 | -3.17 ± 23.345 | 16.67 ± 33.333 |
| AL, CFB to Week 154 | -1.75 ± 23.501 | 8.33 ± 16.667 |
| AL, CFB to Week 157 | 3.92 ± 16.169 | 11.11 ± 19.245 |
| AL, CFB to Week 160 | 9.26 ± 22.304 | 0.00 ± 0.000 |
| AL, CFB to Week 163 | 5.56 ± 23.570 | 11.11 ± 19.245 |
| AL, CFB to Week 166 | 4.44 ± 17.213 | 0.00 ± 0.000 |
| AL, CFB to Week 169 | 3.92 ± 16.169 | 11.11 ± 19.245 |
| AL, CFB to Week 172 | 2.56 ± 21.350 | 11.11 ± 19.245 |
| AL, CFB to Week 175 | 0.00 ± 20.101 | 11.11 ± 19.245 |
| AL, CFB to Week 178 | 2.38 ± 15.821 | 0.00 ± 0.000 |
| AL, CFB to Week 181 | 2.38 ± 15.821 | 11.11 ± 19.245 |
| AL, CFB to Week 184 | 0.00 ± 14.907 | 11.11 ± 19.245 |
| AL, CFB to Week 187 | 3.70 ± 26.058 | 16.67 ± 23.570 |
| AL, CFB to Week 190 | -3.33 ± 18.922 | 11.11 ± 19.245 |
| AL, CFB to Week 193 | 0.00 ± 19.245 | 11.11 ± 19.245 |
| AL, CFB to Week 196 | -4.17 ± 21.362 | 11.11 ± 19.245 |
| AL, CFB to Week 199 | 4.76 ± 12.599 | 11.11 ± 19.245 |
| AL, CFB to Week 202 | -3.70 ± 11.111 | 11.11 ± 19.245 |
| AL, CFB to Week 205 | 0.00 ± 19.245 | 16.67 ± 23.570 |
| AL, CFB to Week 208 | 0.00 ± 19.245 | 16.67 ± 23.570 |
| AL, CFB to Week 211 | -6.67 ± 14.907 | 0.00 ± 0.000 |
| AL, CFB to Week 214 | 0.00 ± 0.000 | 16.67 ± 23.570 |
| AL, CFB to Week 217 | 0.00 ± 0.000 | 16.67 ± 23.570 |
| AL, CFB to Week 220 | -16.67 ± 23.570 | 16.67 ± 23.570 |
| AL, CFB to Week 223 | -8.33 ± 16.667 | 16.67 ± 23.570 |
| AL, CFB to Week 226 | -11.11 ± 19.245 | 33.33 ± NA |
| AL, CFB to Week 229 | -16.67 ± 23.570 | 33.33 ± NA |
| AL, CFB to Week 232 | -11.11 ± 19.245 | 33.33 ± NA |
| AL, CFB to Week 235 | 0.00 ± 0.000 | 33.33 ± NA |
| AL, CFB to Week 238 | — | 33.33 ± NA |
| AL, CFB to EOT (~242 weeks) | 4.27 ± 35.703 | 10.26 ± 25.633 |
| AL, CFB to LFU (~263 weeks) | -5.31 ± 31.635 | 3.33 ± 32.264 |
| Constipation, CFB to Week 4 | -2.10 ± 24.540 | 13.82 ± 27.692 |
| Constipation, CFB to Week 7 | -0.46 ± 24.841 | 9.40 ± 27.861 |
| Constipation, CFB to Week 10 | -1.31 ± 22.772 | 8.85 ± 28.010 |
| Constipation, CFB to Week 13 | -2.45 ± 23.877 | 13.79 ± 27.948 |
| Constipation, CFB to Week 16 | -2.24 ± 24.253 | 12.35 ± 27.697 |
| Constipation, CFB to Week 19 | -0.72 ± 23.559 | 12.00 ± 27.570 |
| Constipation, CFB to Week 22 | -1.43 ± 21.932 | 5.00 ± 23.327 |
| Constipation, CFB to Week 25 | -2.93 ± 20.875 | 11.76 ± 23.039 |
| Constipation, CFB to Week 28 | -1.20 ± 21.744 | 10.48 ± 19.422 |
| Constipation, CFB to Week 31 | -2.16 ± 21.177 | 9.09 ± 19.135 |
| Constipation, CFB to Week 34 | 1.39 ± 24.665 | 6.67 ± 13.608 |
| Constipation, CFB to Week 37 | -2.94 ± 22.107 | 16.00 ± 25.676 |
| Constipation, CFB to Week 40 | 0.48 ± 23.736 | 12.00 ± 21.257 |
| Constipation, CFB to Week 43 | -1.93 ± 20.519 | 9.52 ± 23.905 |
| Constipation, CFB to Week 46 | 1.59 ± 27.714 | 8.33 ± 22.771 |
| Constipation, CFB to Week 49 | -4.23 ± 21.160 | 7.41 ± 18.277 |
| Constipation, CFB to Week 52 | -2.73 ± 18.554 | 5.00 ± 19.571 |
| Constipation, CFB to Week 55 | -4.02 ± 18.812 | 7.02 ± 13.962 |
| Constipation, CFB to Week 58 | -4.17 ± 20.163 | 12.96 ± 30.548 |
| Constipation, CFB to Week 61 | -2.72 ± 23.409 | 11.11 ± 22.866 |
| Constipation, CFB to Week 64 | -1.36 ± 19.196 | 13.33 ± 24.560 |
| Constipation, CFB to Week 67 | -1.39 ± 20.581 | 14.58 ± 27.131 |
| Constipation, CFB to Week 70 | -2.72 ± 19.048 | 15.38 ± 25.875 |
| Constipation, CFB to Week 73 | -2.44 ± 18.842 | 13.33 ± 24.560 |
| Constipation, CFB to Week 76 | -1.63 ± 23.513 | 17.78 ± 27.794 |
| Constipation, CFB to Week 79 | -5.69 ± 18.108 | 13.33 ± 24.560 |
| Constipation, CFB to Week 82 | -6.35 ± 24.680 | 13.33 ± 24.560 |
| Constipation, CFB to Week 85 | -6.48 ± 23.664 | 10.26 ± 25.036 |
| Constipation, CFB to Week 88 | -6.48 ± 20.808 | 12.82 ± 21.681 |
| Constipation, CFB to Week 91 | -4.63 ± 22.752 | 16.67 ± 25.318 |
| Constipation, CFB to Week 94 | -2.78 ± 18.473 | 11.11 ± 16.412 |
| Constipation, CFB to Week 97 | -6.67 ± 18.362 | 15.15 ± 22.918 |
| Constipation, CFB to Week 100 | -2.86 ± 24.749 | 13.33 ± 17.213 |
| Constipation, CFB to Week 103 | -4.90 ± 23.402 | 16.67 ± 25.198 |
| Constipation, CFB to Week 106 | -4.04 ± 21.663 | 14.29 ± 17.817 |
| Constipation, CFB to Week 109 | -3.92 ± 19.703 | 12.50 ± 17.252 |
| Constipation, CFB to Week 112 | -5.75 ± 20.057 | 9.52 ± 16.265 |
| Constipation, CFB to Week 115 | -7.78 ± 16.800 | 12.50 ± 17.252 |
| Constipation, CFB to Week 118 | -2.22 ± 21.323 | 8.33 ± 15.430 |
| Constipation, CFB to Week 121 | 1.39 ± 26.882 | 8.33 ± 15.430 |
| Constipation, CFB to Week 124 | -2.56 ± 26.538 | 5.56 ± 13.608 |
| Constipation, CFB to Week 127 | 0.00 ± 24.944 | 11.11 ± 17.213 |
| Constipation, CFB to Week 130 | 1.33 ± 31.151 | 13.33 ± 18.257 |
| Constipation, CFB to Week 133 | 5.56 ± 32.103 | 27.78 ± 25.092 |
| Constipation, CFB to Week 136 | 3.17 ± 20.829 | 13.33 ± 18.257 |
| Constipation, CFB to Week 139 | 3.17 ± 20.829 | 16.67 ± 18.257 |
| Constipation, CFB to Week 142 | -1.52 ± 12.503 | 16.67 ± 19.245 |
| Constipation, CFB to Week 145 | -1.85 ± 17.977 | 13.33 ± 18.257 |
| Constipation, CFB to Week 148 | -1.75 ± 20.709 | 8.33 ± 16.667 |
| Constipation, CFB to Week 151 | -1.59 ± 19.653 | 8.33 ± 16.667 |
| Constipation, CFB to Week 154 | 3.51 ± 21.928 | 8.33 ± 16.667 |
| Constipation, CFB to Week 157 | -3.92 ± 20.008 | 11.11 ± 19.245 |
| Constipation, CFB to Week 160 | 1.85 ± 21.305 | 0.00 ± NA |
| Constipation, CFB to Week 163 | 0.00 ± 22.866 | 22.22 ± 19.245 |
| Constipation, CFB to Week 166 | 0.00 ± 21.822 | 11.11 ± 19.245 |
| Constipation, CFB to Week 169 | 0.00 ± 20.412 | 11.11 ± 19.245 |
| Constipation, CFB to Week 172 | 0.00 ± 23.570 | 11.11 ± 19.245 |
| Constipation, CFB to Week 175 | 2.78 ± 36.121 | 11.11 ± 19.245 |
| Constipation, CFB to Week 178 | -2.38 ± 20.524 | 11.11 ± 19.245 |
| Constipation, CFB to Week 181 | 2.38 ± 27.625 | 22.22 ± 38.490 |
| Constipation, CFB to Week 184 | 9.09 ± 15.570 | 11.11 ± 19.245 |
| Constipation, CFB to Week 187 | 14.81 ± 33.793 | 33.33 ± 47.140 |
| Constipation, CFB to Week 190 | 3.33 ± 39.907 | 0.00 ± 0.000 |
| Constipation, CFB to Week 193 | 0.00 ± 0.000 | 11.11 ± 19.245 |
| Constipation, CFB to Week 196 | -8.33 ± 23.570 | 11.11 ± 19.245 |
| Constipation, CFB to Week 199 | 0.00 ± 0.000 | 11.11 ± 19.245 |
| Constipation, CFB to Week 202 | -7.41 ± 22.222 | 11.11 ± 19.245 |
| Constipation, CFB to Week 205 | -9.52 ± 25.198 | 16.67 ± 23.570 |
| Constipation, CFB to Week 208 | -9.52 ± 25.198 | 16.67 ± 23.570 |
| Constipation, CFB to Week 211 | -13.33 ± 29.814 | 16.67 ± 23.570 |
| Constipation, CFB to Week 214 | -22.22 ± 38.490 | 16.67 ± 23.570 |
| Constipation, CFB to Week 217 | 0.00 ± 0.000 | 16.67 ± 23.570 |
| Constipation, CFB to Week 220 | 0.00 ± 0.000 | 16.67 ± 23.570 |
| Constipation, CFB to Week 223 | 0.00 ± 0.000 | 16.67 ± 23.570 |
| Constipation, CFB to Week 226 | 0.00 ± 0.000 | 33.33 ± NA |
| Constipation, CFB to Week 229 | 0.00 ± 0.000 | 33.33 ± NA |
| Constipation, CFB to Week 232 | 0.00 ± 0.000 | 33.33 ± NA |
| Constipation, CFB to Week 235 | 0.00 ± 0.000 | 33.33 ± NA |
| Constipation, CFB to Week 238 | — | 33.33 ± NA |
| Constipation, CFB to EOT (~242 weeks) | 3.70 ± 26.180 | 8.72 ± 22.265 |
| Constipation, CFB to LFU (~263 weeks) | 1.45 ± 25.842 | 3.33 ± 26.269 |
| Diarrhea, CFB to Week 4 | -4.17 ± 22.713 | -4.07 ± 20.548 |
| Diarrhea, CFB to Week 7 | -3.91 ± 20.973 | -3.90 ± 21.612 |
| Diarrhea, CFB to Week 10 | -4.43 ± 18.880 | -7.69 ± 18.418 |
| Diarrhea, CFB to Week 13 | -5.11 ± 23.868 | -5.75 ± 18.875 |
| Diarrhea, CFB to Week 16 | -6.60 ± 22.734 | -4.40 ± 21.719 |
| Diarrhea, CFB to Week 19 | -5.56 ± 21.449 | -5.33 ± 15.591 |
| Diarrhea, CFB to Week 22 | -4.86 ± 22.674 | -4.07 ± 26.029 |
| Diarrhea, CFB to Week 25 | -5.07 ± 25.166 | -4.90 ± 23.402 |
| Diarrhea, CFB to Week 28 | -5.95 ± 21.435 | -6.67 ± 22.579 |
| Diarrhea, CFB to Week 31 | -6.41 ± 20.142 | -8.08 ± 18.690 |
| Diarrhea, CFB to Week 34 | -1.37 ± 22.525 | -5.33 ± 15.753 |
| Diarrhea, CFB to Week 37 | -3.48 ± 23.308 | -4.00 ± 14.657 |
| Diarrhea, CFB to Week 40 | -3.81 ± 25.722 | -6.67 ± 13.608 |
| Diarrhea, CFB to Week 43 | -1.43 ± 23.697 | -6.35 ± 17.059 |
| Diarrhea, CFB to Week 46 | -7.29 ± 24.823 | -6.25 ± 13.437 |
| Diarrhea, CFB to Week 49 | -6.25 ± 22.123 | -3.51 ± 10.510 |
| Diarrhea, CFB to Week 52 | -3.17 ± 18.660 | -5.00 ± 12.212 |
| Diarrhea, CFB to Week 55 | -3.33 ± 25.080 | -5.26 ± 12.488 |
| Diarrhea, CFB to Week 58 | -4.68 ± 23.937 | 0.00 ± 16.169 |
| Diarrhea, CFB to Week 61 | -4.08 ± 24.184 | 0.00 ± 11.433 |
| Diarrhea, CFB to Week 64 | -8.50 ± 21.953 | -2.22 ± 8.607 |
| Diarrhea, CFB to Week 67 | -7.48 ± 21.800 | -2.08 ± 14.751 |
| Diarrhea, CFB to Week 70 | -6.00 ± 18.675 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 73 | -6.50 ± 23.828 | -2.22 ± 15.258 |
| Diarrhea, CFB to Week 76 | -3.17 ± 23.058 | -4.44 ± 11.729 |
| Diarrhea, CFB to Week 79 | -7.94 ± 24.205 | -4.44 ± 11.729 |
| Diarrhea, CFB to Week 82 | -4.65 ± 25.801 | -4.44 ± 11.729 |
| Diarrhea, CFB to Week 85 | -10.81 ± 24.912 | -2.56 ± 16.452 |
| Diarrhea, CFB to Week 88 | -3.81 ± 31.072 | -2.56 ± 9.245 |
| Diarrhea, CFB to Week 91 | -4.50 ± 25.046 | 2.38 ± 15.821 |
| Diarrhea, CFB to Week 94 | -8.33 ± 25.666 | 0.00 ± 14.213 |
| Diarrhea, CFB to Week 97 | -8.89 ± 26.164 | -3.03 ± 10.050 |
| Diarrhea, CFB to Week 100 | -6.67 ± 25.309 | 0.00 ± 15.713 |
| Diarrhea, CFB to Week 103 | -8.82 ± 23.654 | -3.70 ± 11.111 |
| Diarrhea, CFB to Week 106 | -8.08 ± 22.096 | -4.76 ± 12.599 |
| Diarrhea, CFB to Week 109 | -8.82 ± 22.185 | -4.17 ± 11.785 |
| Diarrhea, CFB to Week 112 | -10.00 ± 23.407 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 115 | -12.22 ± 23.947 | 0.00 ± 17.817 |
| Diarrhea, CFB to Week 118 | -12.22 ± 23.947 | -4.17 ± 11.785 |
| Diarrhea, CFB to Week 121 | -10.67 ± 28.415 | -4.17 ± 11.785 |
| Diarrhea, CFB to Week 124 | -10.26 ± 26.279 | -5.56 ± 13.608 |
| Diarrhea, CFB to Week 127 | -8.97 ± 25.919 | -5.56 ± 13.608 |
| Diarrhea, CFB to Week 130 | -8.00 ± 27.689 | -6.67 ± 14.907 |
| Diarrhea, CFB to Week 133 | -12.50 ± 25.656 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 136 | -7.94 ± 25.614 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 139 | -7.94 ± 25.614 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 142 | -10.61 ± 23.874 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 145 | -9.26 ± 27.548 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 148 | -5.26 ± 31.940 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 151 | -9.52 ± 26.125 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 154 | -8.77 ± 24.450 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 157 | -3.92 ± 16.169 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 160 | -3.70 ± 15.713 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 163 | -5.56 ± 12.783 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 166 | -2.22 ± 15.258 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 169 | -5.88 ± 13.098 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 172 | -7.69 ± 14.618 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 175 | -5.56 ± 12.975 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 178 | -4.76 ± 12.105 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 181 | 0.00 ± 13.074 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 184 | -6.06 ± 13.484 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 187 | -3.70 ± 20.031 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 190 | -7.41 ± 14.699 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 193 | 4.76 ± 12.599 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 196 | 0.00 ± 0.000 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 199 | -4.76 ± 12.599 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 202 | -3.70 ± 11.111 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 205 | -4.76 ± 12.599 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 208 | -4.76 ± 12.599 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 211 | 0.00 ± 0.000 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 214 | 0.00 ± 0.000 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 217 | 0.00 ± 0.000 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 220 | 0.00 ± 0.000 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 223 | 0.00 ± 0.000 | 0.00 ± 0.000 |
| Diarrhea, CFB to Week 226 | 0.00 ± 0.000 | 0.00 ± NA |
| Diarrhea, CFB to Week 229 | 0.00 ± 0.000 | 0.00 ± NA |
| Diarrhea, CFB to Week 232 | 0.00 ± 0.000 | 0.00 ± NA |
| Diarrhea, CFB to Week 235 | 0.00 ± 0.000 | 0.00 ± NA |
| Diarrhea, CFB to Week 238 | — | 0.00 ± NA |
| Diarrhea, CFB to EOT (~242 weeks) | -3.11 ± 23.464 | -3.54 ± 23.482 |
| Diarrhea, CFB to LFU (~263 weeks) | -3.86 ± 24.612 | -14.04 ± 23.083 |
| FD, CFB to Week 4 | -3.22 ± 29.532 | -3.61 ± 26.551 |
| FD, CFB to Week 7 | -3.88 ± 26.984 | -4.70 ± 21.970 |
| FD, CFB to Week 10 | -1.04 ± 23.267 | -1.54 ± 23.885 |
| FD, CFB to Week 13 | 0.61 ± 30.083 | -5.17 ± 23.197 |
| FD, CFB to Week 16 | 0.65 ± 31.993 | -3.85 ± 24.391 |
| FD, CFB to Week 19 | -2.46 ± 29.271 | -0.67 ± 22.827 |
| FD, CFB to Week 22 | -1.06 ± 27.414 | 0.00 ± 27.546 |
| FD, CFB to Week 25 | -3.33 ± 30.002 | 2.94 ± 26.423 |
| FD, CFB to Week 28 | -2.81 ± 29.543 | -0.95 ± 24.899 |
| FD, CFB to Week 31 | -3.07 ± 26.765 | -2.02 ± 26.272 |
| FD, CFB to Week 34 | -3.70 ± 29.896 | 0.00 ± 31.914 |
| FD, CFB to Week 37 | -1.00 ± 28.996 | -2.67 ± 27.080 |
| FD, CFB to Week 40 | 0.00 ± 35.441 | -2.67 ± 27.080 |
| FD, CFB to Week 43 | -4.35 ± 29.100 | -6.35 ± 29.096 |
| FD, CFB to Week 46 | -3.70 ± 31.742 | 2.08 ± 22.669 |
| FD, CFB to Week 49 | -3.17 ± 31.517 | 0.00 ± 19.245 |
| FD, CFB to Week 52 | -2.69 ± 29.752 | -3.33 ± 28.408 |
| FD, CFB to Week 55 | -2.26 ± 32.674 | -5.26 ± 22.942 |
| FD, CFB to Week 58 | -1.19 ± 34.209 | 1.85 ± 26.746 |
| FD, CFB to Week 61 | -2.67 ± 32.184 | -1.85 ± 21.305 |
| FD, CFB to Week 64 | -4.00 ± 29.075 | -6.67 ± 31.371 |
| FD, CFB to Week 67 | -1.36 ± 30.398 | 0.00 ± 27.217 |
| FD, CFB to Week 70 | -3.40 ± 34.187 | -5.13 ± 22.958 |
| FD, CFB to Week 73 | 4.07 ± 35.115 | -2.22 ± 26.627 |
| FD, CFB to Week 76 | 0.81 ± 34.551 | 0.00 ± 25.198 |
| FD, CFB to Week 79 | 0.00 ± 33.333 | -2.22 ± 23.458 |
| FD, CFB to Week 82 | 3.17 ± 34.382 | -4.44 ± 21.331 |
| FD, CFB to Week 85 | -1.85 ± 34.682 | -7.69 ± 24.167 |
| FD, CFB to Week 88 | 1.85 ± 38.168 | -5.13 ± 22.958 |
| FD, CFB to Week 91 | -1.80 ± 34.198 | -2.38 ± 24.335 |
| FD, CFB to Week 94 | -1.85 ± 35.585 | -2.78 ± 30.011 |
| FD, CFB to Week 97 | 1.11 ± 32.144 | -6.06 ± 25.025 |
| FD, CFB to Week 100 | 2.86 ± 35.582 | -10.00 ± 22.498 |
| FD, CFB to Week 103 | -3.92 ± 34.587 | -18.52 ± 33.793 |
| FD, CFB to Week 106 | -2.02 ± 34.298 | -9.52 ± 31.706 |
| FD, CFB to Week 109 | -2.94 ± 32.169 | -12.50 ± 24.801 |
| FD, CFB to Week 112 | -5.75 ± 30.949 | -14.29 ± 26.227 |
| FD, CFB to Week 115 | -4.44 ± 34.722 | -12.50 ± 24.801 |
| FD, CFB to Week 118 | -3.33 ± 33.160 | -8.33 ± 29.547 |
| FD, CFB to Week 121 | -6.67 ± 30.429 | -12.50 ± 24.801 |
| FD, CFB to Week 124 | -11.54 ± 29.728 | -16.67 ± 27.889 |
| FD, CFB to Week 127 | -3.85 ± 33.102 | -5.56 ± 13.608 |
| FD, CFB to Week 130 | -8.00 ± 30.852 | -6.67 ± 14.907 |
| FD, CFB to Week 133 | -2.78 ± 33.932 | -16.67 ± 27.889 |
| FD, CFB to Week 136 | -1.59 ± 35.709 | -6.67 ± 14.907 |
| FD, CFB to Week 139 | -3.17 ± 34.809 | -16.67 ± 27.889 |
| FD, CFB to Week 142 | -9.09 ± 32.824 | -8.33 ± 16.667 |
| FD, CFB to Week 145 | 0.00 ± 36.155 | 0.00 ± 23.570 |
| FD, CFB to Week 148 | -5.26 ± 29.945 | -8.33 ± 16.667 |
| FD, CFB to Week 151 | -1.59 ± 37.232 | -8.33 ± 16.667 |
| FD, CFB to Week 154 | -1.75 ± 39.242 | 0.00 ± 27.217 |
| FD, CFB to Week 157 | 5.88 ± 24.254 | 0.00 ± 33.333 |
| FD, CFB to Week 160 | 7.41 ± 24.403 | -11.11 ± 19.245 |
| FD, CFB to Week 163 | -3.70 ± 22.547 | -11.11 ± 19.245 |
| FD, CFB to Week 166 | 2.22 ± 29.457 | 0.00 ± 33.333 |
| FD, CFB to Week 169 | 1.96 ± 29.978 | 0.00 ± 33.333 |
| FD, CFB to Week 172 | -5.13 ± 26.688 | 0.00 ± 33.333 |
| FD, CFB to Week 175 | 0.00 ± 31.782 | -11.11 ± 19.245 |
| FD, CFB to Week 178 | -2.38 ± 30.562 | -11.11 ± 19.245 |
| FD, CFB to Week 181 | -2.38 ± 20.524 | 0.00 ± 33.333 |
| FD, CFB to Week 184 | 0.00 ± 29.814 | 0.00 ± 33.333 |
| FD, CFB to Week 187 | -3.70 ± 20.031 | 0.00 ± 0.000 |
| FD, CFB to Week 190 | -7.41 ± 32.394 | -11.11 ± 19.245 |
| FD, CFB to Week 193 | -9.52 ± 25.198 | -11.11 ± 19.245 |
| FD, CFB to Week 196 | -4.17 ± 27.817 | -11.11 ± 19.245 |
| FD, CFB to Week 199 | -4.76 ± 12.599 | -11.11 ± 19.245 |
| FD, CFB to Week 202 | -3.70 ± 38.889 | 0.00 ± 33.333 |
| FD, CFB to Week 205 | -9.52 ± 31.706 | -16.67 ± 23.570 |
| FD, CFB to Week 208 | -14.29 ± 32.530 | -16.67 ± 23.570 |
| FD, CFB to Week 211 | 0.00 ± 47.140 | -16.67 ± 23.570 |
| FD, CFB to Week 214 | 22.22 ± 38.490 | -16.67 ± 23.570 |
| FD, CFB to Week 217 | -16.67 ± 23.570 | -16.67 ± 23.570 |
| FD, CFB to Week 220 | -16.67 ± 23.570 | -16.67 ± 23.570 |
| FD, CFB to Week 223 | -8.33 ± 16.667 | -16.67 ± 23.570 |
| FD, CFB to Week 226 | -11.11 ± 19.245 | 0.00 ± NA |
| FD, CFB to Week 229 | -33.33 ± 47.140 | 0.00 ± NA |
| FD, CFB to Week 232 | -22.22 ± 38.490 | 0.00 ± NA |
| FD, CFB to Week 235 | 0.00 ± 0.000 | 0.00 ± NA |
| FD, CFB to Week 238 | — | 0.00 ± NA |
| FD, CFB to EOT (~242 weeks) | 2.82 ± 32.490 | -1.01 ± 28.627 |
| FD, CFB to LFU (~263 weeks) | -1.47 ± 37.516 | -1.67 ± 36.635 |
The EORTC QLQ-MY20 is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. The module comprised of 20 questions that addressed four myeloma-specific HRQoL domains: disease symptoms (DS), side effects of treatment (SET), future perspective (FP) and body image (BI). Responses are 1 to 4. Scores were averaged and scales were transformed to 0 to 100 scale. A high score for disease symptoms and side effects of treatment represented a high level of symptomatology or problems, whereas a high score for future perspective and body image represented better outcomes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Scores on Scale | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone |
|---|---|---|
| BI, CFB to Week 4 | 7.07 ± 21.663 | 7.14 ± 19.298 |
| BI, CFB to Week 7 | -4.44 ± 27.310 | 2.08 ± 19.124 |
| BI, CFB to Week 10 | -1.23 ± 21.645 | 5.56 ± 19.245 |
| BI, CFB to Week 13 | 1.33 ± 20.367 | 5.13 ± 22.958 |
| BI, CFB to Week 16 | -4.17 ± 26.580 | -4.44 ± 24.774 |
| BI, CFB to Week 19 | -3.03 ± 20.339 | 11.11 ± 21.711 |
| BI, CFB to Week 22 | 5.80 ± 21.678 | 0.00 ± 14.213 |
| BI, CFB to Week 25 | -1.39 ± 23.008 | 0.00 ± 21.082 |
| BI, CFB to Week 28 | 4.76 ± 21.822 | 0.00 ± 25.198 |
| BI, CFB to Week 31 | 4.76 ± 24.234 | 8.33 ± 23.570 |
| BI, CFB to Week 34 | 5.26 ± 25.491 | 4.76 ± 23.002 |
| BI, CFB to Week 37 | 0.00 ± 28.006 | -4.17 ± 21.362 |
| BI, CFB to Week 40 | 3.70 ± 22.547 | 0.00 ± 25.198 |
| BI, CFB to Week 43 | 1.85 ± 21.305 | 0.00 ± 27.217 |
| BI, CFB to Week 46 | 4.17 ± 16.667 | 6.67 ± 27.889 |
| BI, CFB to Week 49 | 5.88 ± 24.254 | -5.56 ± 32.773 |
| BI, CFB to Week 52 | 2.38 ± 20.524 | 4.76 ± 23.002 |
| BI, CFB to Week 55 | -5.13 ± 12.518 | -4.76 ± 35.635 |
| BI, CFB to Week 58 | 0.00 ± 22.646 | 4.76 ± 23.002 |
| BI, CFB to Week 61 | -2.38 ± 15.821 | 0.00 ± 27.217 |
| BI, CFB to Week 64 | 5.13 ± 22.958 | 6.67 ± 27.889 |
| BI, CFB to Week 67 | -2.38 ± 20.524 | 0.00 ± 33.333 |
| BI, CFB to Week 70 | 0.00 ± 19.245 | 0.00 ± 33.333 |
| BI, CFB to Week 73 | -6.67 ± 21.082 | 6.67 ± 27.889 |
| BI, CFB to Week 76 | -8.33 ± 25.126 | 0.00 ± 33.333 |
| BI, CFB to Week 79 | 3.03 ± 27.707 | 0.00 ± 33.333 |
| BI, CFB to Week 82 | 9.09 ± 21.556 | 6.67 ± 27.889 |
| BI, CFB to Week 85 | 4.17 ± 21.362 | 0.00 ± 33.333 |
| BI, CFB to Week 88 | -15.15 ± 22.918 | 0.00 ± 33.333 |
| BI, CFB to Week 91 | -8.33 ± 15.430 | 0.00 ± 33.333 |
| BI, CFB to Week 94 | -3.33 ± 18.922 | 0.00 ± 33.333 |
| BI, CFB to Week 97 | 4.17 ± 11.785 | 0.00 ± 33.333 |
| BI, CFB to Week 100 | 9.52 ± 25.198 | -11.11 ± 19.245 |
| BI, CFB to Week 103 | 0.00 ± 25.198 | -22.22 ± 19.245 |
| BI, CFB to Week 106 | 5.56 ± 25.092 | -33.33 ± NA |
| BI, CFB to Week 109 | 0.00 ± 25.198 | -11.11 ± 38.490 |
| BI, CFB to Week 112 | 11.11 ± 27.217 | -33.33 ± 0.000 |
| BI, CFB to Week 115 | 4.76 ± 23.002 | -22.22 ± 19.245 |
| BI, CFB to Week 118 | -4.76 ± 23.002 | -22.22 ± 19.245 |
| BI, CFB to Week 121 | 0.00 ± 19.245 | -33.33 ± 33.333 |
| BI, CFB to Week 124 | -13.33 ± 18.257 | -33.33 ± 0.000 |
| BI, CFB to Week 127 | 0.00 ± 21.082 | 0.00 ± 0.00 |
| BI, CFB to Week 130 | 5.56 ± 25.092 | 0.00 ± NA |
| BI, CFB to Week 133 | 6.67 ± 14.907 | -16.67 ± 23.570 |
| BI, CFB to Week 136 | 0.00 ± 0.00 | 0.00 ± NA |
| BI, CFB to Week 139 | -8.33 ± 16.667 | -33.33 ± 47.140 |
| BI, CFB to Week 142 | 8.33 ± 16.667 | — |
| BI, CFB to Week 145 | 11.11 ± 19.245 | 0.00 ± NA |
| BI, CFB to Week 148 | 0.00 ± 33.333 | 0.00 ± NA |
| BI, CFB to Week 151 | 22.22 ± 19.245 | 0.00 ± NA |
| BI, CFB to Week 154 | -16.67 ± 23.570 | 0.00 ± NA |
| BI, CFB to Week 157 | 0.00 ± 27.217 | — |
| BI, CFB to Week 160 | 11.11 ± 19.245 | — |
| BI, CFB to Week 163 | 16.67 ± 23.570 | — |
| BI, CFB to Week 166 | 16.67 ± 23.570 | — |
| BI, CFB to Week 169 | 16.67 ± 23.570 | — |
| BI, CFB to Week 172 | 33.33 ± NA | — |
| BI, CFB to Week 175 | 33.33 ± NA | — |
| BI, CFB to Week 178 | 33.33 ± NA | — |
| BI, CFB to Week 181 | 33.33 ± NA | — |
| BI, CFB to EOT (~242 weeks) | -10.14 ± 29.189 | -5.13 ± 18.490 |
| BI, CFB to LFU (~263 weeks) | -11.11 ± 27.217 | -11.11 ± 19.245 |
| DS, CFB to Week 4 | -2.54 ± 15.169 | -3.16 ± 14.272 |
| DS, CFB to Week 7 | -2.38 ± 16.226 | -5.76 ± 16.668 |
| DS, CFB to Week 10 | -3.71 ± 16.488 | -4.82 ± 17.445 |
| DS, CFB to Week 13 | -4.67 ± 18.590 | -7.05 ± 16.100 |
| DS, CFB to Week 16 | -5.51 ± 17.544 | -5.85 ± 18.479 |
| DS, CFB to Week 19 | -5.05 ± 20.806 | -5.67 ± 19.650 |
| DS, CFB to Week 22 | -4.08 ± 19.689 | -6.46 ± 18.330 |
| DS, CFB to Week 25 | -6.92 ± 16.442 | -6.54 ± 16.382 |
| DS, CFB to Week 28 | -4.01 ± 19.672 | -7.68 ± 19.487 |
| DS, CFB to Week 31 | -4.28 ± 18.536 | -7.24 ± 18.865 |
| DS, CFB to Week 34 | -4.21 ± 16.739 | -6.25 ± 11.735 |
| DS, CFB to Week 37 | -7.12 ± 19.892 | -3.47 ± 14.075 |
| DS, CFB to Week 40 | -8.32 ± 18.363 | -3.04 ± 12.989 |
| DS, CFB to Week 43 | -7.50 ± 19.751 | -3.09 ± 14.664 |
| DS, CFB to Week 46 | -9.01 ± 17.512 | -3.85 ± 16.879 |
| DS, CFB to Week 49 | -6.74 ± 17.359 | -3.13 ± 20.883 |
| DS, CFB to Week 52 | -8.83 ± 17.943 | -5.88 ± 14.760 |
| DS, CFB to Week 55 | -7.01 ± 19.811 | -1.39 ± 14.558 |
| DS, CFB to Week 58 | -7.08 ± 20.435 | -1.85 ± 18.505 |
| DS, CFB to Week 61 | -7.02 ± 19.827 | 0.35 ± 16.161 |
| DS, CFB to Week 64 | -6.39 ± 19.010 | -5.95 ± 16.803 |
| DS, CFB to Week 67 | -11.04 ± 16.693 | -5.56 ± 18.426 |
| DS, CFB to Week 70 | -12.64 ± 16.959 | -8.12 ± 15.976 |
| DS, CFB to Week 73 | -9.36 ± 15.274 | -2.78 ± 19.214 |
| DS, CFB to Week 76 | -7.57 ± 15.562 | -5.19 ± 13.684 |
| DS, CFB to Week 79 | -8.39 ± 15.938 | -8.67 ± 13.790 |
| DS, CFB to Week 82 | -6.46 ± 15.596 | -10.00 ± 15.459 |
| DS, CFB to Week 85 | -7.69 ± 14.917 | -10.19 ± 18.628 |
| DS, CFB to Week 88 | -8.77 ± 16.228 | -11.57 ± 17.957 |
| DS, CFB to Week 91 | -8.26 ± 17.888 | -0.46 ± 23.145 |
| DS, CFB to Week 94 | -10.77 ± 17.865 | -4.04 ± 20.502 |
| DS, CFB to Week 97 | -8.30 ± 14.783 | -7.22 ± 15.505 |
| DS, CFB to Week 100 | -8.86 ± 18.135 | -3.89 ± 22.688 |
| DS, CFB to Week 103 | -8.79 ± 17.518 | -2.47 ± 19.859 |
| DS, CFB to Week 106 | -9.39 ± 18.811 | -0.93 ± 17.362 |
| DS, CFB to Week 109 | -7.81 ± 14.082 | -2.78 ± 20.574 |
| DS, CFB to Week 112 | -11.30 ± 15.177 | 1.59 ± 24.993 |
| DS, CFB to Week 115 | -7.41 ± 14.468 | -2.08 ± 15.974 |
| DS, CFB to Week 118 | -6.67 ± 16.272 | 0.00 ± 21.207 |
| DS, CFB to Week 121 | -4.91 ± 25.256 | -2.08 ± 23.181 |
| DS, CFB to Week 124 | -11.56 ± 17.192 | -6.48 ± 20.005 |
| DS, CFB to Week 127 | -7.91 ± 18.337 | -5.56 ± 19.245 |
| DS, CFB to Week 130 | -12.00 ± 14.316 | -1.11 ± 23.040 |
| DS, CFB to Week 133 | -11.34 ± 15.497 | -4.63 ± 25.680 |
| DS, CFB to Week 136 | -8.99 ± 19.283 | -7.78 ± 20.638 |
| DS, CFB to Week 139 | -10.05 ± 14.339 | -11.11 ± 22.222 |
| DS, CFB to Week 142 | -7.83 ± 13.131 | -5.56 ± 27.962 |
| DS, CFB to Week 145 | -7.72 ± 16.185 | -3.33 ± 22.083 |
| DS, CFB to Week 148 | -7.89 ± 16.283 | -5.56 ± 27.962 |
| DS, CFB to Week 151 | -10.32 ± 15.643 | -8.33 ± 20.538 |
| DS, CFB to Week 154 | -9.26 ± 17.568 | 2.78 ± 31.914 |
| DS, CFB to Week 157 | -10.13 ± 16.344 | -5.56 ± 36.430 |
| DS, CFB to Week 160 | -5.56 ± 20.076 | 5.56 ± 52.997 |
| DS, CFB to Week 163 | -9.26 ± 19.339 | -1.85 ± 36.147 |
| DS, CFB to Week 166 | -11.11 ± 18.306 | -3.70 ± 39.021 |
| DS, CFB to Week 169 | -7.84 ± 17.684 | -7.41 ± 33.945 |
| DS, CFB to Week 172 | -16.24 ± 16.738 | -9.26 ± 31.590 |
| DS, CFB to Week 175 | -13.43 ± 17.157 | -7.41 ± 33.945 |
| DS, CFB to Week 178 | -10.32 ± 17.549 | -16.67 ± 24.216 |
| DS, CFB to Week 181 | -9.92 ± 15.281 | -9.26 ± 31.590 |
| DS, CFB to Week 184 | -2.53 ± 19.620 | -5.56 ± 36.430 |
| DS, CFB to Week 187 | -2.47 ± 16.224 | -5.56 ± 54.997 |
| DS, CFB to Week 190 | -5.00 ± 21.667 | -3.70 ± 39.021 |
| DS, CFB to Week 193 | -3.17 ± 7.069 | -9.26 ± 31.590 |
| DS, CFB to Week 196 | -12.35 ± 17.073 | -13.70 ± 26.674 |
| DS, CFB to Week 199 | -2.38 ± 14.649 | -5.56 ± 36.430 |
| DS, CFB to Week 202 | -9.88 ± 18.794 | -7.41 ± 33.945 |
| DS, CFB to Week 205 | -11.11 ± 23.130 | 13.89 ± 19.642 |
| DS, CFB to Week 208 | -11.90 ± 21.855 | 8.33 ± 11.785 |
| DS, CFB to Week 211 | -11.11 ± 23.895 | 13.89 ± 19.642 |
| DS, CFB to Week 214 | -14.81 ± 30.598 | 13.89 ± 19.642 |
| DS, CFB to Week 217 | 0.00 ± 0.000 | 13.89 ± 19.642 |
| DS, CFB to Week 220 | -2.78 ± 3.928 | 5.56 ± 7.857 |
| DS, CFB to Week 223 | -1.39 ± 6.991 | -2.78 ± 3.928 |
| DS, CFB to Week 226 | -5.56 ± 9.623 | 16.67 ± NA |
| DS, CFB to Week 229 | -8.33 ± 11.785 | 16.67 ± NA |
| DS, CFB to Week 232 | -1.85 ± 8.486 | 22.22 ± NA |
| DS, CFB to Week 235 | 0.00 ± 0.000 | 16.67 ± NA |
| DS, CFB to Week 238 | — | 16.67 ± NA |
| DS, CFB to EOT (~242 weeks) | 1.44 ± 21.907 | -1.23 ± 18.763 |
| DS, CFB to LFU (~263 weeks) | -2.12 ± 22.907 | -15.93 ± 23.370 |
| SET, CFB to Week 4 | -2.18 ± 7.659 | 3.92 ± 11.722 |
| SET, CFB to Week 7 | 0.69 ± 8.787 | -1.90 ± 8.875 |
| SET, CFB to Week 10 | 0.09 ± 11.303 | -0.90 ± 11.107 |
| SET, CFB to Week 13 | -1.33 ± 9.146 | 0.19 ± 14.300 |
| SET, CFB to Week 16 | -1.81 ± 9.856 | -1.98 ± 12.199 |
| SET, CFB to Week 19 | -0.22 ± 8.596 | -2.16 ± 14.177 |
| SET, CFB to Week 22 | -1.16 ± 8.625 | -2.58 ± 12.207 |
| SET, CFB to Week 25 | -3.23 ± 9.781 | 4.65 ± 11.792 |
| SET, CFB to Week 28 | -2.49 ± 6.870 | -3.10 ± 8.196 |
| SET, CFB to Week 31 | -2.77 ± 9.936 | -4.77 ± 13.877 |
| SET, CFB to Week 34 | -0.76 ± 7.892 | -6.24 ± 10.216 |
| SET, CFB to Week 37 | -2.08 ± 8.579 | 2.31 ± 9.645 |
| SET, CFB to Week 40 | -3.09 ± 11.054 | -1.81 ± 7.305 |
| SET, CFB to Week 43 | -2.37 ± 11.113 | -1.64 ± 10.541 |
| SET, CFB to Week 46 | -3.06 ± 8.828 | 3.48 ± 3.606 |
| SET, CFB to Week 49 | -2.18 ± 6.875 | 1.17 ± 7.617 |
| SET, CFB to Week 52 | -4.10 ± 6.707 | -4.50 ± 7.433 |
| SET, CFB to Week 55 | -3.79 ± 8.101 | -0.11 ± 8.475 |
| SET, CFB to Week 58 | 0.26 ± 10.728 | -3.07 ± 6.200 |
| SET, CFB to Week 61 | -1.01 ± 9.369 | -0.21 ± 8.462 |
| SET, CFB to Week 64 | -1.08 ± 7.905 | -0.30 ± 6.150 |
| SET, CFB to Week 67 | -2.57 ± 7.500 | -1.70 ± 6.228 |
| SET, CFB to Week 70 | -1.40 ± 8.276 | -3.63 ± 5.168 |
| SET, CFB to Week 73 | 0.54 ± 10.793 | -0.30 ± 5.402 |
| SET, CFB to Week 76 | -0.06 ± 7.798 | -1.04 ± 6.189 |
| SET, CFB to Week 79 | -3.80 ± 8.576 | -2.37 ± 4.897 |
| SET, CFB to Week 82 | -2.69 ± 7.496 | -5.04 ± 5.320 |
| SET, CFB to Week 85 | 1.44 ± 9.980 | -1.36 ± 4.777 |
| SET, CFB to Week 88 | 1.16 ± 8.321 | -1.36 ± 8.049 |
| SET, CFB to Week 91 | -0.74 ± 8.654 | 6.42 ± 3.361 |
| SET, CFB to Week 94 | -2.07 ± 8.985 | -0.25 ± 2.971 |
| SET, CFB to Week 97 | -2.64 ± 8.772 | -0.25 ± 8.545 |
| SET, CFB to Week 100 | -3.39 ± 10.142 | -1.36 ± 8.049 |
| SET, CFB to Week 103 | -0.93 ± 9.147 | -1.36 ± 1.750 |
| SET, CFB to Week 106 | -1.85 ± 5.781 | -0.74 ± NA |
| SET, CFB to Week 109 | -0.93 ± 8.508 | -5.80 ± 6.833 |
| SET, CFB to Week 112 | -2.84 ± 7.138 | -5.37 ± 15.975 |
| SET, CFB to Week 115 | -2.65 ± 9.475 | -3.46 ± 8.837 |
| SET, CFB to Week 118 | 1.43 ± 10.720 | 6.54 ± 5.242 |
| SET, CFB to Week 121 | 1.11 ± 10.005 | 0.12 ± 12.408 |
| SET, CFB to Week 124 | 4.67 ± 14.519 | -2.04 ± 20.689 |
| SET, CFB to Week 127 | 2.65 ± 8.816 | 6.67 ± 1.048 |
| SET, CFB to Week 130 | 2.35 ± 7.343 | -0.74 ± NA |
| SET, CFB to Week 133 | 0.59 ± 8.201 | 2.78 ± 3.928 |
| SET, CFB to Week 136 | 5.90 ± 3.885 | 11.11 ± NA |
| SET, CFB to Week 139 | 9.63 ± 10.102 | 4.63 ± 3.928 |
| SET, CFB to Week 142 | 7.31 ± 8.003 | — |
| SET, CFB to Week 145 | 9.88 ± 4.277 | 3.70 ± NA |
| SET, CFB to Week 148 | 2.96 ± 8.543 | 3.70 ± NA |
| SET, CFB to Week 151 | 7.41 ± 3.704 | 3.70 ± NA |
| SET, CFB to Week 154 | 9.26 ± 2.619 | 3.70 ± NA |
| SET, CFB to Week 157 | 6.85 ± 6.985 | — |
| SET, CFB to Week 160 | 6.67 ± 4.857 | — |
| SET, CFB to Week 163 | 6.30 ± 6.809 | — |
| SET, CFB to Week 166 | 5.56 ± 2.619 | — |
| SET, CFB to Week 169 | 7.41 ± 5.238 | — |
| SET, CFB to Week 172 | 3.70 ± NA | — |
| SET, CFB to Week 175 | 11.11 ± NA | — |
| SET, CFB to Week 178 | 0.00 ± NA | — |
| SET, CFB to Week 181 | 0.00 ± NA | — |
| SET, CFB to EOT (~242 weeks) | 1.73 ± 13.594 | -1.34 ± 15.436 |
| SET, CFB to LFU (~263 weeks) | 4.62 ± 12.905 | 14.69 ± 21.787 |
| FP, CFB to Week 4 | -3.37 ± 18.939 | 3.97 ± 14.194 |
| FP, CFB to Week 7 | 1.48 ± 19.947 | 7.64 ± 9.702 |
| FP, CFB to Week 10 | 1.65 ± 19.172 | 12.96 ± 18.247 |
| FP, CFB to Week 13 | 1.33 ± 20.367 | 15.38 ± 18.447 |
| FP, CFB to Week 16 | 0.93 ± 17.312 | 15.56 ± 23.682 |
| FP, CFB to Week 19 | 8.08 ± 17.207 | 16.67 ± 22.473 |
| FP, CFB to Week 22 | 6.28 ± 12.900 | 9.26 ± 24.995 |
| FP, CFB to Week 25 | 6.48 ± 19.908 | 5.56 ± 11.653 |
| FP, CFB to Week 28 | 9.52 ± 17.315 | 11.11 ± 14.548 |
| FP, CFB to Week 31 | 8.47 ± 24.064 | 12.50 ± 20.945 |
| FP, CFB to Week 34 | 9.36 ± 17.476 | 11.11 ± 20.286 |
| FP, CFB to Week 37 | 12.35 ± 20.835 | 6.94 ± 23.710 |
| FP, CFB to Week 40 | 9.88 ± 23.766 | 4.17 ± 22.954 |
| FP, CFB to Week 43 | 14.20 ± 24.641 | 6.35 ± 27.108 |
| FP, CFB to Week 46 | 6.94 ± 20.638 | -4.44 ± 30.021 |
| FP, CFB to Week 49 | 13.07 ± 24.291 | 7.41 ± 19.458 |
| FP, CFB to Week 52 | 6.35 ± 18.343 | 14.29 ± 19.994 |
| FP, CFB to Week 55 | 8.55 ± 17.066 | 4.76 ± 21.138 |
| FP, CFB to Week 58 | -3.17 ± 19.698 | 7.94 ± 16.623 |
| FP, CFB to Week 61 | 2.38 ± 20.056 | 12.70 ± 23.508 |
| FP, CFB to Week 64 | 1.71 ± 18.618 | 13.33 ± 24.088 |
| FP, CFB to Week 67 | 3.97 ± 16.076 | 15.56 ± 23.040 |
| FP, CFB to Week 70 | 5.13 ± 15.460 | 4.44 ± 16.851 |
| FP, CFB to Week 73 | -2.22 ± 20.820 | 11.11 ± 19.245 |
| FP, CFB to Week 76 | 4.63 ± 19.221 | 11.11 ± 26.058 |
| FP, CFB to Week 79 | 1.01 ± 16.817 | 11.11 ± 26.058 |
| FP, CFB to Week 82 | 3.03 ± 19.933 | 13.33 ± 25.337 |
| FP, CFB to Week 85 | -1.39 ± 28.753 | 0.00 ± 19.245 |
| FP, CFB to Week 88 | -2.02 ± 24.251 | 3.70 ± 12.830 |
| FP, CFB to Week 91 | 1.39 ± 25.502 | 0.00 ± 11.111 |
| FP, CFB to Week 94 | 4.44 ± 22.345 | 3.70 ± 12.830 |
| FP, CFB to Week 97 | 12.50 ± 18.245 | -11.11 ± 11.111 |
| FP, CFB to Week 100 | 4.76 ± 17.982 | -7.41 ± 16.973 |
| FP, CFB to Week 103 | 1.39 ± 22.567 | -14.81 ± 6.415 |
| FP, CFB to Week 106 | 3.70 ± 13.456 | 0.00 ± NA |
| FP, CFB to Week 109 | 2.78 ± 14.242 | -18.52 ± 6.415 |
| FP, CFB to Week 112 | 5.56 ± 20.787 | -11.11 ± 15.713 |
| FP, CFB to Week 115 | 6.35 ± 17.982 | -18.52 ± 6.415 |
| FP, CFB to Week 118 | -3.17 ± 12.363 | -18.52 ± 6.415 |
| FP, CFB to Week 121 | 6.35 ± 16.798 | -18.52 ± 6.415 |
| FP, CFB to Week 124 | -11.11 ± 26.058 | -16.67 ± 7.857 |
| FP, CFB to Week 127 | 1.85 ± 12.989 | -16.67 ± 7.857 |
| FP, CFB to Week 130 | 1.85 ± 16.355 | 0.00 ± NA |
| FP, CFB to Week 133 | 0.00 ± 15.713 | -22.22 ± 0.000 |
| FP, CFB to Week 136 | 0.00 ± 29.397 | -22.22 ± NA |
| FP, CFB to Week 139 | 5.56 ± 19.245 | -22.22 ± 0.000 |
| FP, CFB to Week 142 | 5.56 ± 21.276 | — |
| FP, CFB to Week 145 | 7.41 ± 25.660 | -22.22 ± NA |
| FP, CFB to Week 148 | 7.41 ± 16.973 | -22.22 ± NA |
| FP, CFB to Week 151 | 11.11 ± 19.245 | -22.22 ± NA |
| FP, CFB to Week 154 | 11.11 ± 31.427 | -22.22 |
| FP, CFB to Week 157 | 13.89 ± 16.667 | — |
| FP, CFB to Week 160 | 7.41 ± 16.973 | — |
| FP, CFB to Week 163 | 0.00 ± 15.713 | — |
| FP, CFB to Week 166 | 16.67 ± 7.857 | — |
| FP, CFB to Week 169 | 11.11 ± 0.000 | — |
| FP, CFB to Week 172 | -11.11 ± NA | — |
| FP, CFB to Week 175 | -11.11 ± NA | — |
| FP, CFB to Week 178 | 11.11 ± NA | — |
| FP, CFB to Week 181 | 22.22 ± NA | — |
| FP, CFB to EOT (~242 weeks) | -14.01 ± 32.862 | -5.13 ± 29.262 |
| FP, CFB to LFU (~263 weeks) | -6.67 ± 20.053 | -25.93 ± 27.962 |
European Organization for Research and Treatment of Cancer Item Library 52 (EORTC-QLQ-IL52) is disease symptoms domain from EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module) (EORTC QLQ-MY20). Disease symptoms domain of IL52 contain 6 items covering following concepts: bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. IL52 items are scored on 1 to 4 Likert-type scale, where 1 = Not at all, 2 = A little, 3 = Quite a bit, and 4 = Very much. A raw score is then calculated as mean of completed item responses across 6 disease symptom items. For symptom scales, this raw score is linearly transformed to a 0 to 100 scale using the formula: \[(raw score - 1) / 3\] × 100. Under this approach, a score of 0 indicates no symptoms across items, while a score of 100 indicates the highest level of symptom burden. Accordingly, higher scores indicate greater symptom burden or worse disease symptoms
| Scores on Scale | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone |
|---|---|---|
| Disease Symptoms, CFB to Week 4 | -1.6 (-3.9 to 0.7) | -2.8 (-6.2 to 0.6) |
| Disease Symptoms, CFB to Week 7 | -1.4 (-4.0 to 1.1) | -4.2 (-7.8 to -0.6) |
| Disease Symptoms, CFB to Week 10 | -1.5 (-4.3 to 1.3) | -1.7 (-5.7 to 2.2) |
| Disease Symptoms, CFB to Week 13 | -2.1 (-4.9 to 0.7) | -4.1 (-8.0 to -0.3) |
| Disease Symptoms, CFB to Week 16 | -4.0 (-7.0 to -1.1) | -3.3 (-7.3 to 0.8) |
| Disease Symptoms, CFB to Week 19 | -2.9 (-6.3 to 0.5) | -3.7 (-8.5 to 1.0) |
| Disease Symptoms, CFB to Week 22 | -2.8 (-6.1 to 0.5) | -4.7 (-9.5 to 0.1) |
| Disease Symptoms, CFB to Week 25 | -4.0 (-7.0 to -1.1) | -3.6 (-8.2 to 0.9) |
| Disease Symptoms, Week 28 | -2.3 (-5.6 to 0.9) | -6.4 (-11.3 to -1.4) |
| Disease Symptoms, CFB to Week 31 | -2.7 (-5.9 to 0.6) | -7.2 (-12.1 to -2.2) |
| Disease Symptoms, CFB to Week 34 | -2.8 (-5.7 to 0.2) | -8.1 (-12.9 to -3.2) |
| Disease Symptoms, CFB to Week 37 | -6.2 (-9.6 to -2.8) | -7.1 (-12.9 to -1.4) |
| Disease Symptoms, CFB to Week 40 | -5.9 (-9.0 to -2.7) | -6.8 (-12.3 to -1.3) |
| Disease Symptoms, CFB to Week 43 | -4.9 (-8.6 to -1.2) | -8.6 (-15.6 to -1.6) |
| Disease Symptoms, CFB to Week 46 | -7.1 (-10.0 to -4.1) | -8.4 (-14.4 to -2.3) |
| Disease Symptoms, CFB to Week 49 | -5.4 (-8.9 to -1.9) | -8.3 (-15.2 to -1.3) |
| Disease Symptoms, CFB to Week 52 | -7.7 (-10.7 to -4.7) | -10.0 (-15.8 to -4.1) |
| Disease Symptoms, CFB to Week 55 | -7.6 (-11.2 to -3.9) | -5.4 (-12.5 to 1.7) |
| Disease Symptoms, CFB to Week 58 | -6.5 (-10.7 to -2.3) | -5.5 (-13.6 to 2.6) |
| Disease Symptoms, CFB to Week 61 | -6.5 (-10.6 to -2.4) | -3.2 (-10.7 to 4.4) |
| Disease Symptoms, CFB to Week 64 | -6.7 (-10.7 to -2.8) | -9.4 (-16.8 to -2.0) |
| Disease Symptoms, CFB to Week 67 | -9.9 (-13.3 to -6.5) | -7.9 (-14.1 to -1.7) |
| Disease Symptoms, CFB to Week 70 | -10.7 (-13.8 to -7.6) | -12.3 (-18.1 to -6.5) |
| Disease Symptoms, CFB to Week 73 | -8.7 (-12.7 to -4.8) | -6.4 (-13.4 to 0.6) |
| Disease Symptoms, CFB to Week 76 | -7.2 (-11.0 to -3.5) | -7.0 (-13.6 to -0.5) |
| Disease Symptoms, CFB to Week 79 | -8.8 (-12.6 to -5.0) | -10.5 (-17.1 to -3.8) |
| Disease Symptoms, CFB to Week 82 | -6.9 (-10.5 to -3.2) | -11.9 (-18.3 to -5.4) |
| Disease Symptoms, CFB to Week 85 | -7.1 (-10.7 to -3.5) | -13.0 (-19.4 to -6.7) |
| Disease Symptoms, CFB to Week 88 | -6.7 (-10.5 to -2.9) | -11.4 (-18.0 to -4.7) |
| Disease Symptoms, CFB to Week 91 | -7.0 (-11.7 to -2.4) | -3.8 (-12.0 to 4.4) |
| Disease Symptoms, CFB to Week 94 | -8.9 (-12.8 to -5.0) | -9.1 (-16.2 to -2.0) |
| Disease Symptoms, CFB to Week 97 | -6.4 (-10.6 to -2.1) | -7.6 (-15.2 to 0.0) |
| Disease Symptoms, CFB to Week 100 | -7.8 (-12.7 to -3.0) | -7.5 (-16.7 to 1.6) |
| Disease Symptoms, CFB to Week 103 | -7.8 (-12.2 to -3.3) | -4.7 (-13.3 to 4.0) |
| Disease Symptoms, CFB to Week 106 | -7.9 (-12.2 to -3.6) | -7.2 (-16.4 to 2.0) |
| Disease Symptoms, CFB to Week 109 | -7.7 (-11.7 to -3.6) | -6.1 (-14.4 to 2.2) |
| Disease Symptoms, CFB to Week 112 | -9.9 (-14.4 to -5.3) | -1.4 (-10.7 to 7.9) |
| Disease Symptoms, CFB to Week 115 | -7.9 (-12.0 to -3.7) | -5.0 (-13.4 to 3.3) |
| Disease Symptoms, CFB to Week 118 | -6.5 (-11.7 to -1.3) | -3.1 (-13.4 to 7.3) |
| Disease Symptoms, CFB to Week 121 | -2.3 (-10.0 to 5.3) | -6.7 (-21.3 to 7.8) |
| Disease Symptoms, CFB to Week 124 | -11.3 (-16.1 to -6.5) | -7.3 (-16.9 to 2.3) |
| Disease Symptoms, CFB to Week 127 | -7.5 (-13.2 to -1.8) | -10.9 (-22.6 to 0.7) |
| Disease Symptoms, CFB to Week 130 | -11.5 (-16.0 to -6.9) | -5.1 (-14.6 to 4.5) |
| Disease Symptoms, CFB to Week 133 | -10.2 (-16.0 to -4.4) | -4.2 (-15.8 to 7.5) |
| Disease Symptoms, CFB to Week 136 | -8.9 (-14.8 to -3.1) | -14.4 (-26.4 to -2.4) |
| Disease Symptoms, CFB to Week 139 | -11.5 (-15.6 to -7.3) | -14.0 (-22.2 to -5.8) |
| Disease Symptoms, CFB to Week 142 | -11.9 (-17.0 to -6.8) | -11.1 (-22.1 to -0.1) |
| Disease Symptoms, CFB to Week 145 | -10.0 (-14.7 to -5.2) | -9.6 (-19.3 to 0.1) |
| Disease Symptoms, CFB to Week 148 | -8.7 (-14.3 to -3.0) | -10.1 (-22.5 to 2.3) |
| Disease Symptoms, CFB to Week 151 | -11.2 (-15.4 to -7.0) | -13.0 (-22.6 to -3.3) |
| Disease Symptoms, CFB to Week 154 | -8.8 (-14.9 to -2.8) | -1.5 (-15.1 to 12.1) |
| Disease Symptoms, CFB to Week 157 | -11.8 (-16.5 to -7.1) | -9.1 (-20.3 to 2.1) |
| Disease Symptoms, CFB to Week 160 | -8.0 (-15.2 to -0.9) | 1.8 (-15.6 to 19.2) |
| Disease Symptoms, CFB to Week 163 | -10.7 (-16.1 to -5.3) | -4.6 (-17.9 to 8.6) |
| Disease Symptoms, CFB to Week 166 | -12.8 (-18.6 to -7.0) | -6.0 (-19.8 to 7.8) |
| Disease Symptoms, CFB to Week 169 | -10.0 (-15.8 to -4.1) | -9.4 (-23.3 to 4.5) |
| Disease Symptoms, CFB to Week 172 | -15.0 (-19.9 to -10.0) | -11.1 (-22.1 to 0.0) |
| Disease Symptoms, CFB to Week 175 | -16.1 (-21.4 to -10.8) | -9.4 (-20.6 to 1.9) |
| Disease Symptoms, CFB to Week 178 | -15.9 (-19.5 to -12.4) | -18.8 (-26.2 to -11.5) |
| Disease Symptoms, CFB to Week 181 | -14.5 (-20.6 to -8.3) | -11.1 (-23.8 to 1.7) |
| Disease Symptoms, CFB to Week 184 | -12.4 (-22.2 to -2.5) | -8.1 (-26.8 to 10.6) |
| Disease Symptoms, CFB to Week 187 | -7.8 (-20.2 to 4.6) | -8.3 (-33.4 to 16.8) |
| Disease Symptoms, CFB to Week 190 | -6.7 (-17.5 to 4.1) | -5.2 (-25.9 to 15.5) |
| Disease Symptoms, CFB to Week 193 | -14.0 (-22.7 to -5.2) | -11.3 (-23.7 to 1.1) |
| Disease Symptoms, CFB to Week 196 | -19.8 (-24.0 to -15.6) | -16.0 (-23.1 to -8.9) |
| Disease Symptoms, CFB to Week 199 | -11.8 (-25.2 to 1.6) | -7.6 (-25.9 to 10.8) |
| Disease Symptoms, CFB to Week 202 | -17.9 (-26.3 to -9.4) | -9.9 (-23.6 to 3.9) |
| Disease Symptoms, CFB to Week 205 | NA (NA to NA) | NA (NA to NA) |
| Disease Symptoms, CFB to Week 208 | NA (NA to NA) | NA (NA to NA) |
| Disease Symptoms, CFB to Week 211 | NA (NA to NA) | NA (NA to NA) |
| Disease Symptoms, CFB to Week 214 | NA (NA to NA) | NA (NA to NA) |
| Disease Symptoms, CFB to Week 217 | NA (NA to NA) | NA (NA to NA) |
| Disease Symptoms, CFB to Week 220 | NA (NA to NA) | NA (NA to NA) |
| Disease Symptoms, CFB to Week 223 | NA (NA to NA) | NA (NA to NA) |
| Disease Symptoms, CFB to Week 226 | NA (NA to NA) | NA (NA to NA) |
| Disease Symptoms, CFB to Week 229 | NA (NA to NA) | NA (NA to NA) |
| Disease Symptoms, CFB to Week 232 | NA (NA to NA) | NA (NA to NA) |
| Disease Symptoms, CFB to Week 235 | NA (NA to NA) | NA (NA to NA) |
| Disease Symptoms, CFB to Week 238 | — | NA (NA to NA) |
MRD negativity rate is defined as the percentage of participants who are MRD negative by Next generation sequencing (NGS) method. The number of participants with MRD negativity has been presented
| Participants | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone |
|---|---|---|
| Number of Participants With Minimal Residual Disease (MRD) Negativity Rate | 22 | 1 |
PFS is time from randomization until earliest date of progressive disease (PD), or death due to any cause per investigator-assessed response per IMWG. PD is ≥25% increase from nadir in any of following: serum M-protein (absolute increase ≥0.5 gram per deciliter \[g/dL\]),urine M-protein(absolute increase ≥200 mg/24hr),difference between involved/uninvolved FLC levels (absolute increase \>10 mg/dL) in patients without measurable serum and urine M-protein levels, or bone marrow plasma-cell percentage irrespective of baseline status (absolute increase ≥10%) in patients without measurable serum and urine M-protein levels and without measurable involved FLC levels; appearance of new lesion,≥50% increase in longest diameter of a lesion previously measured \>1cm in short axis, or ≥50% increase from nadir in sum of products of two longest perpendicular diameters of more than 1 lesion; ≥50% increase in circulating plasma cells (minimum of 200 cells/microliter) if this is only measure of disease.
| Months | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone |
|---|---|---|
| Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG) | 11.2 (6.4 to 14.5) | 7.0 (4.6 to 10.6) |
Collected over All-cause mortality, Non-Serious Adverse Events (non-SAEs) and Serious Adverse Events (SAEs) were collected up to approximately 263 weeks. The results presented are based on data cut-off date 22 April 2025.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Belantamab Mafodotin | 139/217 (64.1%) | 101/217 (46.5%) | 205/217 (94.5%) |
| Pomalidomide Plus Dexamethasone | 71/102 (69.6%) | 45/102 (44.1%) | 93/102 (91.2%) |
| Event | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone |
|---|---|---|
| PneumoniaInfections and infestations | 7/217 | 10/102 |
| COVID-19 pneumoniaInfections and infestations | 3/217 | 5/102 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/217 | 5/102 |
| ThrombocytopeniaBlood and lymphatic system disorders | 9/217 | 1/102 |
| COVID-19Infections and infestations | 5/217 | 4/102 |
| PyrexiaGeneral disorders | 8/217 | 0/102 |
| SepsisInfections and infestations | 2/217 | 3/102 |
| AnaemiaBlood and lymphatic system disorders | 6/217 | 1/102 |
| Respiratory tract infectionInfections and infestations | 1/217 | 2/102 |
| Urinary tract infectionInfections and infestations | 4/217 | 0/102 |
| Event | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone |
|---|---|---|
| Vision blurredEye disorders | 105/217 | 7/102 |
| NeutropeniaBlood and lymphatic system disorders | 27/217 | 41/102 |
| Dry eyeEye disorders | 82/217 | 3/102 |
| Foreign body sensation in eyesEye disorders | 80/217 | 5/102 |
| ThrombocytopeniaBlood and lymphatic system disorders | 72/217 | 35/102 |
| AnaemiaBlood and lymphatic system disorders | 63/217 | 35/102 |
| Eye irritationEye disorders | 63/217 | 3/102 |
| PhotophobiaEye disorders | 63/217 | 4/102 |
| Eye painEye disorders | 49/217 | 0/102 |
| Visual acuity reducedEye disorders | 40/217 | 1/102 |
ITT Population
| Age, Continuous(YEARS) | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone | Total |
|---|---|---|---|
| Mean | 66.3 ± 9.67 | 66.6 ± 9.68 | 66.4 ± 9.66 |
| Sex: Female, Male(Participants) | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone | Total |
|---|---|---|---|
| Female | 100 | 41 | 141 |
| Male | 118 | 66 | 184 |
| Race/Ethnicity, Customized(Participants) | Belantamab Mafodotin | Pomalidomide Plus Dexamethasone | Total |
|---|---|---|---|
| ASIAN | 47 | 19 | 66 |
| BLACK OR AFRICAN AMERICAN | 3 | 1 | 4 |
| WHITE | 162 | 84 | 246 |
| NOT REPORTED | 6 | 3 | 9 |
Showing the first 100 of 136 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
Ran from Apr 2020 to primary completion in Sep 2022, 29 months.
Results were first posted in Oct 2023, 1 year after primary completion.
Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 29 months is below that.
Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belantamab mafodotin